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ABSTRACT
ELECTROSPUN FIBERS AND NANOPARTICLES FOR THE PREVENTION OF
SEXUALLY TRANSMITTED INFECTIONS
Kevin Michael Tyo
September 24, 2019
Human immunodeficiency virus-1 (HIV-1) and herpes simplex virus 2 (HSV-2)
affect hundreds of millions of people worldwide, with women disproportionately
impacted by these infections. Currently, only oral pre-exposure prophylaxis (PrEP)
is approved specifically for the prevention of HIV-1, but is challenged with adverse
side effects associated with long-term use. Topical delivery platforms, such as gels
and films, deliver agents directly to the female reproductive tract, but are limited in
providing transient-release. The technology of polymeric electrospun fibers may
serve as alternative topical delivery platform to the female reproductive tract. In
these studies, we fabricated electrospun fibers comprised of different polymers or
polymer blends that possess different physical attributes and fiber architectures.
The goal was to provide sustained-release of agents such as the antiretroviral
tenofovir disoproxil fumarate (TDF) and the antiviral lectin, Griffithsin (GRFT). We
hypothesized that these delivery platforms would prevent HIV-1 and HSV-2
infections, while retaining the safety and biocompatibility of free agent. To
determine the amount of GRFT loading and release from fiber formulations, ELISA
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was conducted, whereas TDF quantification was performed using absorbance
measurements. Next, the in vitro efficacy of composites was assessed in HIV-1
and HSV-2 infectivity assays. From these initial results, multilayered fiber
composites, free NPs, and hydrophilic fibers were tested for safety and antiviral
efficacy within a murine model. Animal studies were conducted using 5-week-old
female BALB/c mice, histology and cytokine expression were evaluated from
mouse reproductive tracts and vaginal lavages collected 24 and 72 hr following
platform administration. In parallel experiments, mice were administered fibers,
followed by a single challenge 4 or 24 hr later with HSV-2 (LD90). Viral progression
was monitored for 14 days post viral challenge to evaluate potential infection.
Statistical significance for all studies was determined using one-way ANOVA with
Bonferroni post hoc test (p < 0.05), while log-ranked post hoc tests were used for
antiviral efficacy studies. Future studies will consider encapsulation of multiple
antiviral compounds to provide synergetic protection against infection.
Chapters included in this dissertation represent papers that have been or
will be submitted, which may result in duplicate descriptions across chapters;
however, these have been provided for the sake of completeness. CHAPTER 1
contains material that has been published in Pharmaceutics. CHAPTER 2 was
published in the International Journal of Pharmaceutics, whereas CHAPTER 3 was
published in the European Journal of Pharmaceutics and Biopharmaceutics.
Finally, the appendices section contains material published in the Journal of
Visualized Experiments. CHAPTERS 4 and 5 are undergoing preparation for
submission.
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CHAPTER 1
BACKGROUND, SIGNIFICANCE, AND RELATING ADVANCED
ELECTROSPUN FIBER ARCHITECTURES TO THE TEMPORAL RELEASE OF
ACTIVE AGENTS TO MEET THE NEEDS OF NEXT-GENERATION
INTRAVAGINAL DELIVERY APPLICATIONS
Background and Significance
Sexually transmitted infections (STIs) represent a global health challenge,
with over one million new cases reported daily. Currently, over 36 and 500 million
people worldwide live with human immunodeficiency virus-1 (HIV-1) and herpes
simplex virus type-2 (HSV-2) respectively1. Due to the socioeconomic conditions
within parts of the developing world, women are disproportionately affected by
these infections1. Furthermore, HSV-2 infection has been shown to significantly
enhance the risk of HIV-1 acquisition by as much as 2 to 4-fold2,3. Additionally,
studies have shown that co-infected individuals harbor higher viral loads relative
to individuals with only one infection type3. Despite decades of research, there is
currently no cure for either HIV-1 or HSV-2, and infection rates among specific
demographics remain high4,5.
The HIV-1 pandemic is a relatively recent phenomena, with the first
confirmed cases of infections originating in the Democratic Republic of the Congo
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during the late 1950s6. Human contraction of HIV-1 is believed to have originated
from cross-species contamination of simian immunodeficiency viruses (SIVs),
which normally infect primates. The first known cases of HIV-1 infection in the
United States were observed in 1981, and were followed by the designation
Acquired Immune Deficiency Syndrome (AIDS) in 1983, with the isolation of virus
confirming its role in causing the disease. The virus itself, can be transmitted
through homo- and heterosexual intercourse, mucosal layer exposure, or bloodto-blood transmission7. To date, over 36 million people worldwide live with HIV-1
infection, with women in the developing world bearing the highest burden of
infection (Figure 1.1).
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Figure 1.1 Map depicting the total number of people living with HIV-1 infection
worldwide. The developing world is more highly affected by HIV-1, with higher
rates of infection. Furthermore, women worldwide are disproportionally more
susceptible to infection. Image taken from online site at OurWorldInData.org8.
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The global challenge in curing HIV-1 is hindered by the sheer genetic
diversity observed in the viral population. Despite the recent origin of the
pandemic, the high mutation rate of HIV-1 has created an immense array of viral
subtype. As of now, there are two types of HIV-1 known, the more virulent and
widespread HIV-1, and HIV-2 which is localized in central Africa9. Because of the
large genetic variability, HIV-1 is further divided into three groups: major (M), outlier
(O), and new (N)10. The largest HIV-1 group, M, can be further divided into
subtypes, or viral clades. These clades, ranging from A to K, are heavily localized
in specific locations, and show high correlation with incidence rates and
geography. In North America, clade B is the most common form of virus, while
clade C is predominant in Africa11.
Despite the diversity of HIV-1 subtypes within the global population, all HIV1 particles share the same general structure. Each HIV-1 particle is comprised of
two single stranded RNAs that are enclosed within a viral capsule comprised of
p24 proteins12. In addition, the capsule is surrounded by an envelope (Env),
comprised of glycoproteins 120 (gp120) and 41 (gp41). The viral envelope plays
an essential role in enabling initial cell binding and virus entry. Within this viral
capsule, reverse transcriptase and integrase proteins also exist, in addition to
single-stranded RNAs13. These proteins are critical in “hijacking” the host cellular
machinery for repurposing in viral replication.
As mentioned previously, HIV-1 glycoproteins gp120 and gp41 are
essential for host cell binding and entry. Once inside the body through intercourse,
mucus, or blood transmission, these glycoproteins allow HIV-1 to target CD4 T4

helper cells, dendritic cells, macrophages, as well as Langerhans cells13. These
cells express the cluster of differentiation 4 (CD4) receptor, as well as chemokine
receptor 5 (CCR5), or chemokine receptor type 4 (CXCR4), which are the targets
of viral glycoprotein interactions13. When the viral envelope glycoproteins bind to
the CD4 receptor, a conformational change occurs on the viral envelope, causing
additional binding to either CCR5 or CXCR4 co-receptors14. This binding leads to
viral fusion with the cell surface, resulting in virus uptake. After entry, the viral
proteins and RNA appropriate host cell machinery for the sole purpose of new viral
particle production, although some infected cells can act as viral reservoirs,
delaying the production of active virus.
Since the first confirmed isolation of HIV-1 in 1983, there has been a
continued effort to eradicate HIV-1. The first antiviral agent to treat HIV-1 was
Zidovudine (or azidothymidine, AZT), and was first approved by the Food and Drug
Administration (FDA) in 1987. AZT is classified as a dideoxynucleoside reverse
transcriptase inhibitor (NRTI), and inhibits the process of viral replication. However,
due to high viral mutation rates and low tolerance in many patients, the sole use
of AZT was not successful. Since the first introduction of AZT, dozens of new
therapeutics have been introduced to combat the AIDS pandemic. Most of these
therapeutics are used in combination to ensure complete viral inhibition. This
course of action, called combinational highly active antiretroviral therapy (HAART)
has shown success in treating infections14.
Currently, there are a variety of drugs that exist to treat HIV-1, with a total
of six main types. These types: nucleoside/nucleotide reverse transcriptase
5

inhibitors (NRTIs), non-nucleoside/nucleotide reverse transcriptase inhibitors
(NNRTIs), protease inhibitors (PIs), fusion inhibitors, co-receptor inhibitors, and
integrase inhibitors are categorized based on mechanism of action15. Nucleotide
and nucleoside reverse transcriptase inhibitors (such as AZT) are agents that
directly bind to the active site of the viral reverse transcriptase enzyme, which
subsequently inhibits viral replication. In contrast, non-nucleotide/nucleoside
reverse transcriptase inhibitors inhibit reverse transcriptase by binding to the active
site of the protein. Protease inhibitors act to inhibit the formation of mature HIV-1
proteins, preventing new particle fabrication. These three classes act against HIV1 after the virus has entered the cell. In contrast, fusion inhibitors bind to and
inactivate envelope (Env) proteins such as gp41, preventing HIV-1 entry into host
cells. The use of co-receptor inhibitors can prevent gp120 and CCR5 interactions,
again preventing viral entry into cells. Finally, integrase inhibitors, much like
reverse transcriptase and protease inhibitors, work after viral infection and prevent
the virus from integrating its genetic material into the host cell DNA.
This large array of HIV-1 therapeutics has been developed due to the highly
mutagenic nature of HIV-1. Previous studies have shown administration of one
agent will only inhibit infection temporarily, with viral mutations rendering the agent
inactive16. Thus, HAART has been implemented, in which at least three drugs
comprised of two different classes HIV-1 antiretrovirals are administered to treat
HIV-116. These medications are taken orally daily, with several RTIs and at least
one PI being used17. The use of drugs with different mechanism of actions reduces
the risk of HIV-1 adaptation. Furthermore, another benefit of using a diversity of
6

agents is the reduction of toxicity and off-target effects, relative to using the same
class of agents15. With the implementation of HAART, patient life expectancy has
increased tremendously by the continuous suppression of HIV-1, preventing AIDS.
In contrast to the more recent emergence of HIV-1, herpes simplex virus
type-2 is estimated to have existed over 1 million years ago18. This virus is the root
cause of genital herpes, of which there are two types. HSV-2 typically results in
genital infection, while HSV-1 predominantly results in oral manifestations, and
very rarely infecting the genital area. To date, there are over 530 million cases of
HSV-2 infection, representing roughly 25% of the global adult population19. This
high incidence of HSV-2 is largely attributed to the ability of virus to infect during
asymptomatic periods, and to infect surface epithelial cells, as well latently
infecting neuronal cells19,20. Although HSV-2 is not life threatening, no cure exists,
resulting in the need for life-long maintenance.
Each HSV-2 virion is comprised of a viral capsid, or capsule containing
double-stranded DNA21. The capsule itself is composed of proteins that form an
icosahedral shape, surrounded by a lipid bilayer that forms the viral envelope. The
lipid bilayer contains a variety of surface glycoproteins, five of which are essential
for binding and entry to host cells: gB, gC, gD, gH, and gL 22,23. Unlike HIV-1, the
capsid only encodes viral DNA; whereas the cellular machinery of the host
provides the means for producing additional viral particles.
Initially, HSV-2 infects epithelial cells; however, following the initial infection
the virus migrates to neuronal ganglia, providing a reservoir for latent infection.
7

Cell entry is enabled by viral glycoproteins gB and gC located on the surface of the
lipid bilayer. These two glycoproteins non-specifically bind to a cell surface
proteoglycan called heparan sulfate20. The initial binding results in envelope
conformational changes stabilized by both gB and the gH-gL dimers, resulting in
receptor-mediated cell binding and internalization via glycoprotein gD facilitation21.
After this complex process, the virus enters the cell, resulting in the transcription
of viral DNA via cellular machinery and subsequent viral replication.
Due to the latent, asymptomatic and irregular recurrences exhibited by the
virus, no cure for HSV-2 exists. Additionally, relatively few agents are available to
treat HSV-2, relative to HIV-124. The most commonly prescribed agents for HSV-2
treatment are: Acyclovir, Valaciclovir, and Famciclovir. Acyclovir is a guanosine
derivative, which acts to specifically inhibit viral DNA polymerase activity after
binding to the enzyme’s active site. Additionally, Acyclovir was one of the earliest
therapeutics available to combat HSV-2; however, due to the relatively low
bioavailability of Acyclovir, newer therapeutics have been developed. One of the
successors of Acyclovir is Valaciclovir, a prodrug that provides a 3-5-fold increase
in bioavailability compared to Acyclovir. Last, Famciclovir, a prodrug of Penciclovir,
possesses a similar mechanism of action as Acyclovir but can be topically
administered25.
Despite the numerous agents available to treat HIV-1 and HSV-2 infections,
to date there are no FDA-approved agents that prevent or completely cure these
infections. The lack of viable prevention agents for HSV-2 further contributes to the
challenges of managing and combating HIV-1 infections. As previously mentioned,
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HSV-2 acquisition increases the risk of HIV-1 infection, by promoting inflammation,
and more chronically causing small epithelial tears and genital lesions that
increase the likelihood of HIV-1 transmission. Additionally, the asymptomatic
nature of HSV-2 may result in the lack of awareness of infection, and hence
increased risk of transmitting26. Therefore, the development of multipurpose
regimens, active agents, or platforms that have the ability to mechanistically
prevent both HSV-2 and HIV-1 infections are urgently needed.
Thus far, in terms of prevention, oral pre-exposure prophylaxis (PrEP) has
been the primary method to prevent HIV-1 infection in high-risk individuals via daily
oral administration. Truvada, a pill containing the antiretrovirals Tenofovir
Disoproxil Fumarate (TDF) and Emtricitabine, is the only FDA-approved oral
PrEP27. Clinical trials such as Centers for Disease Control and Prevention CDC
4243 and CDC 4940, and the International AIDS Vaccine Initiative IAVI E001 and
IAVI E002 have demonstrated the efficacy of oral PrEP, with daily Truvada
administration resulting in an HIV-1 prevention rate of 62%28. Other clinical trials
show similar results, with oral PrEP reducing HIV-1 acquisition in heterosexual
couples (75%), and in young adults (44-62%)28.
Despite the success of oral PrEP, studies have shown that the protection
imparted by oral PrEP is wholly dependent on strict user adherence. This was
underscored in the VOICE (MTN-003) clinical trial, in which oral PrEP (and topical
microbicide gels) failed to provide any meaningful protection due to a lack of user
adherence29. Additionally, there are major concerns regarding long-term use and
off-target side effects. Studies have shown that long-term administration of
9

antiretrovirals may result in renal and bone toxicity due to the high doses required
to overcome first-pass metabolism29. Furthermore, concerns exist over the use of
TDF and Emtricitabine in both prevention and treatment regimens, with the risk of
acquiring viral resistance to therapeutic agents, which would then render
prophylactic methods, based on the same active agents, ineffective.
The challenges of oral PrEP have prompted the development of several
topical delivery platforms that provide localized protection as well as the
incorporation of biologics. Additionally, intravaginal delivery platforms are being
developed to address the disparity of infections seen in women in the developing
world by seeking to provide a convenient, low-cost, and discreet product for selfadministration. To date, intravaginal delivery has been an effective strategy to
improve the localization of antiviral, antibacterial, antifungal, chemotherapeutic,
and contraceptive agents within the female reproductive tract (FRT) 30,31. One of
the key advantages of topical PrEP, relative to oral is the avoidance of first-pass
hepatic clearance and the harsh gastrointestinal environment, due to the dose
localization. This results in an increase in drug bioavailability within target tissue
and corresponding functional activity by decreasing off-target effects and systemic
exposure32. The inherent characteristics of the FRT, including its large surface
area and low enzymatic activity, additionally make the FRT a favorable site for
localized active agent administration and targeting33,34. Furthermore, localized
administration provides the added benefit of decreasing potential drug toxicity. This
results in more efficacious inhibition of HIV-1 at the site of transmission and initial
infection35. The potential of topical PrEP was first demonstrated in the CAPRISA10

004 clinical study, where an intravaginally administered topical gel containing TFV
was used to effectively reduce HIV-1 transmission by 39%36,37.
Although intravaginal delivery offers a variety of advantages to enhance the
delivery of active agents38, challenges unique to the FRT must be overcome to
provide efficacious prophylaxis and treatment. One of the most important
components of the FRT is the mucus layer, which protects the epithelium and
lamina propria from incoming pathogens (Figure 1.2). However, it can also act as
a barrier, impeding active agent transport to underlying epithelial and immune
cells39,40. In addition to these challenges, the frequent shedding and production of
cervicovaginal mucus can decrease active agent retention, while bacterial flora,
enzymes, and the acidic environment created by beneficial bacteria can contribute
to metabolization and degradation of active agents, reducing efficaciousness.
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Figure 1.2 Schematic depicting the structure and specific layers of the vaginal
mucosa that can act as a barrier to active agent transport (not to scale). The mucus
layer of the female reproductive tract (FRT) frequently sheds and can immobilize
active agents (shown in red), leading to decreased efficacy of the administered
agents. The bacterial flora normally present within the FRT can also metabolize
and degrade agents, further contributing to decreased efficacy. Last, the
squamous epithelium can hinder transport to underlying immune cells present near
the epithelial surface and/or in the lamina propria.
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To address these challenges, intravaginal delivery platforms have been
formulated as solid or semi-solid dosage forms that include suppositories, tablets,
capsules, gels, rings, and creams to enhance delivery to and retention in the
FRT41-45. While these dosage forms have enabled high levels of active agent
incorporation and localization, these traditionally used delivery platforms still face
significant challenges, including difficulty of self-administration, economic
feasibility, poor user-compliance, vaginal irritation, the need for frequent
administration, and low residence times46. Of these platforms, intravaginal rings
have provided the “gold standard” for long-term delivery due to their ability to
sustain the release of one or multiple active agents for weeks to months, avoid
leakage and loss of active agent, and improve drug stability 47-51. However, some
biological agents have difficulty withstanding the high temperature and solvent
processes often required for fabrication, limiting their incorporation 52.
Of these topical platforms, , fast dissolving inserts (FDIs), films, and tablets
act to provide transient (≤ 24 hr) protection, requiring use immediately prior to an
exposure event, which may limit their utility35,53-55. Previous clinical trials assessing
the efficacy of intravaginal gels demonstrated suboptimal results, which were
attributed to a lack of user adherence53. Together, the current challenges of user
adherence and the inability to provide sustained-release may limit the
effectiveness of these delivery platforms.
In contrast to the previous technologies, IVRs, as mentioned earlier, provide
the gold standard for sustained-release applications. Previous studies have shown
that IVRs are able to release antiretrovirals for up to 6 months56,57. Additionally,
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IVRs have been developed to release hydrophilic agents, hormones, and recently
biologics58. The recent ASPIRE (MTN-020) clinical trial, has shown the promise of
IVRs, with the reduction of HIV-1 infections by 27% in selected participants using
IVRs encapsulating the antiretroviral dapivirine55. However, within this trial, it was
seen that women ages 18-21, who are most vulnerable to infection, were less likely
to adhere to an IVR regimen. Furthermore, in the recent HOPE study, despite an
estimated user adherence of 90%, intravaginal rings encapsulating dapivirine
imparted only partial protection against HIV-1, by reducing infections in 39% of
women59. These challenges have prompted the development of new dosage
platforms that may also integrate biologics to provide alternative options for
women.
Concurrent with traditional antiretroviral development, the use of biologics
in the field of STI prevention has increased within the last decade. Biologics, or
active agents consisting of, or derived from living organisms, have shown the
ability to provide enhanced specificity and decreased adverse off-target effects
compared to traditional prophylactics and therapeutics60. However, many biologics
lack oral bioavailability, preventing them from being used in oral treatment
regimens. Given this, biologics may be incorporated into topical delivery platforms,
which can overcome this limitation and additionally inhibit viral infection using
different mechanisms of action, thus reducing the likelihood of acquiring antiviral
resistance. One of the most promising biological microbicide candidates is the
antiviral lectin, Griffithsin (GRFT). Originally derived from a species of red algae,
GRFT has demonstrated potent antiviral activity against a variety of viruses,
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including HIV-1 and HSV-261-66. Among the biologically-based agents studied thus
far, GRFT is one of the most potent against HIV-1, inhibiting activity with picomolar
concentrations. GRFT acts against HIV-1 by specifically binding to viral gp120
glycoproteins, and inactivating the viral particle66,67. Additionally, previous studies
using a 0.1% w/w GRFT gel protected mice from intravaginal infection with HSV265. This protection was attributed to the prevention of the cell-to-cell spread of
HSV-2 and demonstrated the potential of GRFT in multipurpose (multi-virus)
applications. Finally, GRFT has been shown to be highly stable and to have high
resistance to denaturation, while simultaneously exhibiting biocompatibility and
safety within human cells and murine models68,69. Despite the potential of GRFT,
the lectin itself lacks oral bioavailability and is poorly absorbed, rendering oral
administration of the antiviral agent unlikely, without the development of oralspecific formulations.
Although GRFT lacks oral bioavailability, it is an excellent candidate for
delivery to the FRT. GRFT has demonstrated synergistic activity against viral
infections, with antivirals such as of Tenofovir (TFV) and other biologics such as
carrageenan70-72. FDIs encapsulating GRFT have demonstrated short-term
protection against HSV-2 infection in vivo, with FDI-incorporated GRFT
maintaining similar efficacy to free GRFT alone73. Additionally, GRFT stability and
activity were demonstrated in gels, which are now under evaluation in clinical trials.
However, despite the interest in GRFT, to date there is no delivery platform
capable of prolonging the release of GRFT for more than 72 hr65,73,74.
Electrospun Fibers
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As a relatively new microbicide delivery technology, electrospun fibers
(EFs) may provide a promising alternative for prolonged and localized agent
delivery, with the potential to protect against multiple STIs. Some of the
advantages of EFs include the ability to highly incorporate a diversity of active
agents including drugs and biologics33,75, to tailor sustained-release by selecting
different polymeric materials, and to maintain agent stability during the course of
delivery76,77. Biodegradable polymers, such as poly(lactic-co-glycolic acid (PLGA)
and poly(caprolactone) (PCL), are approved by the U.S. Food and Drug
Administration (FDA) for therapeutic use, indicating their proven biocompatibility
and potential for translation78. Together, these attributes have recently established
polymeric EFs as an attractive platform for localized delivery against STIs.
Electrospun fibers have recently gained attention for intravaginal delivery
due to their ease of use, ability to be fabricated into various geometries and sizes,
and tunable release properties79,80. They have been considered for sustaineddelivery, a characteristic that is often desirable for intravaginal applications, due to
their high surface area-to-volume ratio, degree of interconnected porosity, tunable
pore sizes, surface-modification potential, interchangeable polymer options, and
diverse fiber architectures that enable finer control over the rate, duration, and site
of agent release81. Electrospun fibers have the additional advantage that they can
be fabricated using a variety of natural or synthetic polymers to tailor release
properties82, and these polymer types are typically selected based on their
biocompatibility, hydrophobicity, and related degradation properties.
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Over the past decade, researchers have begun to incorporate antiviral
agents into polymeric EFs to prevent HIV-1 infection. One of the first studies to
utilize EFs to combat HIV-1 developed pH-responsive fibers that encapsulated
cellulose acetate phthalate (CAP)83. While CAP EFs exhibited long-term stability
in low pH environments characteristic of the female reproductive tract, the EFs
quickly degraded with the introduction of semen, to release active CAP and
neutralize HIV-1 particles. Later research by the same group utilized surfacemodified polystyrene and polypropylene fibers to bind to and inhibit HIV-1 with
higher efficacy than unmodified fibers alone84.
In addition to pH-sensitive and surface-modified fibers, researchers have
utilized EFs to provide tunable release of one or more incorporated active agents
for HIV-1 prevention85,86. Polymer blends of polyethylene oxide (PEO) and poly(Llactic acid) (PLLA) were synthesized to encapsulate and tailor the release of the
antivirals Maraviroc (entry inhibitor) and AZT for up to several weeks86. In another
study, PLGA and PCL fibers were loaded with various concentrations of the
antiretroviral TFV85. These fibers demonstrated sustained-release of TFV for 30
days, as well as efficacy against HIV-1 infection in vitro. Similarly, but less
extensively for HSV-2, sustained-release delivery vehicles have been recently
developed. In one study, ACV was incorporated into EFs. Release eluate collected
up to 28 days post-release provided sustained protection against HSV-2 infection
in vitro87.
One of the most significant factors that contributes to active agent release
from fibers is the relative hydrophobicity of the selected polymer material 88,89. In
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addition to polymer hydrophobicity, the medium (in vitro) or environment (in vivo)
surrounding the fiber can impact drug release. Simulated vaginal and seminal
fluids, often used to preliminarily assess intravaginal release, may alter the release
of agents relative to testing in water or phosphate buffered saline (PBS) (in vitro)
or in vivo, due to differences in viscosity, salt, and protein concentrations, as well
as pH. Therefore, depending on the degree of polymer hydrophobicity and the
environment release it is tested in, the same encapsulated active agent can have
distinctly different release profiles, in some cases ranging from hours to
months90,91. Usually, independent of these conditions, the use of hydrophilic
polymers often results in the immediate release of both hydrophilic and
hydrophobic active agents due to the high solubility and degradation rate of
hydrophilic polymers in aqueous environments92. Natural polymers such as
collagen, gelatin, chitosan, elastin, and laminin, and synthetic polymers including
poly(ethylene oxide) (PEO), polyvinyl alcohol (PVA), and polyvinylpyrrolidone
(PVP) are examples of hydrophilic materials that have been fabricated into fibers
with micron- and nanometer-scaled properties. In contrast, synthetic hydrophobic
polymers including polycaprolactone (PCL), poly(lactic-co-glycolic acid) (PLGA),
and polyurethane (PU) have demonstrated burst or sustained-release kinetics
depending on the hydrophobicity of the incorporated active agent 93-97. Moreover,
synthetic hydrophobic polymers can also serve as a mechanical and structural
basis for different fiber architectures in which the release of single or multiple
encapsulants may be tailored by using more complex fiber designs or composites.
Fiber release rates can also be optimized by adjusting the polymer molecular
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weight or hydrophilicity, for example, by adding hydrophilic groups such as
aliphatic poly(phosphoester) to the polymer structure98. Together, these features
have enabled the incorporation and release of a variety of antiviral, antimicrobial,
and biological agents from fiber scaffolds99-101.
Active agent release from polymeric fibers typically occurs via diffusion,
polymer degradation, and erosion89. When fibers are first administered, solvent or
solution diffuses through the porous fiber matrix. Once in contact with the solvent
or solution, the polymer matrix swells, loosening polymer chains and enabling the
diffusion of active agents, dependent in part on molecular size. Concurrently, the
fiber surface may undergo bulk erosion at a rate corresponding to polymer
hydrophilicity. These features in combination with the large surface-to-volume ratio
of the fibers allows for the increased diffusion of encapsulants relative to diffusion
from non-porous bulk materials102. Traditionally, fibers have been electrospun as
uniaxial fibers or fibers that comprise a single polymer or polymer blend and exhibit
homogeneous morphology. Diffusion of active agents from more traditional
uniaxial fibers is dependent upon the compatibility of the encapsulant, polymer,
and surrounding eluant. In contrast with diffusion, polymer degradation is observed
when fibers are exposed to aqueous environments, and polymer bonds are
cleaved by either passive hydrolysis or enzymatic reaction 103, resulting in slow
degradation of the fiber scaffold. This degradation alters the distance between and
size of interconnected pores, thereby impacting the diffusion and release of
incorporated active agents. For most synthetic polymers, hydrolysis is the most
common mechanism of degradation, although hydrolysis-resistant polymers have
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been utilized104, which significantly impact active agent release. As the fibers
degrade, they can also undergo surface or bulk erosion, which is dependent upon
solvent diffusivity into the fiber, polymer solubility, and overall fiber matrix
dimensions105.
As a result of these mechanisms and the materials selected, electrospun
fibers can tailor the release of encapsulated agents within different durations to
achieve immediate (transient or rapid), short-term, or sustained-release. Within
this review, we defined release as transient, when the complete release of active
agents occurs within 24 h of administration; short-term, when the release occurs
from one day to one week; or sustained, when the release of the active agent
occurs over a duration of weeks to months. A schematic showing an example of
these different potential release profiles is provided in Figure 1.3. Factors including
the electrospinning parameters, polymer materials, fiber architecture, the resulting
structure and morphology, and the distribution and amount of incorporated active
agent each contribute to the resulting release kinetics and efficacy of delivery80.
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Figure 1.3 Schematic depicting examples of transient, short-term, and sustainedrelease profiles.

21

Traditional uniaxial electrospun fibers in which each individual fiber is
composed of a single cohesive polymer layer were the first fiber architectures to
be fabricated106 and have been utilized in a variety of drug delivery applications
over the past decade79,80,107-109. While uniaxial fibers offer high encapsulation
efficiencies, cost-effectiveness, and ease of use, they have suffered from burst
release and challenges in tailoring release properties80,90,110. These challenges are
most evident in achieving the sustained-release of hydrophilic agents, often
necessitating hydrophilic polymers to attain high encapsulation efficacy as well as
hydrophobic polymers for sustained-release. More complex fiber architectures
offer alternative options to address these limitations by combining different polymer
types in distinct layers to modulate the release.
While the release characteristics of traditional uniaxial electrospun fibers
have been thoroughly reviewed in literature76,111-115, to our knowledge, there has
not yet been a review of the more advanced fiber architectures used to deliver
active agents, nor a review that considers the impact these architectures may have
on intravaginal delivery applications. Here, we seek to provide an overview of
different polymer architectures including coaxial, multilayered, and nanoparticlefiber composites (Figure 1.4) as a function of the materials used to construct these
architectures that have been utilized in a diversity of health applications. We seek
to present different material combinations in these architectures to systematically
relate material type and fiber architecture to active agent release kinetics. Last, we
explore how lessons derived from these different architectures might be applied in
the context of intravaginal delivery to address the needs of future topical sustained22

release platforms for a given prophylactic or therapeutic application. The overall
goal of this review is to provide a summary of different fiber architectures that have
been useful for active agent delivery and to provide guidelines for the development
of new formulations based on the knowledge obtained from previous work across
other applications. While some of these more complex architectures have only
recently been investigated relative to uniaxial fibers, they have demonstrated
promise in enabling greater tunability of release and may be useful to apply as new
dosage forms for intravaginal delivery and other similar applications.
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Figure 1.4 Schematic of different electrospun fiber composites. Diagrams
representing (A) traditional uniaxial fibers, (B) coaxial fibers, (C) multilayered
fibers, and (D) nanoparticle-fiber composites. (A) Uniaxial fibers are comprised of
a single polymer or polymer blend (shown in blue) that is distributed homogenously
throughout the fiber structure. (B) In contrast, coaxial fibers contain both core
(orange) and shell (blue) layers that are chemically distinct. (C) Multilayered fibers
result from sequentially electrospinning different fiber layers together or integrating
individual layers post-fabrication. (D) Finally, nanoparticle-fiber composites consist
of hydrophilic or hydrophobic fibers (orange) that encapsulate nanoparticles
(green).
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Coaxial Electrospun Fibers
Coaxial Architectures and Properties
Coaxial

electrospinning,

adapted

from

uniaxial

or

single

axial

electrospinning, provides a multicomponent fiber scaffold that easily allows the
tunable release of active agents116,117. Coaxial fibers are usually comprised of two
parts, an outer protective layer or shell and an inner layer or core118, where
encapsulants are typically localized (Figure 1.4B and Figure 1.5). Coaxial fibers
can provide several advantages relative to uniaxially spun fibers. First,
electrospinning the core and shell polymer solutions simultaneously through a
coaxial spinneret allows for the design of unique fiber architectures. The thickness
and ratios of the core and shell layers can be modulated, providing more
reproducible fiber properties with a greater ability to alter encapsulant release
relative to other fabrication methods. Additionally, coaxial electrospinning ensures
that the active agent in the core phase is protected within harsh physiological
environments, such as the female reproductive tract101. Furthermore, a variety of
materials can be used as either the core or shell to finely regulate encapsulant
release (Figure 1.5) 116,119.

25

Figure 1.5 Schematic of anticipated release profiles from different coaxial fiber
architectures. Generally, the release of encapsulants from coaxial fibers is
dependent on the core and shell hydrophobicity. The release of active agents from
coaxial fibers with (A) hydrophilic core and shell, (B) hydrophobic core and
hydrophilic shell, (C) hydrophilic core and hydrophobic shell, and (D) hydrophobic
core and shell are shown. Hydrophilic polymers (shown in orange) typically
promote transient release, while more hydrophobic polymers (blue) are typically
used to provide short-term or sustained-release.
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Despite these advantages, the added complexity of simultaneously
electrospinning two or more polymer phases and the additional interactions
between the core and shell solutions requires additional optimization relative to
uniaxial electrospinning in terms of selecting compatible polymers and solvents. In
addition to the core-shell architecture itself, the release profiles of active agents
from coaxial fibers are impacted by solvent choice, polymer-solvent miscibility, the
miscibility between core and shell solvents/solutions, solvent volatility, and layer
thicknesses120,121. Solvent choice has been shown to alter fiber diameter and
structure122, thereby impacting active agent release123. Additionally, miscible core
and shell solvents/solutions may lead to the partial dissolution of core
encapsulants in the shell, whereas, immiscible core and shell solvents may
promote material delamination at the core-shell interface, facilitating burst release
of the core encapsulant. Therefore, the polymers and solvents for both core and
shell layers must be selected based on their individual properties as well as their
anticipated interactions124,125. In addition, solvent volatility and evaporation rate
can affect the distribution and subsequent release of active agents, while the
thickness of the polymer shell, polymer composition, and spinning conditions
influence encapsulant diffusion rates126. Here, we discuss coaxial fibers as a
function of their core-shell design, composition, and incorporated active agents to
help relate these considerations to the resulting transient, short-term, or sustainedrelease characteristics.
Release Kinetics from Coaxial Fibers
Transient Release (within 24 h)
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Hydrophobic Shell—Hydrophilic Core
Electrospun fibers can be designed to release the active agent immediately
or within 24 h of administration if a rapid onset of action is needed for a given
application127. Moreover, multiple active agents can be incorporated into different
layers of a coaxial fiber (core or shell) to provide transient release.
For application to infectious diseases, coaxially spun fibers that
demonstrate burst release followed by lower levels of short-term release may
provide on-demand protection against incoming pathogens, increasing the
immediate efficaciousness of agents by releasing initially high (burst)
concentrations. This type of release can be achieved by employing coaxial fibers
comprised of hydrophobic shells and hydrophilic cores. In one study, coaxial and
triaxial fiber multi-drug delivery platforms that used PCL as the outermost shell
released ~15% and ~80% of two different hydrophilic dyes, keyacid blue and
keyacid uranine (KAB and KAU), from the PVP core and PCL shell fibers,
respectively, within one hour116. In both the coaxial and triaxial fibers, the PVP core
containing KAB was protected by the surrounding PCL layer containing KAU,
which helped to extend the release of the remaining KAB to 24 h. For the triaxial
fibers, a blank PCL layer was electrospun between the outer PCL shell and the
inner PEO core. In both the coaxial and triaxial fibers, KAU was released from the
shell within 3 h; however, the triaxial fibers better modulated the release of KAB
from the core, releasing 50% less during the first hour. The burst release of the
KAU dye, observed from both coaxial and triaxial fibers, was attributed to water
penetrating the porous fiber shell, allowing transient release. In another example
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of coaxial fiber design, water-soluble PVP was used as a core with a hydrophobic
ethyl cellulose (EC) shell to encapsulate hydrophobic compounds of either
quercetin or ketoprofen. Using this architecture, ~75% of both hydrophobic
encapsulants were released within 24 h.
Hydrophilic Shell—Hydrophobic or Hydrophilic Cores
Similarly, coaxial fibers that have hydrophilic shells can facilitate the rapid
release of encapsulated agents with an initial burst release of 1 to 4 h followed by
continued transient release within 24 h of administration. One architecture that has
been adopted to achieve rapid- or on-demand release from coaxial fibers is a
hydrophilic shell in combination with a hydrophilic or hydrophobic core. In one
study, zein-PVP core-shell fibers were developed that incorporated the active
agent in both the core (zein) and the shell (PVP) layers128. Zein, a natural,
moderately hydrophobic polymer was used to achieve immediate and transient
release of the hydrophobic drug, ketoprofen. A burst release of 43% was observed
within the first hour, followed by transient release of the remaining ketoprofen over
10 h. The initial burst release was correlated with rapid dissolution of the
hydrophilic shell, while the more transient 10 h release was attributed to the
hydrophobic core. In another study, the release profile of a hydrophobic drug,
asiaticoside, was compared between coaxial fibers composed of chitosan cores
with either a hydrophilic alginate and PVA-blended polymer shell or a hydrophobic
centella triterpenes cream shell129. The coaxial fiber with the alginate-PVA shell
demonstrated 80% more asiaticoside release relative to the centella control within
10 h, which was attributed to the shell hydrophilicity 129. Additionally, the trend of
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burst release followed by more gradual transient release was attributed to rapid
degradation of the alginate-PVA shell, followed by subsequent degradation of the
chitosan core. While this example incorporated a polymer blend (alginate-PVA) as
the hydrophilic shell, to be considered a core-shell structure, it should be noted
that the material itself needs to be electrospinnable without other polymers. As this
example demonstrates, hydrophilic polymers such as PVP, PVA, or PEO can be
electrospun alone or in blends to create hydrophilic core and shell layers.
Core-Shell Architectures with Similar Core-Shell Hydrophobicity
Coaxial fibers comprised of both hydrophilic core and shell layers have also
been investigated to provide transient release of active agents. For example,
coaxial fibers fabricated with a hydrophilic PVP shell and hydrophilic cellulose
acetate core were investigated. These coaxial fibers with both a hydrophilic core
and shell released 31% of their hydrophobic encapsulant (epicatechin) within 10
min, followed by 80% release after 4 h130.
In addition to the utilization of materials with similar hydrophobicities, coaxial
fibers consisting of identical core-shell materials have been fabricated to provide
the rapid release of active agents. In one study, fibers with PVP shells and cores
were investigated to provide rapid release of the hydrophobic drug, quercetin. The
PVP shell-PVP core fibers released quercetin within one minute 131, and this burst
release was similarly observed in a separate study that used the same fiber
formulation to deliver acyclovir132. In another study, the hydrophobic antibiotic,
allyltriphenylphosphonium bromide, was incorporated within the core of coaxial
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fibers, and the volumetric ratios of core-shell solutions were varied to study
release. Fibers comprised of zein-zein with core-shell volume ratios greater than
1:2 were found to suppress the burst release of the antibiotic, only releasing 15%
within the first hour. In contrast, 35% and 45% of the antibiotic were released from
fibers with a 1:1 core:shell volumetric ratio or blended fiber controls over the same
duration133. In a separate study, a triaxial fiber in which all three layers were
comprised of ethyl cellulose provided zero-order release of ketoprofen over 20 h
due to the gradual increase in the drug content moving from shell to the core134.
These studies highlight the role of the active agent distribution within the fiber
layers, suggesting that encapsulant localization within the fiber core may enhance
release.
Finally, the release of fluorescently labeled bovine serum albumin (BSA)
from core-shell hydrogel nanofilaments composed of a poly(lactide-co-εcaprolactone)

(PLCL)

shell

and

N,N-isopropylacrylamide

(NIPAAm)/N,N′-

methylene bisacrylamide crosslinked core was studied. The crosslinker, N,N′methylene bisacrylamide, was used to polymerize NIPAAm during the
electrospinning process. This study showed that by changing the NIPAAmcrosslinker (w/w) ratio from 4:1 to 37:1, the release of BSA increased from 0.15 to
0.7 ug/mg over 24 h. However, in the absence of a hydrogel within the core, BSA
showed nearly complete release over the same duration. This study demonstrated
that the mechanical and corresponding drug release properties could be more
finely tailored by altering the NIPAAm-crosslinker (w/w) ratio135.
Stimuli-Responsive Coaxial Architectures
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Another method to modulate the release of active agents from coaxial fibers
is to integrate stimuli-responsive layers to precisely release agents in response to
surrounding physiological conditions136. Unlike stimuli-responsive uniaxial fibers,
the more complex interactions between the core and shell layers in coaxial fibers
can provide increased control of active agent release via pH- or other stimuli-based
mechanisms. A variety of natural and synthetic materials have been investigated
for their use in pH-responsive applications. In one example, a coaxial fiber
comprised of a lecithin-diclofenac sodium core and a Eudragit S100 shell provided
the pH-responsive release of ferulic acid for 10 h137. Ferulic acid release was
facilitated under conditions of neutral pH (pH 7), with minimal release occurring in
a more acidic (pH 2) environment. Another pH-sensitive polymethacrylate-based
copolymer137-139, Eudragit EPO, was used to fabricate pH-responsive antibacterial
fibers. Here, Eudragit EPO cores, which dissolve below pH 5, were used in
combination with Eudragit L100 shells, which dissolve at a pH greater than 6.
These coaxial fibers provided pH-responsive release for an hour under slightly
acidic conditions (pH 6) while demonstrating attenuated release in very acidic
conditions (pH 2)29. Additionally, two separate studies investigated coaxial fibers
comprised of Eudragit S100 shells and PEO cores to stimulate pH-responsive
release within the gastrointestinal tract140,141. In both studies, the release of
hydrophobic indomethacin and hydrophilic mebeverine hydrochloride agents was
minimal (~10%) after 2 h under acidic conditions, followed by rapid release for 6 h
when switched to neutral conditions (pH 7.4). Coaxial fibers comprised of cellulose
acetate phthalate shells with polyurethane cores, as well as gelatin-sodium
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bicarbonate shells with PLCL cores have also been used to provide similarly rapid
pH-responsive release of ciprofloxacin and rhodamine B (Rhd B). These studies
demonstrated the potential of coaxial fibers as pH-sensitive delivery systems142,143.
Coaxial fibers with other stimuli-responsive properties have been
investigated for on-demand, rapid release applications. Although studies with other
stimuli-responsive systems have been limited, one study investigated the use of
self-immolative polymers, or polymers that depolymerize when exposed to specific
external stimuli, for rapid stimuli-responsive release144. In this study, selfimmolative

fibers

comprised

of

dibutyltin

dilaurate

and

phenyl

(4-

(hydroxymethyl)phenyl) carbamate were blended with polyacrylonitrile and used
as shells to surround PVP cores. The fibers provided minimal release of KAB dye
when incubated in water; however, the fibers depolymerized when exposed to
trifluoroacetic acid, resulting in zero-order release of ~40% dye within a week.
Short-Term Release (One Day to One Week)
Hydrophobic Shell—Hydrophilic Core
A key advantage of short-term release specifically for intravaginal delivery
is that the burden of frequent or daily administration may decrease, thereby
increasing user adherence of prophylactics and therapeutics. Traditionally,
hydrophobic materials have been well-suited to provide longer durations of release
(depending on the encapsulant) due to their decreased degradation rates in
aqueous environments. For more traditional uniaxial hydrophobic fiber platforms,
most hydrophobic small molecule drugs or larger macromolecules achieve release
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for up to one week due to the similar hydrophobic properties of the polymer and
encapsulant38. This compatibility allows for hydrophobic encapsulants to partition
more evenly within and distribute throughout hydrophobic polymers. However,
hydrophilic agents, which have low solubility in nonpolar polymers, often partition
to the fiber surface, resulting in burst release and suboptimal short-term and/or
sustained-release properties. To address this challenge, coaxial fibers in which
hydrophilic agents are encapsulated within a hydrophilic core and surrounded by
a protective hydrophobic shell can prolong and adjust the release of hydrophilic
molecules.
The use of coaxial fibers with hydrophobic shells and hydrophilic cores has
been shown to extend the release of many encapsulants118,145,146. In one study, a
coaxial fiber comprised of a hydrophobic ethyl cellulose shell with a hydrophilic
PVP core was investigated for short-term release. These fibers released maraviroc
over a duration of hours to days depending on the thickness of the hydrophobic
shell, which was modulated via flow rate and total electrospun volume. The
increased thickness of the hydrophobic shell extended encapsulant release from
24 h to five days by increasing the shell-to-core volume ratio from 0.5 to 4145. In
another study, a PCL fiber shell surrounding a PVP-graphene oxide blended core
was studied. These fibers released 65% of hydrophilic vancomycin hydrochloride
within 4 h and attained full release of vancomycin after 96 h 147. Although this
coaxial fiber provided short-term release, the long-term safety of graphene oxide
within the FRT is unknown, and further studies are required to assess its safety in
intravaginal delivery applications. Finally, a coaxial fiber composed of a synthetic
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hydrophilic poly-cyclodextrin core and hydrophobic poly(methacrylic acid) shell
reduced the burst release of a hydrophilic drug, propranolol hydrochloride, by 50%,
and extended release to 180 h relative to the 140 hour release obtained from
uniaxial fibers148.
Hydrophobic Shell—Hydrophobic Core
In addition to the widely used hydrophobic shell-hydrophilic core coaxial
architectures, the use of hydrophobic materials in both the core and the shell layers
has also been investigated to provide the short-term release of active agents. In
one study, a PCL core surrounded by an outer PCL shell was used to prolong the
release of the antibiotic ampicillin. Ampicillin, a hydrophilic compound, normally
localizes to the surface of PCL when spun as a uniaxial fiber, resulting in burst
release149. As an alternative, a 4% (w/v) PCL solution was used to fabricate an
ultra-thin shell to delay release. In addition, the parameters for coaxial
electrospinning were modified using dilute sheath solutions to improve the control
of fiber diameter and morphology. The resulting coaxial fiber efficiently
encapsulated ampicillin and provided short-term release for ~80 h149. In another
study, coaxial fibers comprised of a zein shell with a PCL core reduced the burst
release of the hydrophilic antibiotic, metronidazole, achieving short-term release
for more than four days125.
Stimuli-Responsive Coaxial Architectures
Coaxial fibers exhibiting stimuli-responsive properties have also been
investigated to provide short-term release of active agents. As one example,
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poly(N-isopropylacrylamide), a thermoresponsive polymer, was used as a core
layer in combination with an ethyl cellulose and anhydrous ethanol shell solution.
At room temperature, poly(N-isopropylacrylamide) exhibits hydrophilic properties;
however, at temperatures above 32 °C, the polymer demonstrates more
hydrophobic characteristics. At room temperature and after 55 h, the fibers
released 65% of ketoprofen in PBS, while only 40% of the same drug was released
at 37 °C150.
Blended Polymers in Coaxial Architectures
Another method of prolonging release is to use blended polymers to
formulate coaxial fibers, which can decrease fiber wettability. One study combined
gelatin, a natural hydrophilic protein, with the hydrophobic polymer, PCL, to create
coaxial fibers with increased hydrophobicity and mechanical stability relative to
gelatin alone151. In one study, the release of hydrophilic doxycycline was measured
from three different fiber architectures—a uniaxial PCL-gelatin blended fiber,
coaxial fibers with three different cores (PCL, gelatin, or a PCL-gelatin blend) and
a PCL-gelatin blended shell, and a triaxial fiber with both a PCL-gelatin blended
core and outer shell and an intermediate gelatin layer. Among these five designs,
uniaxial PCL-gelatin blended fibers released the most doxycycline within 24 h
(90%), while coaxial fibers with a PCL-gelatin core and shell released the least
(50%). Additionally, only coaxial fibers with either a PCL-gelatin or gelatin core
prolonged release over five days. Furthermore, the other architectures including
the uniaxial PCL-gelatin blend, coaxial fiber with PCL core, and triaxial fibers failed
to release doxycycline for more than 30 h. The burst release observed in fibers
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with PCL cores was attributed to the lack of compatibility between the hydrophobic
PCL cores and hydrophilic encapsulant, which caused doxycycline to localize on
the core surface. Additionally, the subsequent suboptimal encapsulant release
was attributed to low water penetration into the hydrophobic core. These studies
demonstrate that utilization of both hydrophobic and hydrophilic polymers alone or
as blends can modulate the short-term release of hydrophilic encapsulants due to
the variation in the permeability of different layers and core-encapsulant
interactions.
Sustained-Release (One Week to Multiple Months)
Hydrophobic Shell—Hydrophilic Core
Similar to fibers that provide short-term release, fibers designed for
sustained-release commonly use hydrophobic polymers as the outer shell to
prevent the fiber from undergoing rapid hydrolysis. Studies have demonstrated that
the most promising coaxial architecture to achieve sustained-delivery utilizes a
hydrophobic shell and hydrophilic core38. A polymer that is frequently used in
coaxial fibers to provide sustained-release is poly(lactic-co-glycolic acid) (PLGA).
In one study, a coaxial fiber composed of a PLGA shell was used to shield a
hydrophilic core consisting of tragacanth gum. The encapsulant, tetracycline
hydrochloride, served as a model hydrophilic agent. Investigators observed that
PLGA (shell)-tragacanth gum (core) coaxial fibers diminished burst release and
provided sustained-release of tetracycline hydrochloride for 75 days, releasing
68% of tetracycline hydrochloride during this period 152 . In another study, a PLGA
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(shell)-polyethylenimine (PEI, core) architecture was used to prolong the release
and stability of bone morphogenetic protein-2 plasmid (pBMP2-2). The hydrophilic
PEI core was used to encapsulate and retain the bioactivity of pBMP2-2, while the
hydrophobic PLGA shell was used as a protective barrier to prolong release. When
compared to uniaxial PLGA-PEI blended fibers, the PLGA (shell)-PEI (core)
coaxial fiber exhibited both improved bioactivity and prolonged release of the
pBMP2-2 plasmid. The coaxial fiber released 80% of the plasmid over 20 days,
while the uniaxial fibers released the same amount over seven days153.
Polymers other than PLGA have been used as hydrophobic shells to sustain
the release of active agents from coaxial fibers. One study formulated coaxial
fibers containing a hydrophilic dextran core and hydrophobic PCL shell. The
addition of polyethylene glycol (PEG) to the PCL shell increased the release of the
encapsulated BSA by forming pores in the shell layer. Although all fibers released
~20% BSA within the first 24 h, increasing the PEG concentration increased the
amount of BSA released over extended durations. Interestingly, all fibers
demonstrated sustained-release regardless of PEG concentration; coaxial fibers
fabricated with 5% PEG shells released ~60% BSA, while fibers containing 40%
PEG shells released 90% BSA over 27 days154. In another study, the relationship
between PEG (core):PCL (shell) molar ratio and the release of BSA or lysozyme
was investigated. The thinnest shell layers with a core:shell molar ratio of 1.59 and
a core flow rate of 2 mL/h provided complete release of both encapsulants within
24 days, compared to only 50% release from thicker fibers with a core:shell molar
ratio of 0.32 and a core flow rate of 0.6 mL/h. Moreover, the fibers preserved the
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bioactivity of lysozyme and released BSA over 29 days, with no noticeable
differences between BSA and lysozyme release rates155. In addition to
conventional coaxial spinning, the use of emulsion electrospinning has also been
investigated to fabricate coaxial fibers, which can be electrospun using a uniaxial
spinneret117. One study that used emulsion electrospinning fabricated core-shell
fibers composed of a PEG-poly(d,l-lactic acid) shell and methyl cellulose core to
minimize the burst release of lysozyme156. The release of lysozyme from the core
was achieved over 15 days and was dependent on the percent of lysozyme loaded,
while the structural integrity and bioactivity of lysozyme was protected by the shell.
A later study compared these same coaxial fibers to blended uniaxial fibers
composed of PCL and PEG and showed that the coaxial fibers improved
sustained-release by releasing ~50% of BSA over 35 days relative to blended
fibers, which released ~75% BSA157.
Another study explored the effects of multiple processing parameters,
including PEG and PCL concentrations, PEG molecular weight, encapsulant
concentration, and fiber diameter, in modulating the release of plasmid DNA
(pDNA). Plasmid DNA was encapsulated in a PEI core, and a non-viral gene
delivery vector (r-PEI-HA) was incorporated within a PCL shell158. An increase in
fiber diameter was observed with an increase in all of the three other parameters,
while the loading and release of r-PEI-HA were correlated to pDNA concentration
in the fiber core and PEG molecular weight. The fibers formulated with high PEG
molecular weight and low pDNA concentration exhibited ~30% release of r-PEI-
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HA over 60 days, while the fibers with high pDNA concentration and low molecular
weight PEG completely released pDNA within 60 days.
Core-Shell Architectures with the Same Core-Shell Hydrophobicity
Although coaxial architectures with similar core and shell hydrophobicities
have been utilized to obtain transient and short-term release, coaxial fibers that
use the same materials have been less frequently investigated to provide
sustained-release. In one study, PLGA was utilized in both the core and shell
layers to investigate the effect on vancomycin and ceftazidime delivery 159. Both
hydrophilic drugs were encapsulated within the core PLGA layer and exhibited
similar burst release kinetics within the first day, followed by a second phase of
more gradual release over five to ten days. Ninety percent of the antibiotics were
released after 11 days, followed by complete release after 25 days, with the more
gradual release attributed to the PLGA barrier layer.
Applications for Intravaginal Delivery
The enhanced tunability and versatility provided by the core and shell layers
of coaxial fibers make them excellent candidates for intravaginal delivery
applications. While uniaxial fibers have been studied for sustained- and stimuliresponsive release of active agents in the FRT38,75,85,87,160-162, they have faced
challenges in providing the sustained-release of therapeutically relevant
concentrations of individual active agents and effectively modulating the release
of multiple agents core38. Often, compatibility between the polymer and
encapsulant can pose challenges to achieving sustained-release with uniaxial
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fibers, while coaxial fibers may circumvent this issue by integrating two different
polymers, enabling the separation of agents within a compatible polymer
formulation (core or shell). Moreover, the additional outer shell can help to
modulate release. One can envision that with a coaxial architecture, multiple
agents may be delivered against a particular infection to provide a synergistic
effect or to provide protection against multiple types of viral or bacterial infections.
Together, these features allow for enhanced tunability with the option of providing
immediate to short-term release for on-demand applications while also providing
long-term release that may be particularly useful in prophylactic or contraceptive
applications.
A variety of release kinetics can be attained from coaxial fibers by using
different combinations of materials in the core and shell layers. Transient or rapid
release of active agents is often accomplished with the use of hydrophilic polymers
due to their rapid dissolution in aqueous environments. To achieve short-term
release extending to one week, a hydrophilic core in combination with a
hydrophobic shell is the most frequently used architecture, enabling the slow
dissolution of the shell layer, which acts as a barrier to encapsulant diffusion from
the core. For sustained-release applications that require delivery on the order of
weeks to months, hydrophobic polymers such as PLGA and PCL are often
selected as shell polymers due to their slower degradation kinetics and
biocompatibility. Yet, due to the number of parameters involved in the synthesis of
coaxial fibers, two similar architectures may still be tailored to perform very
differently by altering physical versus chemical properties. An example may be
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seen in which fibers composed of similar or even the same polymers display very
different release rates due to the modulation of shell thickness. In these cases,
thinner shells have been shown to provide more transient release, while increasing
the shell thickness delays or alters the trend to more gradual release.
Coaxial fibers have been investigated previously for intravaginal
delivery142,145. In one study, maraviroc release from coaxial fibers was adjusted by
varying the drug loading and solution flow rates to provide release over five
days145. In addition, pH-responsive coaxial fibers have been fabricated to react in
the presence of semen by utilizing the pH-sensitive polymer cellulose acetate
phthalate as a shell. The outer shell dissolved immediately after exposure to PBS,
promoting pH-responsive release of Rhd B142.
Although coaxial fibers have shown promise in general drug and initial
intravaginal delivery applications, further refinements are required to expand their
overall utility. First, compatibility between the solvents of the two polymer
electrospinning solutions may limit the potential combinations of core-shell
materials and encapsulated agents to achieve successful electrospinning.
Additionally, residual solvents from the electrospinning process may interact with
and inactivate encapsulated active agents in the core layer. Therefore, while
research in coaxial fiber design is still ongoing, other fiber architectures such as
multilayered fibers may offer additional advantages to advance intravaginal
delivery.
Multilayered Electrospun Fibers
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Multilayered Fiber Architectures and Properties
Multilayered fibers can provide layer-by-layer delivery platforms that are
relatively simple and inexpensive to fabricate while allowing for the encapsulation
of different active agents within the individual layers. The topology, thickness, and
composition of each individual layer can be easily tuned to provide different release
properties based on the envisioned application. Moreover, multilayered fibers have
been shown to have increased mechanical stability and flexibility compared to
coaxial fibers163. While the interactions between two or more polymer solution
interfaces must be considered for coaxial fibers, multilayered fibers can be
fabricated from normally incompatible polymers due to their sequential versus
simultaneous fabrication process.
Electrospun multilayered fibers can be fabricated by sequential layering,
stacking, or interweaving fibers164-166. In sequential layering, the first layer of
polymer is electrospun onto a collector, followed by electrospinning additional
polymer layers directly onto the same collector. In comparison, “stacking” fibers
refers to individually electrospinning each layer separately and subsequently
adhering individual layers together post-spin. Stacked fibers share similar physical
properties with sequentially-layered fibers, enabling temporally-programmed or
spatially-specific delivery of active agents167. Finally, the fabrication of interwoven
fibers utilizes dual or multiple-syringes to simultaneously electrospin two or more
different polymer solutions (usually one hydrophilic and hydrophobic) onto the
same collector. In contrast to fibers produced using the sequential layering and
stacking processes, which have distinct, separate layers of polymeric fibers,
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interwoven fibers result from the blending of these different polymer solutions from
syringes placed opposite of or adjacent to each other into one integrated layer 168170.

This technique seamlessly integrates both hydrophilic and hydrophobic

polymers in a way that prevents unwanted interactions between the electrospun
polymer solutions170,171 while enabling the porosity of the hydrophilic fibers to be
altered to more finely tune fiber degradation172. Although interwoven fibers do not
have a shell layer, the interwoven architecture has been beneficial in promoting
cell adhesion and growth and has the potential to more finely modulate active
agent release via porosity-based mechanisms for drug delivery applications173,174.
Regardless of fabrication technique, multilayered fibers are beneficial in that
they can temporally modulate the release of multiple agents from a single delivery
platform and can provide additional tunability by modulating the barrier or discrete
layers of the multilayered structure (Figure 1.6). In addition, the ability to impart
spatially-specific release—where specific layers of the multilayered fiber possess
distinct release profiles—is a key advantage of this architecture. This advantage
may be envisioned for intravaginal delivery applications where one layer provides
rapid active agent release to the mucus while another layer enables sustaineddelivery specific to underlying epithelial or immune cells 164,165. For interwoven
multilayered fibers, studies have shown that the incorporation of a hydrophilic
polymer can alter the overall porosity and wettability172,175,176, while using a
hydrophobic outer layer in multilayered fibers (similar to coaxial fibers) can
decrease surface wettability and corresponding active agent release 177.
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Figure 1.6 Schematic of anticipated active agent release from multilayered fibers.
One method to modulate the release of active agents (shown in green) is to vary
the thickness of the outer layer (shown in blue). (A) A thin outer layer provides both
rapid burst release and limited sustained-release of encapsulants. (B) In contrast,
increased outer layer thickness can delay the release of some active agents.
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While the process of creating multilayered fibers is well established, more
work is required to elucidate how each polymer layer impacts release kinetics.
Physical properties including the pore size, fiber diameter, and thickness of
traditional uniaxial fibers are known to impact the delivery kinetics of active agents
from individual layers. Thus, the presence of one or more fiber layers can
contribute to the complexity in establishing and predicting the release kinetics of
diverse active agents from differently layered architectures. Despite these
considerations and complexities, the adoption of different layering techniques to
create multilayered fibers can achieve diverse patterns of release for transient,
short-term, and sustained-release applications.
Release Kinetics from Multilayered Fibers
Transient and Short-Term Release
Multilayered fibers have shown promise in providing transient and shortterm release of active agents. Conventionally, a hydrophilic layer serves as a
reservoir for active agents, while hydrophobic materials provide an outer shell layer
to prolong release. One study utilized a multilayered fabrication approach to
encapsulate the hydrophobic antibiotic, gentamicin, in a hydrophilic PVA center
layer and utilized a PU outer layer to envelop the inner PVA fiber 178. Three
separate fibers were fabricated by altering the thickness of the PU outer layer
between 3.4 and 8.1 µm. The release of gentamicin was modulated with the
thinnest PU layer (3.4 µm) demonstrating complete release within 1 h, relative to
10% release obtained from the thickest layer (8.1 µm). Furthermore, the thickest
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PU layer continued to release gentamicin for 24 h. Another study using interwoven
electrospun fibers containing PEO and PCL demonstrated that by adjusting the
ratio of the two polymers, tunable fiber degradation could be achieved from the
resulting changes in pore size and porosity170. Although this study investigated
interwoven fibers to enhance cell infiltration through the pores, the use of sacrificial
fiber layers may be applied to modulate active agent release from the fibers for
intravaginal delivery applications170.
In addition to modulating the outer layer thickness and overall fiber
composition, alterations to the number of layers have been shown to impact active
agent release. In one study, fibroin-gelatin blended uniaxial fibers exhibited release
of trypan blue, fluorescein isothiocyanate (FITC)-inulin, and FITC-BSA within
minutes179. In contrast, multilayered fibers composed of the same materials
extended the release of all three model compounds to 28 days 179. In another study,
dual-release, multilayered electrospun fibers containing the model dyes,
5,10,15,20-tetraphenyl-21H,23H-porphinetetrasulfonic acid disulfuric acid (TPPS)
and chromazurol B, were encapsulated in four-layered PLCL (75:25) fibers. The
release rate and duration of the dyes were controlled by the fiber diameter and
individual fiber layer thicknesses. Minimal release of both dyes was observed for
the first 15 min, followed by a quasi-linear release profile for up to 4 h. However,
increasing the thickness of dye-loaded layers resulted in higher quasi-linear
release rates due to the reduced density of the fiber surface 180. In another study,
the transient release of ketoprofen was achieved using trilayer fibers composed of
two EC outer layers surrounding a center PVP fiber. These fibers provided nearly
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complete release of ketoprofen within 24 h164. Last, asymmetric multilayered
polylactide fibers with different designs on each side were fabricated to prevent
liver cancer recurrence by promoting one-sided prolonged chemotherapeutic
release181. The fiber was composed of five poly(lactic acid) (PLA) layers, with each
layer serving as either a barrier to release or a drug encapsulating reservoir. In
vivo studies in a murine model demonstrated tumor suppression for at least four
days, indicating that the multilayered fiber may provide localized chemotherapy for
short-term durations181.
Multilayered fibers with stimuli-responsive properties have also been
investigated for transient and short-term release applications. In one of the first
studies to investigate multilayered architectures, the pH-responsive polymers,
poly(acrylic acid) (PAA) and poly(allylamine hydrochloride) (PAH), were
electrospun together to create a blended fiber. These fibers were loaded with a
low molecular weight cationic molecule, methylene blue, and demonstrated rapid
release of methylene blue (~10 min) at a neutral pH (7.4). However, by gradually
adjusting the pH from 6 to 2 in aqueous solutions, the step-wise pH-responsive
release of methylene blue was achieved over three and a half days. Building upon
this work, the effect of coating the fibers with a thermoresponsive polymer blend,
poly(N-isopropylacrylamide)-PAA, or perfluorosilane was assessed. The addition
of the thermoresponsive poly(N-isopropylacrylamide)-PAA coating modulated
methylene blue release via temperature. Above a critical temperature, the
thermoresponsive polymer became insoluble and formed intramolecular hydrogen
bonds, which led to the release of methylene blue within 50 min (PBS, pH 7.4). In
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comparison, coating with perfluorosilane modulated release for up to 20 h at
neutral pH. When both the pH-responsive and multiple layers of thermoresponsive
polymers were integrated and evaluated at 25 and 40 °C, dye released for a
maximum of 10 h regardless of layer thickness182.
Sustained-Release
The ability of multilayered fibers to provide long-term release has been
demonstrated in a variety of studies113,114,183. In one study, the release of a
hydrophobic chemotherapeutic agent, 7-ethyl-10-hydroxycamptothecin (SN-38),
was prolonged to 30 days by using a triple-layered fiber in which SN-38 was
encapsulated in the center layer and surrounded by two superhydrophobic outer
layers consisting of PCL and poly(glycerol monostearate-co-ε-caprolactone)

177.

Similar to the trends seen for transient and short-term release from multilayered
fibers, increasing the thickness of the outer fiber substantially improved the
longevity and amount of drug released. In another study, multilayered fibers
comprised of a PCL shell and a PEO/Rhd B core were fabricated to assess the
effect of increasing the outer layer thicknesses between 46.1, 68.9, and 186.1
µm184. While the thinnest 46 µm layers released 85% of Rhd B in one day, the 68.9
and 186.1 µm layers increased release to 15 and 25 days, respectively. Moreover,
the release from the two fibers with the thicker outer layers demonstrated zeroorder kinetics, producing gradual, even release of drug with respect to time.
Applications for Intravaginal Delivery
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Multilayered fibers have shown promise as a platform to co-deliver or
prolong the release of active agents in different environments. The process of
creating multilayered fibers is relatively simple, eliminating the more complex setup and considerations of polymer-solvent interactions between the adjacent,
simultaneously spun layers present in coaxial spinning. By removing this
complexity of interactions, multilayered fibers can achieve “programmed release”
by simply modulating the thickness of each layer.
Multilayered fibers possess other unique features that make them excellent
candidates for intravaginal delivery applications. One of the unique strengths of
multilayered fibers is that they can provide spatially-specific release in that, unlike
other architectures, the individual layers of multilayered fibers can be designed for
specific and discrete purposes. For example, one layer may be designed to
improve mucoadhesion for enhanced longevity and biocompatibility within the
FRT, while another layer may provide release of active agents dependent on its
location within the multilayered matrix. Compared to coaxial fibers, the optimization
of multilayered fibers is not limited by solvent compatibility, as they can be
sequentially spun and assembled post-fabrication. Moreover, multiple individually
spun layers can increase the ease of encapsulating multiple types of active agents,
which serve mechanistically different roles against a single type of viral infection
or as a multipurpose viral-contraceptive or viral-bacterial dosage form. Finally,
each fiber layer can be adjusted to have distinct mechanical properties that include
tensile strength, porosity, and elasticity, important for comfort and user
preference185.
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To date, the use of multilayered fibers for intravaginal delivery has been
briefly explored104,145,166. In one study, circular sheets of pre-spun PVP and PVPEC fibers were stacked and annealed via a pressed metal die that was dipped in
solvent. The die annealed the edges of the stacked fibers, creating a multilayered
fiber with a PVP inner layer surrounded by blended PVP-EC sheaths. Other
multilayered fibers were also constructed by folding the outer layers and pressing
the seams. Both types of multilayered fibers encapsulated the hydrophilic
compound maraviroc and provided biphasic release, exhibiting an initial burst
release followed by short-term release for up to five days. Another study from the
same group examined tenofovir (TFV) localization within stacked PCL/PLGA
fibers. It was found that TFV localization within the multilayered fiber could be
predicted by considering the changes in polymer crystalline structure caused by
encapsulant-polymer interactions and correlating drug-polymer hydrophilicity104.
Both multilayered and coaxial fibers have the potential to provide tunable
and sustained-release; however, each architecture still faces the challenges
surrounding FRT delivery. For example, the interplay between two polymer
solutions still needs to be considered for interwoven multilayered (and coaxial)
fibers, which may result in challenges to altering active agent release. Additionally,
as stated previously, the most significant obstacles to intravaginal delivery are
providing a dosage form that can facilitate active agent penetration of mucus and
retention and release of therapeutically relevant agent concentrations within the
FRT. To improve retention, fibers can be fabricated using polymers or polymer
blends that have mucoadhesive properties. However, this longevity is rarely
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translated to active agents once they have been released from fibers. Thus, new
measures may be considered to provide efficacious and sustained-delivery from
fibers.
Composite Nanoparticle-Fiber Delivery Vehicles
Nanoparticle-Fiber Architectures and Properties
Over the past two decades, polymeric NPs have been extensively studied
as efficacious drug delivery platforms for a variety of applications. Polymeric
nanoparticles are an attractive option for intravaginal delivery relative to traditional
delivery platforms such as gels and films due to the tunability of active agent
release, ability for surface modification, potential for targeted delivery, enhanced
distribution potential, and the often resulting enhanced efficacy of encapsulated
agents. Additionally, polymeric NPs have been shown to elicit minimal immune
response and to improve the delivery and bioactivity of biologics 186-188. Although
metallic nanoparticles have also been explored for use in many drug delivery
applications, they have been less commonly administered within the FRT, hence,
a more comprehensive review of their applications may be found in 189,190.
Many physicochemical characteristics of NPs can be altered, such as
particle size, surface charge, and hydrophobicity, which contribute to their success
in achieving sustained-release and localization to target sites191. Although NPs
have proven to be effective delivery platforms, as discussed in previous
reviews192,193, achieving the prolonged release of active agents can be difficult due
to the natural clearance mechanisms of the FRT. In particular, NPs are challenged
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with retention in the vaginal cavity due to mucus clearance and transport through
mucus to underlying tissue194-196. These challenges may be overcome by
incorporating NPs into electrospun fibers, thereby creating a composite delivery
vehicle that complements the capabilities of both technologies. One might envision
that fibers may act as a reservoir for NPs, improving NP and active agent retention,
while the innate fiber porosity can help to more finely tune encapsulant release
from NPs relative to the release observed from freely administered NPs or fibers.
Nanoparticle-fiber composites are dual-component systems that have the
ability to alter the release kinetics of active agents from NPs or NPs
themselves197,198. Often, the active agent of interest is encapsulated within the
NPs, which are then preloaded into polymer solutions for subsequent
electrospinning. While a variety of inorganic NPs have been incorporated into
fibers199-201, concerns still persist regarding the safety of their use relative to
polymeric NPs, particularly for intravaginal applications. By utilizing biocompatible
polymeric materials for both nanoparticles and fibers, composites may provide safe
and prolonged release for clinical applications.
Release Kinetics from Nanoparticle-Fiber Composites
Transient Release
Nanoparticle-fiber composites have been used to rapidly release NPs and
their encapsulated agents. A study was conducted with hydrophilic PVA and PEO
fibers that incorporated PLGA NPs that contained the dye, Coumarin 6 202. PEO
fibers released 90% of NPs within 30 min when immersed in a 50:50 ethanol:PBS
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solution, followed by additional release (5%) after 3.5 h. In comparison, PVA fibers
released approximately 70% of PLGA NPs within 30 min, followed by a decrease
in NP release (15%) over 8 h. Slightly slower release over 24 h was observed when
PVA fibers were crosslinked prior to NP incorporation. This study highlights that
nanoparticle-fiber composites can be used to successfully incorporate NPs and to
modulate the transient release of NPs from these composites within aqueous
solutions202.
Short-Term Release
Several studies have utilized nanoparticle-fiber composites to provide the
short-term release of active agents. One group explored a composite drug delivery
system that encapsulated the antibiotic, erythromycin, in gelatin NPs and free
lidocaine hydrochloride within PVA-chitosan blended fibers203. Eighty percent of
the lidocaine hydrochloride was released from the fibers within 54 h, while 70% of
the erythromycin was released after 70 h. In contrast, free gelatin NPs released
90% of erythromycin within the same duration. In a separate study, chitosan-PEO
blended fibers containing methoxypolyethylene glycol (mPEG)-b-PLA micelles
demonstrated a low initial burst release (15%) of 5-fluorouracil (5-FU), followed by
prolonged release (91%) for 109 h204. In another study, the release of free
hydrophobic naproxen and chitosan nanoparticles containing Rhd B was studied
from PCL fiber scaffolds205. Rhodamine B exhibited low levels (5%) of burst
release, while 30–40% of naproxen was released within the first 2 h. Moreover,
after 72 h, only 20% of Rhd B was released, while 60% of naproxen was released.
The rapid release of naproxen was achieved via incorporation within the fiber
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scaffold, while the extended release of Rhd B was obtained and enhanced through
nanoparticle-fiber encapsulation. These results demonstrate the utility of
nanoparticle-fiber composites in providing the short-term release of multiple
agents.
Sustained-Release
Nanoparticle-fiber composites have also demonstrated long-term release
capabilities in several studies. In one study, dual-release nanoparticle-fiber
composites were used to mend and treat critically sized calvarial defects in rats206.
These

composites,

consisting

of

PCL-co-PEG

fibers

encapsulating

dexamethasone and BSA NPs and loaded with bone morphogenic protein-2 (BMP2), demonstrated sustained-release of both molecules over 35 days. Another study
explored the incorporation of siRNA into chitosan NPs and PLGA fiber
composites198. In these composites, the release of active siRNA was sustained in
vitro, with 95% of siRNA released from the fibers over 32 days, while gene
silencing activity was maintained. Sustained-release from nanoparticle-fiber
composites was also demonstrated in another study with chitosan-PEO
electrospun fibers that were loaded with PLGA NPs encapsulating phenytoin.
Nearly complete release of phenytoin from the composite scaffold was achieved
over nine days207. Lastly, PLA fibers encapsulating chitosan particles provided
sustained-release of BSA (45%) for 27 days, while chitosan particles alone
released 80% BSA in 14 days208.
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In addition to NP incorporation within traditional uniaxial or blended fibers,
NPs have been incorporated in more complex fiber architectures to prolong the
release of active agents. For instance, the effect of combining a multilayered fiber
architecture with nanoparticle-fiber composites was investigated by fabricating
alternating layers of poly-l-lactic acid (PLLA) and PCL fibers with layers of PCL
fibers encapsulating positively-charged chitosan BSA NPs209. The multilayered
composite released 80% of the BSA in approximately eight days, whereas the
monolayer control released the same concentration of BSA within 24 h.
Applications for Intravaginal Delivery
Composite delivery vehicles containing nanoparticles and fibers have thus
far been primarily studied in wound healing and tissue engineering to fabricate
scaffolds for tissue regeneration and bone remodeling 133,210-212. However, these
platforms may be promising candidates for intravaginal delivery applications due
to their structural stability and ability to sustain the release of active agents. In such
systems, the fibers may be utilized as a reservoir for NPs to aid in intravaginal
retention by helping to decrease NP clearance during shedding. In addition, it is
envisioned that, depending on fiber formulation and, importantly, NP size and
charge, NP (and active agent) release may be modulated, enabling NPs to
traverse mucus and deliver agents to target cells that reside in the epithelium or
underlying lamina propria. Similar to other architectures, fiber parameters such as
polymer composition and size can be tailored to impact release in combination with
altering NP composition, size, and loading within the fiber.
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For intravaginal delivery applications, NPs can impart cell specificity, cell
internalization, as well as mucoadhesive or mucopenetrative properties to their
encapsulated active agents46. Numerous studies have demonstrated the ability of
NPs to enhance cell targeting via surface modification213,214. Additionally, surface
modification can increase cell internalization, which may enhance the transport,
subcellular localization, and corresponding efficacy of drugs like tenofovir
disoproxil fumarate (TDF), which require cell internalization. Furthermore, the NP
surface charge can be modulated to provide either mucoadhesive or
mucopenetrative properties that further enhance active agent delivery.
Additionally, fibers can be fabricated to encapsulate NPs for sustained-release as
well as free agents for rapid release, providing both on-demand and sustainedrelease in one platform. Finally, nanoparticle-fiber composites, when coupled with
coaxial or multilayered fiber architectures, provide an attractive strategy to retain
and sustain the release of active agents within the FRT (Figure 1.7).
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Figure 1.7 Schematic of electrospun nanoparticle-fiber composites that integrate
coaxial and multilayered fiber architectures. (A) Coaxial fibers can be fabricated to
encapsulate nanoparticles (NPs) within the core fiber, conferring sustained- or
delayed-release of active agents that are encapsulated in NPs (shown in green).
(B) Multilayered fibers that encapsulate NPs can also act as reservoirs for either
NP or active agent release.
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As with multilayered fibers, the use of nanoparticle-fiber composites has
only recently been investigated for intravaginal delivery. In a proof-of-concept
study, rapid-release PEO, PVA, or PVP fibers encapsulated PLGA NPs containing
C6 dye or etravirine drug215. In this study, composites and free NPs were
administered within murine FRTs and assessed for retention and release. The
encapsulated nanoparticles exhibited a 30-fold increase in retention in the mouse
FRTs relative to free NPs. Furthermore, nanoparticles alone provided transient
release of etravirine, while all nanoparticle-fiber composites demonstrated release
for up to seven days. To date, this is the only investigation of nanoparticle-fiber
composites for use in intravaginal delivery. However, the significant difference in
retention and release rate achieved with nanoparticle-fiber composites highlights
the immense potential of this architecture for sustained-delivery in the FRT.
Although combining nanoparticles and electrospun fibers into one delivery
vehicle has demonstrated potential, challenges exist for this platform. The major
concern is related to the concentration of nanoparticles that can be effectively
encapsulated within fibers without hindering the ability of the polymer solution to
be electrospun216. Furthermore, the concentration of active agent may decrease
with the use of a coaxial or multilayered architecture, as only specific layers of the
fiber will encapsulate NPs. Finally, polymeric NPs are often comprised of the same
or similar polymers as electrospun fibers, thus care must be taken to prevent
polymer solvents from dissolving the NPs prior to or during the electrospinning
process217. Moreover, the morphology of NPs may also be adversely affected by
electrospinning voltage. These factors limit the combinations of fiber and
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nanoparticle materials available for composite fabrication. Thus, for composite
delivery applications to succeed, polymer choice and electrospinning conditions
must be taken into consideration.
Future Directions and Discussion
Within the past decade, electrospun fibers have been explored as a
multipurpose delivery platform to prevent and treat sexually transmitted infections
(STIs). For intravaginal applications, fibers have typically been uniaxially
electrospun to release active agents targeted to HIV-1/HSV-2 infections and
contraceptive applications. However, other electrospun architectures have been
developed that may provide more finely-tuned active agent release, the
encapsulation of multiple agents, and longer release durations, desirable for nextgeneration vehicles. Given this, the goal of this review was to summarize the
advancements in electrospun fiber architectures including coaxial, multilayered,
and nanoparticle-fiber composites, to meet these needs, and to review their use in
other drug delivery applications. We sought to relate different temporal regimens
of delivery, including transient (occurring within hours), short-term (spanning hours
to one week), and sustained (extending from one week to months), to architectural
design and materials selection to help guide the design of future platforms that
meet the unique temporal needs of intravaginal delivery.
One of the major challenges facing intravaginal delivery is the lack of user
adherence surrounding the administration of current delivery platforms. Several
clinical trials have highlighted how a lack of user adherence contributes to
60

decreased efficacy in clinical trials. In both the FACTS-001 and VOICE trials, South
African women deemed high risk for HIV-1 exposure were given antiretroviral TFV
gels to administer prior to intercourse29,218. Despite the known efficaciousness of
TFV, the gels provided suboptimal protection against HIV-1 infection, which was
attributed to low user adherence of the gels prior to intercourse. Another study
examined the efficacy of gels that incorporated the antiviral polysaccharide,
carrageenan, in women in Thailand. This study demonstrated similarly
disappointing clinical outcomes, with low user adherence considered the most
significant reason for the lack of clinical efficacy219. Negative outcomes in other
trials such as PRO-2000 and cellulose sulfate gel studies, which examined the
efficacy of anti-HIV gels in female populations, further validated these studies,
highlighting that both user preference and adherence regimens must be
considered during product design rather than at the clinical trial stage. As a result
of these studies, there has been an increased emphasis to design vehicles that
decrease the administration frequency by prolonging active agent release after a
single topical application.
In conjunction with improving user adherence, the development of
multipurpose delivery vehicles that offer long-term protection against the various
stages of a single infection or a diversity of different types of infections is highly
desirable220. For single infections, a delivery platform may administer multiple
agents with different mechanisms of action that target different stages of the viral
or bacterial life cycle. However, the increased likelihood of viral co-infections, such
as HSV-2 and HIV-1, as well as bacterial and fungal infections will likely require
61

co-administration of antiviral and antimicrobial agents to be successful.
Furthermore, applications that seek to meet both antiviral and contraceptive needs
in the same dosage form will require the incorporation of multiple types of agents
to expand a platform’s effectiveness. Therefore, a delivery platform that has the
capability to release multiple active agents, each over time frames relevant to the
application or active agent, will have greater utility and enable more convenient
administration schedules based on specific user needs.
Despite these needs, tailoring the delivery of multiple types of active agents
for viral, bacterial, fungal, and contraceptive applications is an ambitious goal given
the unique chemical properties of each agent. For example, the antiretroviral TFV
and its pro-drug TDF have similar structures and both work as nucleoside reverse
transcriptase inhibitors yet possess markedly different hydrophobicities. As such,
a delivery platform designed to prolong TFV release may result in different release
kinetics of TDF, requiring the formulation of distinct delivery vehicles specific to the
selected active agents104,161,162,221,222. Furthermore, each active agent may
necessitate specific temporal dosing regimens to provide protection or treatment.
For example, it may be desirable to administer viral entry inhibitors, which
inactivate virions prior to cell entry, over a different time frame than active agents
that work inside of cells and need to transport through and localize to target tissue.
Several studies have investigated this and have found that more complex and
specialized architectures may be useful to achieve temporal delivery goals by
tuning the release properties of multiple encapsulants for multiple targets

223,224.

Similarly, for contraceptive applications, on-demand and/or zero-order release with
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equivalent daily dosing may be desirable for spermicides and hormonal/nonhormonal contraceptives, respectively. Conversely, it may be desirable to deliver
active agents such as hormones and small hydrophilic drugs (e.g., etonogestrel
and acyclovir) within the same time frame for simultaneous long-term
contraception and prevention. However, the drastically different chemical
properties of these agents will require more complex solutions to achieve similar
release profiles. Given this, multipurpose intravaginal delivery platforms must be
tailored to maximize the efficacy of individual active agents, including small
molecule drugs, proteins, antibiotics, hormones, and live organisms (e.g.,
probiotics), to meet the needs of these diverse applications.
While providing distinct release profiles of different active agents is an
important criterion for the development of future intravaginal platforms, to date,
intravaginal rings (IVRs) are the only platforms that provide delivery over a duration
of weeks to months225-229. Furthermore, IVR studies indicate that more complex
dosage forms, such as rings with drug-encapsulating pods, may more likely
succeed, particularly in challenging delivery scenarios, e.g., achieving the
sustained-release of small hydrophilic molecules223. These and other studies
223,224,230,231

emphasize the need to offer alternative delivery vehicles for women,

with the key lesson that platform architecture must be designed to consider the
hydrophobicity and chemical compatibility of the encapsulants in combination with
its surrounding materials.
In addition to the development of fibers with more complex architectures,
active agent release and transport from these platforms must be assessed. Tissue
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mimetics and ex vivo tissues have been used to assess these parameters within
the context of intravaginal delivery applications161,232-237. One of the most common
ways in which to assess intravaginal delivery is by using human ectocervical tissue
explants derived from patients233-237. These explants provide a representative
environment in which to measure transport by accounting for the three-dimensional
structure of patient tissue. However, patient-specific variations and tissue
availability can limit the use of vaginal explants. Given this, organotypic threedimensional vaginal tissue models such as EpivaginalTM tissue have been created
to help evaluate the safety, transport, and efficacy of active agents within an FRT
mimetic238,239. Other in vitro models have also been developed to explore bacteria
and host cell interactions in the reproductive environment240. Moreover, within the
past decade, new biomarkers and assay endpoints have been identified and
studied in different models to more fully assess microbicide interactions with the
FRT241. The use of tissue models promises to streamline the assessment of future
fiber platforms as viable intravaginal delivery platforms.
To date, a variety of studies have developed uniaxial electrospun fibers for
intravaginal applications, including HIV-1 prevention75,83,85,86,104,160-162,221,222,242,243.
In these studies, electrospun fibers have demonstrated promising potential for
intravaginal applications due to their mucoadhesive characteristics, mechanical
properties, and ability to be fabricated in different shapes and sizes 101. Depending
upon the polymer hydrophilicity, traditional uniaxial fibers have been formulated as
transient, short-term, or long-term delivery platforms. For the purposes of ondemand and short-term release, many of these studies use hydrophilic fibers,
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which dissolve or degrade quickly. In contrast, fibers consisting of more
hydrophobic materials are expected to persist within the FRT, acting as reservoirs
to sustain the release of active agents. We envision (and have observed) that longterm delivery vehicles maintain their structure during the delivery duration of
interest and may require physical removal from the FRT, similar to current IVRs.
However, one of the key challenges for intravaginal delivery has been to sustain
the release of small hydrophilic antiretrovirals due to their rapid diffusion through
the porous fiber matrix, solubility in aqueous solutions, and chemical
incompatibility with hydrophobic polymer cores38. Many of these uniaxial fibers
demonstrated burst release of hydrophilic agents followed by short-term
release107,244, partially attributed to the localization of hydrophilic agents on the
fiber surface. Compounding this, concerns exist that the subsequent release of
active agents may be insufficient to provide complete protection against future
infections. While blended uniaxial fibers have been moderately successful in
addressing these challenges, more work is required85.
The primary parameters that impact release from uniaxial fibers are the
choice of solvent and polymer. Other factors such as polymer concentration and
electrospinning parameters also play a role in attaining different release profiles;
however, it is unlikely that these factors alone are sufficient to overcome the
challenge of delivering sustained and therapeutically-relevant concentrations of
hydrophilic agents. Furthermore, it is difficult to utilize traditional uniaxial fibers for
the encapsulation of multiple diverse agents such as large proteins and small
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drugs. Due to these issues, other electrospinning architectures may be better
suited to meet the diverse challenges of intravaginal delivery.
As discussed previously, coaxial fibers have shown promise for the
encapsulation and release of small hydrophilic and hydrophobic molecules, which
may be useful for intravaginal delivery applications. The different goals of transient,
short-term and long-term release can be achieved by changing the composition
and hydrophobicity of core and shell materials as well as by modulating the shell
thickness and core:shell ratio. As described, the shell layer can help regulate active
agent release, while the core layer is designed to provide optimal compatibility with
an encapsulant. For instance, by using pH-responsive polymer shells, an
immediate stimuli-responsive release of agents can be achieved when the fiber is
in contact with semen. In this scenario, the core layer may be tailored to
encapsulate multiple agents, while the shell, comprised of pH-sensitive polymers,
retains encapsulants until needed. Another advantage of coaxial fibers is that they
can be fabricated to exploit drug-polymer hydrophilicities. For example, a coaxial
fiber comprised of a hydrophobic shell and hydrophilic core can be utilized to
provide long-term release of hydrophilic compounds. Agent encapsulation into
both layers would allow for both transient burst release from the shell due to
surface localization and high loading and sustained-release from the core layer.
Finally, coaxial fibers can provide release of biological agents such as large
proteins. Coaxial cores may be engineered to achieve high protein encapsulation
and biocompatibility, while shells can be constructed with porous surfaces,
allowing tunable release. This is particularly significant given that many biologics
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are being investigated as future viral prophylaxes and therapeutics. Although
coaxial electrospinning is a more complex process that requires additional
optimization, relative to uniaxial spinning, it may enable a versatile platform for
transient, short-term, and long-term release85.
Multilayered fibers combine different polymer layers via sequential or postspinning to incorporate multiple and chemically distinct drugs within specific layers,
thereby tailoring the release kinetics for each encapsulated agent. Multilayered
interwoven fibers can be utilized to provide transient release using sacrificial layers
to encapsulate agents for on-demand applications. The sacrificial layers
comprised of hydrophilic polymers would provide on-demand release of agents
based on their immediate degradation when exposed to physiological fluids. Active
agent release can be further modulated by the number, thickness, and porosity of
each fiber layer245. Moreover, blank fibers may be incorporated within the
multilayers to either act as a physical barrier for sustained-release or for
contraceptive purposes. The layer thickness and level of porosity of blank fibers
can be conveniently modulated to delay the release of small hydrophilic molecules
from the drug-loaded layers, serving to prolong release. Additionally, multilayered
fibers have the potential to deliver biologics and non-hormonal contraceptives.
These agents, although efficacious, may degrade when exposed to harsh solvents
during the electrospinning process. By incorporating these active agents in distinct
layers and integrating barrier layers, multilayered fibers can provide long-term
release of drugs and biologics while retaining their activities.
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While each of these strategies offers advantages relative to uniaxial
spinning, the delivery of active agents may be further enhanced by integrating
nanoparticles with fibers. A composite platform may offer a new alternative to
address the challenges of intravaginal delivery, such as the maintaining active
agent stability, providing cell-specific targeting (via NPs), and enhancing cell
internalization. Like electrospun fibers, nanoparticles can be designed to
encapsulate virtually any compound. The limitations of nanoparticle-fiber
composites mentioned earlier may be overcome by utilizing fibers as a reservoir
for both active agents and nanoparticles to release multiple therapeutics.
Furthermore, the release rates of encapsulants from both nanoparticles and fibers
may be modulated by adjusting the composition of the polymeric scaffold. For ondemand transient release, hydrophilic polymers may be used to enable rapid
release of NPs for immediate distribution through and enhanced retention within
tissue. In contrast, more hydrophobic fibers may be used to delay the release of
NPs or NP-encapsulated agents. Although drug-polymer hydrophobicity is a major
contributor to release, other factors such as polymer choice, molecular weight, and
crystallinity, as well as solvent choice and electrospinning parameters, also affect
the release of agents from fibers.
The application of advanced fiber architectures has only recently been
explored in the context of intravaginal delivery. Advanced fiber architectures
demonstrate the potential to provide the sustained-release of individual active
agents in addition to concurrently providing both transient and sustained-delivery
of multiple active agents. These are key advantages over traditional uniaxial fibers,
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which are challenged with the long-term delivery of small hydrophilic molecules, in
addition to providing transient and sustained-release simultaneously. We envision
that future fiber architectures will localize active agents within specific sections of
the fiber to tailor the release of individual agents independent of other
encapsulants. Moreover, we anticipate that future platforms will combine
architectures to maximize or complement the advantages of individual platforms.
As previous clinical trials have shown, effective protection will be dependent upon
fulfilling user preferences, offering convenience, and providing necessary release
profiles from one vehicle, which fibers have the potential to realize.
Building upon this previous research, the goal of this work was to employ
EFs to topically deliver antiviral agents and provide dual-protection against both
HIV-1 and HSV-2 infections. Towards this end, fibers were fabricated to
incorporate and provide release (> 1 week) of TDF. Additionally, we began to
develop delivery vehicles to deliver the antiviral biologic GRFT, using a variety of
uniaxial fiber types. These included fibers that were covalently surface-modified
with GRFT to serve as “viral traps”, and pH-responsive GRFT fibers, enabling ondemand protection against infections. In addition, hydrophilic rapid-release
polymer formulations were fabricated to high incorporate GRFT, to provide ondemand protection against viral infections. Finally, EFs and nanoparticles were
combined to create a NP-EF composite, incorporating the attributes of both
technologies. It was hypothesized that fibers would serve as long-term NP
reservoirs to modulate the release of GRFT from incorporated GRFT NPs.
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All fiber formulations incorporating either TDF or GRFT were assessed for
loading and (where applicable) release characteristics. All formulations were
tested against both HIV-1 and HSV-2 infections in vitro, and the potential
cytotoxicity of all formulations was evaluated using MTT assays. Finally, several
animal studies were conducted using 5-week-old female BALB/c mice to assess
selected fiber formulations for GRFT delivery. First, the in vivo safety of blank fiber
formulations was assessed. Histology and cytokine expression were evaluated
from collected mouse reproductive tracts and vaginal lavages from mice
administered fibers or composites for either 24 or 72 hr. Finally, it was
hypothesized that these platforms would provide in vivo protection against viral
infection, and demonstrate comparable antiviral activity relative to free GRFT. In
these studies, mice were administered GRFT fibers or NP-EF composites,
followed by a single challenge later with HSV-2 (LD90) after 24 hr platform
incubation. Following viral challenge, mice monitored for 14 days post-infection to
evaluate survival and possible viral progression.
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CHAPTER 2
MULTIPURPOSE TENOFOVIR DISOPROXIL FUMARATE ELECTROSPUN
FIBERS FOR THE PREVENTION OF HIV-1 AND HSV-2 INFECTIONS IN VITRO
Introduction
In this study, the goal of our work was to develop PLGA and poly(DL-lactideco-ε-caprolactone) (PLCL) EFs containing TDF to demonstrate safe and
efficacious inhibition of both HIV-1 and HSV-2 infections in vitro. TDF was selected
as a model ARV to demonstrate proof-of-concept of our delivery vehicles, as at the
time of this study, it was a next-generation, more lipophilic form of TFV, that had
demonstrated strong protection after sustained-release from IVRs. Here we
fabricated both PLGA and PLCL EFs to evaluate and compare two different
biodegradable polymers known to impart the sustained-release of active agents.
We synthesized 3 different formulations for each polymer, PLGA and PLCL, and
characterized the loading and sustained-release of TDF from EFs. We
subsequently assessed the efficacy of fiber release eluates against both HSV-2
and HIV-1 infections in vitro, while demonstrating EF biocompatibility in vaginal
keratinocytes, ectocervical and endocervical cells, and EpiVaginal tissue.
Materials and Methods
Materials
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Poly(lactic-co-glycolic acid) (PLGA 50:50, 0.55-0.75 dL/g, 31–57k MW) and
poly(DL-lactide-co-ε-caprolactone) (PLCL 80:20, 0.75 dL/g, 37k MW) were both
purchased from Lactel Absorbable Polymers (Cupertino, CA). Solvents 1, 1, 1, 3,
3, 3—hexafluoro-2-propanol (HFIP) and trifluoroethanol (TFE) were obtained from
Fisher Scientific (Pittsburgh, PA). TDF was purchased as Viread® (Tenofovir
disoproxil fumarate, Gilead Sciences Inc., Foster City, CA) tablets from the
University of Louisville Pharmacy. Other chemicals, including dimethyl sulfoxide
(DMSO), acetonitrile, trifluoroacetic acid and thiazolyl blue tetrazolium bromide
(MTT) were purchased from Sigma Aldrich (St Louis, MO). Fetal bovine serum
(FBS), antibiotics (penicillin/streptomycin and gentamicin), minimum essential
medium (MEM, Corning), keratinocyte serum-free medium (KSFM, Gibco), and
Dulbecco’s modified Eagle medium (DMEM, Invitrogen) were all purchased from
VWR and Thermo-Fisher. Simulated vaginal fluid (SVF) was prepared in house
using a previously established protocol246. Finally, pure TFV and TDF were kindly
provided by the NIH AIDS Reagent Program.
Cell Lines, Virus, and Tissue Culture
TZM-bl cells were obtained from the NIH AIDS Reagent Program. These
cells are a genetically engineered HeLa cell clone that express CD4, CXCR4, and
CCR5 and contain Tat-responsive reporter genes for firefly luciferase (Luc) and
Escherichia coli β-galactosidase under regulatory control of an HIV-1 long terminal
repeat247,248. TZM-bl cells were maintained in DMEM containing 10% heatinactivated FBS, 25 nM HEPES, and 50 μg/mL gentamicin, in a vented T-75 culture
flask. Env-pseudotype HIV-1 was kindly provided by Dr. Nobuyuki Matoba from
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the University of Louisville, and originally obtained from the NIH AIDS Reagent
Program. To conduct HSV-2 plaque assays, African green monkey kidney cells
(Vero E6, originally obtained from ATCC), HEK-293T (human embryonic kidney
cells originally purchased from ATCC) and HSV-2 (4674) were kindly provided by
Dr. Kenneth Palmer from the University of Louisville. Cells were maintained in
MEM supplemented with 10% FBS, and 1% penicillin and streptomycin (100 μg/mL
each).
To assess cytotoxicity, endocervical, End1/E6E7 (End1); ectocervical,
Ect1/E6E7 (Ect1); and vaginal keratinocyte, VK2/E6E7 (VK2) cell lines were used
(courtesy of Dr. Kenneth Palmer, originally from ATCC). These cell lines were
selected because they are representative of the cell types in the female
reproductive tract that would be exposed to the topical EFs. End1, Ect1, and VK2
cells were maintained in KSFM supplemented with bovine pituitary extract (50
μg/mL), epidermal growth factor (0.1 ng/mL), and 1% penicillin and streptomycin.
The media was further supplemented with calcium chloride (CaCl2) to a final
concentration of 0.4 mM. During cell trypsinization for plating and cell count, cells
were neutralized using DMEM/F12 (Gibco) with 10% FBS, and 1% penicillin and
streptomycin. Organotypic EpiVaginal cultures of normal human vaginalectocervical epithelial cells were purchased from and cultivated as suggested by
MatTek.
Synthesis of Electrospun Fibers
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PLGA and PLCL EFs were prepared with different solvents and TDF
concentrations spanning (1–20% wt drug/wt polymer (w/w)). Powder from crushed
Viread tablets (700 mg tablets containing 300 mg TDF) were used as the source
of TDF. The presence of inactive excipients in these samples was accounted for
when determining the theoretical loading of TDF into polymer fibers. Blank fibers
containing no TDF were prepared as negative controls. For blank EFs, 15–20%
PLGA w/w and 12–20% PLCL w/w were dissolved in either 3 mL TFE or HFIP
solvent overnight while shaking at 37 °C. The following day, 2 mL of PLGA or PLCL
solution was aspirated into, and electrospun from, a 3 mL plastic syringe as
previously described75,87. All formulations were electrospun with a flow rate of 2.0
mL/h and an applied voltage of 20 kV. EFs were collected on a rotating 4 mm
outer-diameter stainless steel mandrel, located 20 cm from the blunt needle tip.
Sample flow rate was monitored by an infusion pump (Fisher Scientific, Pittsburgh,
PA) and the voltage was applied using a high voltage power supply (Spellman CZE
1000R). For fibers incorporating TDF, either 1, 10, or 20% w/w TDF was dissolved
in 1.2 mL solvent overnight. The next day the TDF solution was added to 1.8 mL
polymer solution prior to electrospinning. After electrospinning, fibers were
removed from the mandrel and dried overnight in a desiccator cabinet.
Electrospun Fiber Size and Morphology
The impact of various parameters including: solvent choice, polymer
composition, and TDF concentration on fiber size and morphology were evaluated
using scanning electron microscopy (SEM). Desiccated EFs were placed on
carbon tape, sputter coated with gold, and imaged using SEM (Supra 35 SEM
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Zeiss). SEM images were acquired at magnifications ranging from 1000–5000 x to
enable clear visualization of the fiber microstructure. The average fiber diameter
was determined by analyzing SEM images in NIH ImageJ, and drawing line
elements across a minimum of 50 fibers per image. Statistical significance
between fiber diameters was determined using the Bonferroni post hoc t-test (p <
0.05).
Fiber Characterization: Loading, Encapsulation Efficiency, and Controlled
Release
Incorporated TDF was quantified via HPLC-UV/Vis using a modified
established method85. Briefly, 10 mg of PLGA and PLCL fibers were dissolved in
1 mL of DMSO prior to analysis. Dilutions of these samples were injected into a
Waters 515 HPLC pump using a Waters 717 Plus auto sampler with a Waters 2487
absorbance detector. The mobile phase was comprised of an isocratic mixture of
72% Milli-Q water with 0.045% trifluoroacetic acid and 28% acetonitrile with
0.036% trifluoroacetic acid. The column used for this procedure was a Waters Sun
Fire C18 Column, (100 Å, 5 μm, 4.6 mm × 250 mm). The instrument method
comprised a 1 mL/min flow rate, 15 min run time, UV/vis detection at 259 nm, and
20 μL sample injection volume. TFV was found to elute from the column 2.2 min
after injection, while TDF eluted 12 min post-injection. The initial quantification of
fibers was performed using combined TDF and TVF standards prepared in DMSO.
Standard curves of both TDF and TFV (0.7–100 μg/mL) were used to quantitate
incorporated TDF and to assess TDF degradation. Samples from Viread tablets
were assessed to verify TDF concentration and were used as standards in
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subsequent experiments. Controls included blank fibers and fibers spiked with a
known concentration of TDF. TDF values determined from HPLC measurements
were compared with the quantity of TDF added prior to electrospinning to obtain
percent

encapsulation

efficiency

(EE),

where

EE

=

[(Mass

of

TDF

Incorporated)/(Mass of TDF Initially Added)] x 100. Unless otherwise noted, all
samples were analyzed in triplicate.
Controlled release experiments were performed to assess the release of
TDF from EFs. Triplicate 10 mg fiber pieces were cut and suspended in 1 mL of
simulated vaginal fluid (SVF) to represent intravaginal conditions in vitro. Samples
were incubated at 37 °C and constantly shaken. The complete volume of SVF was
removed and replaced with fresh SVF at time points: 1, 2, 4, 6, 24, 48, 72 h, and
1, 2, 3, and 4 wk. The amount of TDF in the supernatant was measured using
HPLC. Quantification was performed using a Viread standard diluted in SVF, with
eluate from blank fibers in SVF used as background correction. Statistical
significance of both loading and release profiles between fiber formulations was
determined by one-way ANOVA with the Bonferroni post hoc t-test (p < 0.05).
In vitro efficacy of PLGA and PLCL fibers against HIV-1 infection
HIV-1 pseudovirus assays were used to assess the efficacy of TDF
released from EFs against HIV-1 infection in vitro. TZM-bl cells were infected with
Env-pseudotype HIV-1, kindly provided by both Dr. Nobuyuki Matoba (University
of Louisville) and the NIH AIDS Reagent Program. To produce and propagate HIV1 Env-pseudovirus, HEK293T/17 cells were transfected with two plasmids, one
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containing an Env-defective HIV-1 genome and a plasmid solely expressing Env.
Transfection was facilitated with the use of FuGENE (Promega). HEK293T cells
were allowed to incubate for 48 h, after which viral particles were collected and
titered using the 50% Tissue Culture Infectious Doses assay (TCID50). Viral
particles were stored at −80 °C until use249.
To determine the in vitro efficacy of PLGA and PLCL TDF EFs against Envpseudotype HIV-1 infection, TZM-bl cells were seeded in 96-well plates at 100,000
cells/well in 100 μL of DMEM. Fifty microliters of fiber eluate media (DMEM 10%
FBS) collected from time points: 1 and 24 h; week 1 (release from days 0–7); week
2 (release from days 8–14), week 3 (release from days 15–21), and week 4
(release from days 22–28) were diluted by a maximum of 5 orders of magnitude
from collected eluate (1:100,000 maximum dilution). Eluate dilutions were added
to cells in triplicate, and 50 μL of diluted virus stock (1:8) was subsequently added
to each well. The administered virus dose resulted in relative luminescence units
(RLU) of at least twenty times that of background observed in untreated/uninfected
cells, yielding an average of 100,000 RLUs in our experiments. Experimental
controls included untreated/uninfected cells, untreated/infected cells, and blank
fiber eluate-treated/infected cells. For wells containing untreated/uninfected and
untreated/infected cell controls, 100 μL DMEM was added to the wells; for infected
cells with blank fiber eluate, 50 μL DMEM was added to 50 μL blank fiber eluate,
resulting in a final volume of 200 μL for all wells. After infection, plates were
incubated 48 h at 37 °C, and 100 μL of media was subsequently removed from
each well (post-incubation), and replaced with 100 μL of Bright Glo Reagent
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(Promega). Cells were incubated at room temperature for another 5 min and the
luminescence of each well was read at an integration time of 1 s and a gain of 135
(Synergy HT luminometer). The amount of virus inhibition was determined by
normalizing the RLUs of treated/infected cells to untreated/infected cells.
Additionally, all RLU values were corrected by subtracting the RLU of
untreated/uninfected cells. IC50 values were determined using GraphPad 6.0
sigmoidal regression analysis. Unless otherwise noted, all experiments were run
with three or more replicates per treatment group. Statistical significance between
the IC50s was determined using one-way ANOVA with the Bonferroni post hoc ttest (p < 0.05).
In Vitro Efficacy of PLGA and PLCL Fibers against HSV-2 Infection
HSV-2 plaque assays were conducted to test the efficacy of TDF EFs
against HSV-2 infection in vitro. Fibers were incubated in 10 mL complete plating
media (1% FBS MEM) for 1 and 24 h. Additional fiber eluates were collected at
week 1 (release from days 0–7); week 2 (release from days 8–14); week 3 (release
from days 15–21); and week 4 (release from days 22–28) to assess the ability of
PLGA and PLCL TDF EFs to provide prolonged delivery and corresponding HSV2 protection. The antiviral activity of PLGA and PLCL TDF EF eluates was
determined using HSV-2 (4674) plaque assays in Vero E6 cells. Vero E6 cells were
seeded with 600,000 cells/well and grown to near confluence for 24 h in a 6-well
flat bottom plate. After 24 h, the media was removed and cells were simultaneously
administered 2 mL of fiber eluate serial dilutions from the above collected time
points and 3000 PFU of HSV-2 per well. Free TDF was used as a positive control
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for HSV-2 inhibition, in parallel with untreated/uninfected cells; whereas
untreated/infected cells were used as a positive control of cell infection and death.
After 48 h, cells were fixed with methanol for 10 min, stained with 0.1% crystal
violet for 30 min, and washed with DI water. Plaques were counted, and plaque
numbers from experimental groups were normalized relative to the number of
plaques in untreated/infected cells (∼280-300 plaques). Samples were analyzed
in triplicate, and GraphPad was used to determine the IC 50 values of the TDF EF
formulations. Statistical analysis was performed by comparing the average percent
inhibition of HSV-2 using one-way ANOVA with the Bonferroni post hoc t-test (p <
0.05).
In Vitro Cytotoxicity of PLGA and PLCL Fibers
Vaginal epithelial (VK2/E6E7), ectocervical (Ect1/E6E7), and endocervical
(End1/E6E7) cells were incubated with TDF EFs in KSFM to assess the in vitro
biocompatibility of TDF fibers. Cells were plated at a density of 300,000 cells/well
in 12-well plates and incubated in triplicate with 10 mg fiber pieces placed in
transwell inserts (10 mg/mL final concentration). No treatment (media alone) and
10% DMSO were used as positive and negative controls of cell viability,
respectively. After 24, 48, and 72 h incubation, 10 mL of MTT reagent was added
to the cells, cells were lysed, and absorbance was read at 570 nm the following
day. PLGA and PLCL EF-treated cell absorbance values were normalized to
untreated cell absorbance to obtain percent viability.
EpiVaginal Cytotoxicity of PLGA Fibers
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Full thickness vaginal epithelial (VEC-100 FT) EpiVaginal™ tissues
(MatTek) were administered low (5 mg/mL) and high (50 mg/mL) concentrations
of PLGA TDF fibers to best represent administration in a future in vivo model.
PLGA samples were chosen due to our initial experiments demonstrating its
enhanced TDF release profile and efficacy relative to PLCL. Control samples
included untreated, blank PLGA fiber-treated, and toxic (0.2% nonoxynol-9)treated control groups. The tissues were incubated at 37 °C, 5% CO2 for 2 and 3
days.
To monitor the tissue viability following exposure to TDF PLGA EFs, the
basal side tissue culture media was collected on days 2 and 3. Cytotoxicity was
measured using a lactate dehydrogenase (LDH) cytotoxicity assay kit (Pierce). The
viability of the TDF EF treated tissues was determined by normalizing the
absorbance of the treated tissues to the absorbance of the untreated tissue.
Percent cell viability was expressed as: % Viability = [OD (treated tissue)/OD
(untreated tissue)] × 100. Transepithelial electrical resistance (TEER) was
measured using an EVOM2 Epithelial Voltohmmeter equipped with an Endohm
electrode chamber (World Precision Instruments, Sarasota, FL) on days 0, 1, 2,
and 3 of the treatment.
To assess inflammatory markers resulting from fiber exposure, tissue media
was analyzed for cytokine production. Based on previous work238,239,250,251,
cytokines: IL-1α, IL-β, IL-6, IL-8, and TNF-α were assessed in all collected media
via Luminex assay. Additionally, GM-CSF, IFN-γ, and MCP-1 expression were
assessed based on previous microbicide studies using Luminex 68,69,252. Cytokine
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expression in samples was compared with untreated EpiVaginal tissue via fold
increase. The fold-increase was calculated by dividing the sample expression level
by the untreated tissue values.
To visually examine the structural integrity of the tissue after 3 days of
consecutive treatment, the tissue samples were washed with PBS and fixed with
4% paraformaldehyde. The tissue specimens were embedded in a paraffin block,
stained with hematoxylin and eosin (H&E), and cross-sections were observed
under 20× magnification using an Aperio Imagescope (Leica Biosystems Inc.,
Buffalo Grove, IL). Tissue samples were subjected to histological analysis by a
pathologist blinded to treatment group assignment.
Results
Electrospun Fiber Size and Morphology
Fiber morphology was evaluated using SEM, and NIH ImageJ software was
used to assess fiber diameters. Blank PLGA and PLCL fibers fabricated using
either HFIP or TFE solvent are shown in Figure 2.1. For fibers electrospun in HFIP,
15% w/w PLGA or 12% w/w PLCL provided well-defined fiber morphologies.
However with TFE, both polymers required an increase in concentration to 20%
(w/w) to produce well-delineated microstructures. The average diameters were 2.0
± 0.8 and 1.7 ± 0.4 μm for 15% PLGA and 12% PLCL fibers made with HFIP, and
1.9 ± 0.9 and 1.9 ± 0.8 μm for 20% PLGA and 20% PLCL fibers made with TFE
(Table 2.1). Once well-delineated fibers were established, the effect of TDF
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incorporation on PLGA and PLCL EF morphologies electrospun with HFIP was
evaluated (Figure 2.2).
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Figure 2.1 SEM images of blank PLGA and PLCL fibers electrospun using
different solvents. (A) 15% w/w PLGA in HFIP; (B) 20% w/w PLGA in TFE; (C)
12% w/w PLCL in HFIP; and (D) 20% w/w PLCL in TFE. Scale bars represent 10
μm.
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Table 2.1 Diameters of electrospun fibers. Blank and TDF fibers were fabricated
using HFIP or TFE solvents. EFs incorporating TDF exhibited decreased
diameters compared with blank fibers.

Average Width (μm)

Fiber Formulation

HFIP 15% PLGA

HFIP 12% PLCL

Blank Fiber

1.7 ± 0.6

1% TDF

1.1 ± 0.3

10% TDF

0.8 ± 0.3

20% TDF

1.1 ± 0.4

Blank Fiber

1.7 ± 0.5

1% TDF

1.1 ± 0.5

10% TDF

0.9 ± 0.3

20% TDF

0.7 ± 0.2

TFE 20% PLGA Blank Fiber

2.0 ± 1.0

TFE 20% PLGA 10% TDF

1.2 ± 0.4

TFE 20% PLCL Blank Fiber

1.9 ±0.9

TFE 20% PLCL 10% TDF

0.6 ± 0.2
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Figure 2.2 SEM images of PLGA and PLCL fibers prepared with increasing
concentrations of TDF, using HFIP as the solvent. (A) Blank PLGA, (B) 1% TDF,
(C) 10% TDF, and (D) 20% TDF PLGA fibers; (E) Blank PLCL, (F) 1% TDF, (G)
10% TDF, and (H) 20% TDF PLCL fibers. Scale bars represent 10 μm.
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The morphologies and diameters of TDF EF formulations are shown in
Figure 2.2, Figure 2.3, respectively. Prior to TDF incorporation, the average
diameters of all blank fiber formulations were similar, ranging from 1.7 to 2.0 μm,
with no statistically significant differences observed between formulations. In
comparison, PLGA fibers incorporating TDF showed no particular trend in fiber
diameters; whereas PLCL fiber diameters decreased with increased TDF
concentration. The average fiber diameters for HFIP 15% PLGA 1%, 10%, and
20% TDF were 1.1 ± 0.3, 0.8 ± 0.3, and 1.1 ± 0.4 μm. For HFIP 12% PLCL 1%,
10%, 20% TDF fibers, the resulting fiber diameters were 1.1 ± 0.5, 0.9 ± 0.3, 0.7 ±
0.2 μm (Table 2.1). TDF-incorporated fibers electrospun with TFE solvent,
displayed a similar decrease in diameters to 1.2 ± 0.4 μm and 0.6 ± 0.2 μm, for
PLGA and PLCL respectively. All TDF fibers exhibited statistically significant
decreases in fiber diameter relative to blank PLGA (1.7 and 2.0 μm for HFIP and
TFE blank EF respectively) and PLCL (1.7 and 1.9 μm for HFIP and TFE blank EF
respectively) EFs. However, no statistical significance was observed between the
1, 10, and 20% TDF fiber formulations as a function of TDF incorporation. Thus,
TDF incorporation resulted in decreased fiber diameter relative to blank fibers;
whereas variation in the amount of TDF incorporation had no significant effect on
fiber diameter.
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Figure 2.3 Average diameters of electrospun fibers measured from SEM images,
using ImageJ. (A) Diameters of blank PLGA and PLCL fibers electrospun with
either HFIP or TFE solvents. Diameters ranged from 1.7 to 2.0 μm. Statistical
significance between fiber diameters was determined using one-way ANOVA with
Bonferroni post hoc test (p < 0.05, n=150, 3 images, 50 measurements per image).
No statistical significance was observed between fiber diameters prepared with
either HFIP or TFE. (B) Diameters of TDF EFs electrospun with HFIP were
significantly smaller than those of blank fibers, ranging from 0.7 to 1.2 μm. While
the PLGA TDF fiber diameters seemed randomly distributed, PLCL TDF fibers
demonstrated a trend of decreased diameter with increasing TDF concentration.
Statistical significance was observed between blank fibers and all TDF fiber
diameters; however, no statistical difference in diameters was observed between
the TDF EF formulations.
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Fiber Characterization: Loading, Encapsulation Efficiency, and Controlled
Release
To determine the loading of TDF in PLGA and PLCL fibers, different
concentrations of TDF (1, 10, and 20% w/w) were incorporated. The TDF, TFV,
and Viread standard curves, used to quantify TDF in fibers, maintained linearity
and similar peak intensities in both DMSO as well as SVF (Supplemental Figure
2.1). For all samples examined, TDF incorporated into fibers remained stable
against degradation or hydrolysis. Although TFV peaks were present in many
loading samples, they were either below the limit of quantification or comprised
less than 2% of TDF sample concentration. In addition to TFV peaks, a minor peak
eluting at 3.5 min was present in all samples and standards containing TDF. This
peak, dubbed “minor TDF” comprised an area that was 4% of the TDF peak area
(Supplemental Figure 2.1) and may be attributed to the monoester derivative of
TDF (mPTFV). This proportionality was observed in all loading samples as well as
controlled release samples collected during the first week of release. After 1 wk,
the proportion of mPTFV increased, reaching a 1:1 ratio with TDF in some samples
(data not shown). This increased ratio of mPTFV:TDF is attributed to the increased
exposure of fibers to aqueous solution at later time points, coupled with an overall
decrease in TDF release. The mPTFV concentration was quantified using the TDF
standard.
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Supplemental Figure 2.1 HPLC chromatogram of (A) a standard containing pure
TDF and TFV, (B) 20% PLGA TDF EF eluate, and (C) 20% PLCL TDF EF eluate.
(A) Standards containing both TFV and TDF were prepared to quantify TDF
incorporated into fibers. TDF peaks elute at 12 min while TFV elutes 2 min after
injection. For fiber samples, EFs were weighed and dissolved in DMSO and
analyzed. (B) 20% PLGA fibers and (C) 20% PLCL fibers exhibited peaks for TDF
while showing minimal hydrolysis products. The elution times were maintained
throughout the experiment.

89

Table 2.2 summarizes the total loading (μg TDF/mg fiber) and
encapsulation efficiency (EE) achieved for the various fiber formulations. Overall,
we observed that fibers electrospun with HFIP resulted in high EEs spanning 60–
89%. Furthermore, proportional increases in loading were observed based on the
amount of TDF added to PLGA and PLCL formulations. However, comparing
polymer formulations electrospun with different solvents, PLGA and PLCL fibers
electrospun with HFIP demonstrated higher loading and encapsulation efficiency,
relative to PLGA and PLCL fibers electrospun with TFE. Ten percent TDF fibers
electrospun with HFIP showed high encapsulation efficiencies spanning 76 to
89%, relative to fibers electrospun with TFE (∼60%). Considering the higher
polymer concentration required to fabricate well-delineated fibers with TFE (20%
for PLGA and PLCL vs. 12 and 15% for PLGA and PLCL, respectively) and the
lower EE, HFIP was selected to electrospin subsequent formulations.

90

Table 2.2 Quantification of TDF fiber loading and encapsulation efficiency. PLGA
and PLCL fibers electrospun with HFIP demonstrated higher loading and
encapsulation efficiency, relative to PLGA and PLCL fibers electrospun with TFE.
Increases in encapsulation efficiency were observed based on the amount of TDF
added to 10% TDF PLGA and PLCL formulations.
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After determining PLGA and PLCL fiber loading, we assessed the release
of TDF from PLGA and PLCL EFs in SVF for up to 4 weeks (Figure 2.4). Figure
2.4A demonstrates increased TDF release per mass of fiber, and corresponds with
increased incorporation of TDF in 1, 10, and 20% PLGA and PLCL fibers. While
both the 1% TDF PLGA and PLCL formulations exhibited release near the limit of
TDF detection, the cumulative release of TDF from the 10% and 20% PLCL fibers
resulted in 16 and 26 μg/mg (31 and 29% total release), while the PLGA fibers
averaged only 9.3 and 19.7 μg/mg (20 and 22% total release) within 1 h. Within
the first 24 h, the 10% and 20% formulations demonstrated a burst release, with
the amount of TDF release increasing with increased TDF incorporation. Overall,
the 10 and 20% PLGA fibers released up to 40% more TDF than PLCL fibers.
Although appreciable increases in release were only observed for approximately
72 h, PLGA fibers released more TDF than PLCL fibers for the 10 and 20% TDF
formulations. The 10% PLGA and PLCL fibers released 66 and 39% of their cargo,
respectively, while the 20% PLGA and PLCL fibers released 64 and 43% of their
cargo after 4 wk.
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Figure 2.4 Release profiles of TDF from 1, 10, and 20% TDF PLGA and PLCL
fibers in SVF. (A) Cumulative release of TDF per milligram of fiber (μg TDF/mg
fiber) and (B) as percent total loading over 4 wk. While PLCL fibers showed a
higher burst release after 1 h, PLGA fibers exhibited greater release, as early as
24 h, relative to PLCL fibers.
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In Vitro Efficacy of PLGA and PLCL Fibers against HIV-1 Infection
Short-Term Efficacy
To assess the antiviral activity of TDF PLGA and PLCL fibers, HIV-1
inhibition assays were performed using fiber eluates collected at different release
time points. Both short- and long-term release samples were collected to assess
efficacy. For short-term assessment of antiviral activity, 10 mg fibers were
incubated in 1 mL DMEM for 1 or 24 h. A histogram of the HIV-1 inhibition after
administration of the 1 h (Figure 2.5A) or 24 h fiber release eluates (Figure 2.5B)
is shown, and the corresponding IC50s are shown in Table 2.3. All 10 or 20% TDF
fibers (PLGA or PLCL) completely inhibited viral infection in TZM-bl cells down to
a 1:100 eluate dilution. For 1 and 24 h eluate dilutions exceeding 1:100, viral
inhibition was more pronounced after administration of the 24 h eluates, relative to
1 h eluates. The increased efficacy observed with 24 h eluates can be attributed
to the higher amount of TDF released within 24 h. However, for both time points,
the IC50s of both fibers were similar against in vitro infection (Table 2.3).
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Figure 2.5 PLGA and PLCL fiber eluates inhibit HIV-1 infection in vitro after 1 and
24 h, and 1 and 2 wk of release. Dilutions of release eluate from 10 mg/mL fiber
concentrations at different time points were normalized to untreated/infected cell
control RLUs to assess percent HIV-1 inhibition in vitro. Figures show the percent
of cells infected, after incubation with: (A) 1 and (B) 24 h release eluates from all
PLGA and PLCL EF formulations; (C) 1 and 2 wk release eluates from 20% TDF
PLGA and PLCL fibers; (D) 3 and 4 wk eluates from 20% TDF PLGA and PLCL
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fibers; compared to (E) free TDF (200 μg/mL) 1 and 2 wk eluate, and (F) blank
fiber eluates at each time point.
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Table 2.3 The IC50s of PLGA and PLCL fibers (against HIV-1) after administration
of the 1 and 24 h release eluates. The IC50s of PLGA and PLCL TDF 1 and 24 h
fiber eluates were similar to, or less than free TDF. Using one-way ANOVA with
Bonferroni post hoc test, no statistical significance was observed between the
IC50s of fiber eluates taken at the same time, there was a statistically significant
increase in the IC50s of all formulations after 24 h release (p < 0.05). Confidence
intervals of the IC50s are shown in parentheses.
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Overall, the antiviral activities of these eluate dilutions demonstrate that the
amount of TDF in the fiber corresponds with increased HIV-1 inhibition. For the 1%
TDF PLGA and PLCL fibers, 1 h undiluted eluates decreased infection to 27% and
10%, relative to untreated/infected controls. However, subsequent dilutions of the
1% TDF 1 h eluates yielded decreased protection against HIV-1 infection. In
contrast, after 24 h release, the 1% TDF PLGA and PLCL fibers completely
inhibited virus infection, with subsequent decreases in virus inhibition
corresponding with increased eluate dilution. Full infection resulted after
administration of the 1% PLGA and PLCL fibers at a dilution of 1:10 and 1:1000,
respectively for the 1 h eluates; and 1:1000 and 1:100 for the PLGA and PLCL 24
h eluates.
For the 10% TDF formulations, both PLGA and PLCL fibers exhibited
complete protection against HIV-1 down to 1:100 and 1:1000 eluate dilutions,
respectively after 1 h. After administration of the 24 h eluates, complete protection
was observed even after a 1:1000 dilution of each formulation. Subsequent
dilutions of PLGA eluates for 1 h and 24 h time points exhibited an increase in
infectivity (decrease in prevention) to 31% and 13% for 1:1000, and complete
infectivity for 1:10,000 dilutions, respectively. For PLCL, complete protection was
achieved with the 1:1000 eluate dilutions at both 1 and 24 h time points.
Additionally, these fibers showed efficacy even at eluate dilutions of 1:10,000; with
48% and 69% infectivity at 1 and 24 h. The corresponding IC50s for 10% TDF
PLGA and PLCL EFs were 2.4 and 3.1 ng/mL TDF after 1 h, and 7.2 and 7.4 ng/mL
after 24 h (Table 2.3).
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As expected, the 20% TDF fibers exhibited the highest efficacy against HIV1 infection per mass of fiber tested. Similar to the 10% TDF PLGA and PLCL EFs,
20% TDF fibers completely inhibited infection after a 1:1000 dilution, and exhibited
partial efficacy (58–100%) between 1:10,000 and 1:100,000 dilutions. The
corresponding IC50s for 20% TDF PLGA and PLCL EFs were 4.6 and 3.1 ng/mL
after 1 h release, and 5.1 and 1.9 ng/mL after 24 h release (Table 2.3). Despite
these small differences, the PLGA and PLCL TDF fibers were equally efficacious
at their respective time points (Table 2.3). While statistical analysis was performed
between each formulation and time point, no clear pattern emerged. There was no
statistical significance between any of the formulations after 1 h release, with the
exception of free TDF, which had a significantly higher IC50 than the TDF fiber
formulations. However, after 24 h there was marked decrease of the IC 50 of free
TDF (12.1 and 5.3 ng/mL at 1 and 24 h respectively) which resulted in no statistical
difference between free TDF and fibers. However, most of the IC 50s at 24 h
possessed statistical significant differences at that time point. Furthermore, the
IC50s at 24 h generally were larger than their 1 h counterparts, although this trend
was not seen in all formulations. Considering that all EF formulations possessed
similar IC50 to their free TDF counterparts, suggests that any formulation could be
used to provide short-term protection for 1 or 24 h.
Long-Term Efficacy
To assess the long-term efficacy of the fibers against HIV-1 infection in vitro,
eluates were collected from 10 mg of 20% TDF PLGA and PLCL fibers after 1, 2,
3, and 4 wk. Twenty percent TDF fibers were selected due to their greater
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encapsulation, release, and applicability to future dosing in vivo. The resulting HIV1 inhibition after administration of 1 and 2 wk fiber release eluates is shown in
Figure 2.5C and the corresponding IC50s are quantified in Table 2.4. After 1 and
2 wk, eluates from 10 mg/mL PLGA and PLCL EFs completely inhibited HIV-1
infection. However, only the 1 wk eluates completely inhibited HIV-1 infection, after
a 1:100 or 1:1000 dilution. Two week eluates demonstrated weaker activity,
showing only marginal protection (14% and 27%) at 1:10 dilutions of PLGA and
PLCL fiber eluates, respectively. The corresponding IC50s were 1.9 and 11.9
ng/mL for 1 wk PLGA and PLCL eluates and 10.2 and 72.3 μg/mL for 2 wk PLGA
and PLCL eluates. Free TDF controls showed a similar decrease in inhibition,
relative to their IC50s after 1 and 24 h exposure to media (12 and 5.2 ng/mL), to
4.5 and 4.9 μg/mL at 1 and 2 wk, suggesting the hydrolysis of free TDF into its
monoester derivative after prolonged exposure to media (Figure 2.5E, which has
been documented in similar studies56. Undiluted eluates from weeks 3 and 4
showed minimal protection against HIV-1 at the doses tested (Figure 2.5D). Blank
fiber eluates were tested as a negative control for inhibition (Figure 2.5F). The
decreased efficacy of TDF EFs against HIV-1 may be attributed to increased levels
of mPTFV within the solution, as well as decreased TDF release from the fiber.
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Table 2.4 The IC50s of PLGA and PLCL fibers (against HIV-1) after administration
of 1 and 2 wk release eluates. As exposure time to media increased, the efficacy
of TDF fibers decreased. However, both PLGA and PLCL fiber eluates were more
efficacious than free TDF after 1 wk exposure to media. Confidence intervals of
the IC50s are shown in parentheses.

101

As the incubation time increased, the level of protection seen from both TDF
EFs and free TDF decreased. Although 1 wk PLGA fiber eluates showed higher
efficacy (1.9 ng/mL), relative to PLCL (11.9 ng/mL), the IC50s were not statistically
significant. However, when compared to free TDF, the IC50s of both PLGA and
PLCL fibers demonstrated statistically significant increases in protection (p < 0.05,
Table 2.4). Furthermore, all IC50s of the 1 wk eluates were statistically significant
(p < 0.05) relative to the 1 h, 24 h, and 2 wk time points. Thus for applications
spanning one week, TDF fibers demonstrated prolonged activity, relative to free
TDF. Additionally, less PLGA fiber was needed, relative to PLCL, to release
therapeutically relevant amounts of TDF.
In Vitro Efficacy of PLGA and PLCL Fibers against HSV-2 Infection
To evaluate the potential of these fibers to inhibit HSV-2 infection, the
antiviral efficacy of the 20% TDF EFs was also assessed in HSV-2 plaque assays.
Similar to the HIV-1 infection assay, eluate from 5 mg/mL fibers at 1 and 24 h was
shown to completely inhibit viral plaque formation. Figure 2.6 illustrates the results
of 1 and 24 h eluate serial dilutions on infectivity. Both PLGA and PLCL fiber
eluates completely inhibited HSV-2 infection, and exhibited decreased protection
with increased dilution. Eluates from 24 h showed greater efficacy against HSV-2
infection due to the increased amount of released TDF.
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Figure 2.6 Both PLGA and PLCL fiber release eluates prevent HSV-2 infection in
vitro. Plaque assays were conducted to assess the efficacy of 20% TDF PLGA and
PLCL fiber eluates (5 mg/mL) against HSV-2 infection in vitro. Plaques were
counted and normalized to untreated/uninfected cells. Results demonstrate HSV2 efficacy attained with: (A) 1 and (B) 24 h fiber eluate dilutions.
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The IC50s of PLGA and PLCL TDF fibers were assessed using these eluate
dilutions. Table 2.5 shows that the IC50s of PLGA and PLCL 1 and 24 h eluates
were comparable to the IC50 of free TDF (8.9 μg/mL). The plaque assays showed
a trend of enhanced protection across dilutions provided by PLGA EFs after 1 and
24 h, compared with PLCL fibers. However, no statistical significance was
observed between formulations or compared to free TDF. Fiber eluates were also
collected to assess HSV-2 protection after 1, 2, and 3 wk. For these time points
and fiber concentration (5 mg/mL) tested, no virus inhibition was observed (data
not shown). Similar to the HIV-1 studies, both 20% EF formulations demonstrate
similar short-term protection compared with free TDF.
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Table 2.5 The IC50s of PLGA and PLCL fibers (against HSV-2) after administration
of the 1 and 24 hr release eluates. Plaque assays were performed to assess the
antiviral activity of 20% TDF fiber eluates against HSV-2 infection. Fiber eluates
from 1 and 24 hr showed similar activity, relative to free TDF. Confidence intervals
of the IC50s are shown in parentheses.
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In Vitro and EpiVaginal Cytotoxicity of PLGA and PLCL Fibers
To assess the potential of these fibers to safely interact with epithelial cells,
fiber cytotoxicity was assessed in VK2, Ect1, and End1 E6E7 cells, using the MTT
assay. As seen in Figure 2.7, high cell viability was maintained after administration
of TDF fibers for 24, 48, and 72 h. All cells demonstrated greater than 93, 91, and
96% cell viability at 24, 48, and 72 h respectively, for all formulations tested. In
addition to cell monolayers, EpiVaginal tissue viability after PLGA fiber application
was examined using the LDH cytotoxicity assay and H&E staining (Figure 2.8).
Due to the limited availability of EpiVaginal tissue samples, PLGA EFs were
selected for analysis due to their enhanced release profiles and therapeutic
potential, relative to PLCL fibers. PLGA EFs incorporating 20% TDF (5 and 50
mg/mL) were incubated 48 and 72 h with EpiVaginal tissue. Microscopic
examination of the untreated, blank PLGA EF-treated, and TDF PLGA EF-treated
tissues, revealed normal full thickness vaginal epithelium, while tissue treated with
0.2% non-oxynol 9 (N-9) exhibited severe degeneration of the epithelium (Figure
2.8A). No adverse histological findings were noted in EpiVaginal tissue treated
with PLGA or TDF PLGA EFs. Furthermore, tissue incubated with either 5 or 50
mg/mL fiber exhibited comparable viability in the LDH assay relative to untreated
tissue controls after 48 and 72 h (Figure 2.8B).
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Figure 2.7 Cytotoxicity assessed via MTT assay. Vaginal epithelial cell lines: (A)
Ect1 E6/E7, (B) VK2 E6/E7, (C) and End1 E6/E7, were incubated with blank or
20% TDF PLGA or PLCL fibers (10 mg/mL) for 24, 48, and 72 h. All cells
demonstrated greater than 93, 91, and 96% cell viability at 24, 48, and 72 h
respectively, for all formulations tested.
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Figure 2.8 EpiVaginal cytotoxicity was assessed via H&E staining (A) and LDH
assay (B). (A) H&E stained cross-sections of EpiVaginal VEC-100-FT tissues
following 3-day exposure to PLGA TDF fibers, relative to untreated and toxic
control (0.2% N-9) groups. Scale bar represents 200 μm. (B) Tissue viability (LDH)
measurements for EpiVaginal VEC-100-FT tissues following two or three day
exposure to PLGA TDF fibers, relative to untreated and toxic control (0.2% N-9)
groups.
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In parallel, cytokine production from EpiVaginal tissue was analyzed after
48 and 72 h of PLGA fiber administration. Cytokine expression, including GM-CSF,
IFN-γ, IL-1α, IL-1β, IL-6, IL-8, MCP-1 and TNF-α, was compared to untreated and
N-9 treated controls (Figure 2.9). After 48 h administration of TDF EFs, only GMCSF and IL-6 expression showed statically significant increase in expression
(approximately two-fold) compared with untreated tissue. After 72 h, only the 50
mg/mL TDF fibers showed a slight increase of GM-CSF and MCP-1 cytokine
expression (1.3-fold increase for both) relative to untreated tissue. Cytokine
expression from tissue samples exposed to blank fibers was comparable with
untreated samples at both time points, showing no statistical significance. In
contrast, EpiVaginal tissue exposed to N-9 for 48 h showed a marked decrease in
GM-CSF, IFN-γ, IL-6, MCP-1, and TNF-α (0.7, 0.1, 0.12, and 0.4 respectively)
while showing a slight increase of both IL-1α and β (1.7 and 1.2-fold increases,
respectively). After 72 h, the expression of all cytokines following N-9 treatment
was lower than observed in untreated samples, which is attributed to the loss of
the vaginal epithelium. The negligible increase in cytokine expression (0–2 fold
difference) from exposure of TDF EFs demonstrates promising preliminary safety
profiles of these fiber formulations69.
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Figure 2.9 Cytokine expression from EpiVaginal studies after (A) 48 and (B) 72 h
administration of fibers. TDF EFs elicited minimal cytokine expression relative to
untreated samples after 72 h. Positive N-9 treated samples failed to induce
cytokine expression due to epithelial cell death.
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Discussion
There is an urgent need for new topical PrEP technologies that can confer
the sustained-release of active agents, while providing discreet and convenient
protection against STIs. The emerging application of polymeric electrospun fibers
for intravaginal delivery offers the potential to fill this unique role. In these studies,
we evaluated two electrospun fiber delivery platforms, comprised of PLGA or PLCL
polymers, for their ability to release TDF, and protect against both HIV-1 and HSV2 infections in vitro. Here TDF served as a model antiretroviral drug, as it is only
one of two agents approved by the FDA to prevent HIV-1 infection. Furthermore,
TDF has demonstrated antiviral activity against both HIV-1 and HSV-2 in vivo,
establishing its versatility as a multipurpose active agent. The goal of this work was
to develop and characterize polymeric electrospun fibers to safely and efficaciously
provide protection against both HIV-1 and HSV-2 in vitro, as a potential
multipurpose prevention platform. For the doses tested in our studies, TDF PLGA
and PLCL fibers demonstrated equivalent protection, relative to free TDF, against
both HIV-1 and HSV-2 infections upon exposure to short-term (24 h) release
eluates. In addition, enhanced efficacy of TDF EFs compared with free TDF
against HIV-1 was demonstrated after exposure to release eluates taken through
2 wk. Moreover, this is the first time the safety of PLGA and PLCL TDF fibers has
been investigated in EpiVaginal tissue.
The first goal of this study was to determine the formulation of TDF PLGA
and PLCL fibers that resulted in the most cohesive and well-defined fiber macroand microstructures. During the fabrication of blank PLGA and PLCL fibers,
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several solvents were assessed (Figure 2.1). We observed that both HFIP and
TFE solvents yielded reproducible PLGA and PLCL fiber morphologies. These
solvents also enabled the incorporation of high weight percent polymer to solvent,
which is critical to incorporating high concentrations of active agents in polymers.
Using PLGA and PLCL fibers electrospun with HFIP as our baseline platforms, we
sought to evaluate the effect of TDF incorporation on fiber diameter (Figure 2.2,
Figure 2.3).
Fiber diameter has a critical role in the release properties of active agents.
Previous research has shown that decreasing fiber diameter can enhance the
release of active agents. This is attributed to the increased surface-to-volume ratio,
and decreased distance necessary for encapsulate diffusion 253,254. In our studies,
the incorporation of TDF resulted in decreased fiber diameters relative to blank
fibers (Figure 2.3). The diameters of blank fibers ranged from 1.7 to 2.0 μm;
whereas TDF fiber diameters ranged from 0.7 to 1.1 μm. Even for the lowest
concentration (1%) TDF fibers tested, a 50% decrease in fiber diameter was
observed. This decrease in fiber diameter may be attributed to the charge of the
active agent, and/or increased polymer jet instability resulting from these charge
effects. Correspondingly, this jet instability may result in the polymer traveling
longer distance/duration during the electrospinning process prior to reaching the
mandrel, promoting elongation and decreased fiber diameter 255,256. Thus,
incorporated active agents can affect the microstructural morphologies and
diameters of electrospun fibers.
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The incorporation of antiviral or biological agents has been shown to affect
fiber diameter in a number of ways. In previous studies, Tenofovir (TFV), a
compound less hydrophobic (solubility = 1.87 mg/mL) than TDF (the
phosphorylated fumaric salt form of TFV, used in this study 0.71 mg/mL 257,258, was
shown to slightly increase fiber diameter, though the differences were not
statistically significant166. In other studies, the incorporation of antivirals resulted in
the opposite effect on fiber diameter. Incorporation of TFV in polyvinyl alcohol
polymers resulted in slightly smaller diameters, attributed to the increased
instability described above242. Finally, some experiments show no change in fiber
diameter after active agent incorporation. Fibers comprised of the pH-responsive
CAP polymer, incorporating TDF, showed no change in fiber diameter relative to
blank fibers83. These studies highlight that a variety of parameters including solvent
choice, polymer selection, solvent-polymer/polymer-drug interactions, active agent
characteristics, and solvent viscosity all contribute to the microstructural properties
of electrospun fibers.
After obtaining well-defined and reproducible EFs, we next assessed the
loading of TDF in PLGA and PLCL fibers as a function of solvent type (HFIP vs.
TFE) used in the electrospinning process. From these loading studies (Table 2.2),
we observed that fibers electrospun with HFIP showed ∼30% higher encapsulation
efficiency, relative to fibers electrospun with TFE. Furthermore, higher polymer
concentrations were needed to obtain well-defined fiber microstructure, based on
solvent type (15 and 12% w/w for PLGA and PLCL in HFIP; 20% PLGA and PLCL
in TFE). Despite both HFIP and TFE sharing many characteristics such as high
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polarity and similar molecular structure, there are several key differences that may
impact fiber properties. As previously described87, TFE has a higher dielectric
constant (26.1 F/m) compared to HFIP (16.7 F/m)259. This increased charge
capacity may confer additional instability to TFE solvents during electrospinning,
requiring more polymer to produce well-defined fiber morphology260. Additionally,
this increase in dielectric constant may result in decreased TDF incorporation, and
even TDF localization on or near the fiber surface. HFIP also possesses a much
lower boiling point (58.2 °C) relative to TFE (73.6 °C)261,262. Solvents with lower
boiling points tend to produce more stable fiber morphology due to complete
evaporation during electrospinning; whereas less volatile (higher boiling point)
solvents may not fully evaporate from the polymer, causing beaded
morphologies76. These undesirable properties, in addition to the higher polymer
concentrations required

to

produce

TFE

fibers with

well-defined

fiber

microstructures and lower loading efficiencies, prompted us to fabricate
subsequent formulations with HFIP.
Controlled release studies using TDF EFs yielded several interesting results
(Figure 2.4). First, as expected with most polymeric delivery vehicles 263, PLGA
and PLCL formulations demonstrated a burst release of TDF during the first 24 h.
The exception was 1% TDF fibers, which released TDF quantities near our limit of
detection. While the 10% and 20% TDF PLCL fibers showed a higher burst release
relative to 10 and 20% PLGA fibers within the first hour, after 24 h, all PLGA
formulations released more TDF. While burst release is a common phenomenon
in polymer drug delivery263, here TDF surface localization may be exacerbated
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during the electrospinning process, due to charge effects between the incorporated
drug, polymers, and solvent. Solution instability during electrospinning due to these
charge effects, as well as hydrophilic interactions between the solvent and drug
can also result in agent localization near the fiber surface 256,264. In the case of
PLCL EFs, due to the increased hydrophobicity, more TDF may have accumulated
on the fiber surface, increasing burst release within the first 1 h. Another
observation in the release studies was that all PLGA fibers released higher
percentages of TDF compared to PLCL fibers, after ∼1 wk in SVF. We attribute
this increased TDF release to the hydrophilicity of PLGA, enabling enhanced
wettability of the fiber, resulting in increased diffusion of TDF from the fiber into the
surrounding eluate259,265.
Other studies using similar polymers yielded similar release results. In one
recent study, TFV (relative to TDF) was incorporated in PLGA and PCL polymers
and polymer blends, and controlled release was evaluated for 10 days 85. Similar
to our work, PLGA demonstrated greater overall release of drug while showing an
initial lower burst release. In contrast, PCL released all incorporated TFV after 24
h, while PLGA released only ∼20% of incorporated drug during this time. While
TDF was not extensively evaluated, similar burst release of TDF was also
observed with 20:80 PCL:PLGA fibers, a trend that differed from the prolonged
release observed from polymer blends that incorporated TFV 266. These studies
highlighted the effect that small molecular changes in drug design can have on the
release kinetics from polymeric delivery vehicles. Furthermore, several
formulations of PCL/PLGA blends were fabricated, demonstrating decreased burst
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release of TFV with increasing PLGA concentration29. We expect that in future
work, similar blends will prove favorable to tailor the release of TDF, despite its
increased lipophilicity.
Polymer hydrophobicity is another important consideration for providing
sustained-release. In another study relevant to microbicide delivery, the antiviral
compounds, MVC (Maraviroc) and AZT, were encapsulated in PCL, polyethylene
oxide (PEO), and poly-l-lactic acid (PLLA) polymer blends. Sustained-release from
70:30 PEO/PLLA blends showed almost complete release of hydrophilic
compounds after 1 h, due to the hydrophilicity and quick degradation of PEO. In
contrast, 30:70 PEO:PLLA blends exhibited lower burst release and higher
sustained-release relative to the more hydrophilic 70:30 PEO:PLLA blends.
Additionally, the moderately hydrophobic 30:70 PEO:PLLA fibers demonstrated
better release profiles relative to pure PCL fibers, which released around 95% of
incorporated drugs after 1 h. This more efficacious release profile was attributed
to the intermediate hydrophobicity and crystallinity of PLLA compared to PEO and
PCL86. Whereas the hydrophilicity of PEO confers quick degradation in aqueous
solutions, resulting in burst release; PCL is highly hydrophobic, causing
incorporated compounds to localize on the fiber surface, thereby significantly
contributing to high burst release. The results from these studies are in agreement
with our observations that polymers comprised of lactic and glycolic acid, relative
to the more hydrophobic PLCL (or PCL), exhibit less burst release of moderately
hydrophilic compounds. Moreover they emphasize the advantages of fabricating
blended formulation to tune release properties.
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After characterizing these fibers, TDF EFs were evaluated for their potential
to protect against HIV-1 and HSV-2 infections in vitro (Figure 2.5, Figure 2.6). In
these studies, TDF EF eluates collected for up to 2 wk, conferred protection
against HIV-1, particularly for the 10 and 20% formulations (Figure 2.5); whereas
HSV-2 inhibition was only achieved using the 1 and 24 h release eluates (Figure
2.6). The most evident factor that contributes to this lack of efficacy associated
with longer release times is the difference in TDF potency against HSV-2 and HIV1. While TDF is efficacious against both HSV-2 and HIV-1, TDF is much less
efficacious against HSV-2 (IC50 = 8.9 μg/mL) relative to HIV-1 (0.0053 μg/mL).
Based on the release profiles of the 20% TDF PLGA and PLCL polymers, we
expect that we would need approximately 15–20 mg fiber to provide 3–4 mg of
TDF release (over one month), and corresponding efficacy after 2 wk release. This
dose corresponds to previous studies indicating that concentrations ranging from
100 to 500 μg/mL are needed to completely prevent HSV-2 replication in vitro56.
These estimates are within the dosing we envision for in vivo studies, in which
similar studies have delivered a range of 0.2 to 0.7 mg/mL TDF per day within the
murine reproductive tract to prevent HIV-1/HSV-2 infections57,69.
In addition to the increased amount of TDF needed to prevent HSV-2
relative to HIV-1 infection, the duration of fiber exposure to eluate likely impacts
the potency of TDF released from the fibers. This is clearly observed in our efficacy
studies where the administration of 1 and 24 h TDF fiber eluates demonstrated
similar efficacy to free TDF; whereas, after 1 wk of release, TDF fiber eluates
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exhibited greater efficacy against HIV-1, relative to free TDF (Table 2.3, Table
2.4).
One factor that supports the improved IC50s of TDF fibers, relative to free
TDF with respect to time, is that TDF is known to hydrolyze to the monoester
derivative (mPTFV) in aqueous environments both in vitro and in vivo56,265,267,268.
While increasing the stability of active agents is a benefit of utilizing delivery
platforms such as fibers, we acknowledge that even TDF fiber eluate exhibited
decreased efficacy against HIV-1 after 1 to 2 wk in media (Table 2.4). HPLC
analysis showed that fiber-incorporated TDF was protected from hydrolysis, with
no indication of mPTFV accumulation for samples collected during the first week
of release. This lack of mPTFV measured in loading and early release samples
indicates that the monoester derivative was formed subsequent to fiber release,
and that EFs function as an appropriate delivery vehicle to provide drug stability in
solution. However, drug that is released and exposed to surrounding fluid for
longer durations (here > 1 wk), will be less efficacious. Additionally, for long-term
applications, lactic acid release may enhance TDF hydrolysis and contribute to the
decreased efficacy of TDF268. Thus, as expected, the longer an incorporated drug
remains within the polymer under physiological pH, the longer it will retain efficacy.
To modulate release in future work, utilization of a different polymer or polymer
blends may more optimally maintain active agent activity against HIV-1 and HSV2 for durations exceeding 1 to 2 weeks.
Finally, the safety of both TDF PLGA and PLCL fibers was assessed after
administration to vaginal and cervical cells, and to EpiVaginal tissue. In VK2, Ect1,
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and End1 E6E7 cells, all cell lines demonstrated strong viability after fiber
administration for 1 to 3 days (Figure 2.7). This is in agreement with our
expectations, given that the polymers have demonstrated biocompatibility and that
TDF is FDA-approved. Similarly, after 2 and 3 days exposure to blank or TDF
PLGA fibers, EpiVaginal tissue exhibited comparable viability relative to untreated
tissue controls. Furthermore, blank PLGA EF- and TDF PLGA EF-treated tissues,
revealed normal full thickness vaginal epithelium, with no apparent adverse
histological findings. Based on these in vitro results, we expect to see similar safety
profiles in in vivo studies.
Another critical aspect of intravaginal delivery is the assessment of
inflammatory response. Studies have shown that increased expression of
cytokines such as IL-6, IL-8, as well as IL-1α and β is strongly associated with
increased susceptibility to HIV-1 infection137,269. Nonoxynol-9, once a promising
microbicide candidate against HIV-1, was shown to increase the rate of HIV-1
infection in clinical studies due to its pro-inflammatory properties and disruption of
the reproductive epithelium270,271. Therefore, it is critical that any active agents or
delivery vehicles used as a microbicide must minimally induce pro-inflammatory
cytokines. For these experiments, PLGA was selected for examination due to the
polymer exhibiting both decreased burst release and longer sustained-release
properties relative to PLCL fibers. Despite analyzing a plethora of cytokines, TDF
EFs were found only to weakly induce (0–2 fold increase) the expression of GMCSF, IL-1α, and IL-6. This cytokine expression was not observed after 72 h, and
may have been the result of the actual application of EF onto the EpiVaginal
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tissue252. Finally, the nonoxynol-9 control showed a marked decrease of cytokine
expression after 72 h, which we attribute to epithelial necrosis and shedding.
Previous studies have shown that concentrations of N-9 as low as 0.03% can
induce epithelial disruption and necrosis after 24 h 272. However, no epithelial
disruption was observed from TDF EF exposure, indicating that these fibers are
non-inflammatory and will not elicit a cytokine response. As in previous studies
with microbicides, antiviral compounds may induce cytokine production as high as
3–10 fold, which is still considered reliably safe69.
While our preliminary work with EpiVaginal tissue demonstrates promising
biocompatibility, future mechanical testing with respect to the interactions between
the fibers, vaginal mucosa, and virus will need to be investigated in vivo.
Importantly, tissue contact studies will need to assess how mechanical properties
(e.g., flexibility, rigidity, size) impact host tissue interactions. Additionally, while we
envision that electrospun fibers may be administered similarly to vaginal films,
appropriate studies will need to assess the retention time and distribution of fibers
within the vaginal cavity and relate these to the structural properties and
mechanical durability after different durations of administration in vivo.
More broadly, the user preference and feasibility of different dosage forms
and administration methods must be considered for subsequent clinical
development. A variety of studies have highlighted the lack of correlation and
reporting of user adherence in clinical trials273,274. Hence, there is a need for more
accurate reporting and adherence, to fully achieve the prophylactic and/or
therapeutic potential of intravaginal delivery vehicles. In particular, if women
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experience user adherence challenges (resulting in unadministered doses), or feel
uncomfortable using the dosage form, lower adherence (and efficacy) may result.
Given these factors, women’s input is critical to the development of microbicide
dosage forms that women not only want to use, but are able to use correctly and
consistently275. Interestingly, recent work that investigated user preferences in
vaginal films (for more “on-demand” applications) identified factors ̶ such as the
opacity and size of films ̶ that most significantly impacted user preference276. As
we further develop electrospun fibers for intravaginal applications, we are aware
that addressing similar considerations will be necessary to ensure vehicle success
in subsequent development stages.
In parallel with these long-term goals of advancing fiber formulations for in
vivo studies and clinical applications, in the near-term our laboratory seeks to
improve the release profiles, and enhance the efficacy of our electrospun fibers
against multiple STIs. The use of different polymers or polymer blends will likely
reduce the initial burst release of incorporated products while simultaneously
providing for prolonged (> 1 wk) release. Additionally while these fibers were not
specifically formulated for mucoadhesion, surface-modification or a different
polymer choice/blend (e.g., chitosan, acrylic acid polymers) may be considered to
improve mucoadhesivity. Furthermore, the development of multilayered and
coaxially-spun fibers may also provide a more suitable platform for the delivery of
multiple compounds with sustained-release profiles.
Conclusion
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There is an urgent need to develop new and alternative sustained-release
technologies to prevent HIV-1 and HSV-2 infections. To address these needs, we
fabricated PLGA and PLCL electrospun fibers, and compared the loading and
release properties of these fibers, using TDF as a model antiviral. Both PLGA and
PLCL fibers provided complete protection against both HIV-1 and HSV-2 infections
in vitro. Both short- (1 and 24 h) and long-term release eluates (1 and 2 wk)
provided protection against HIV-1; whereas short-term protection (attributed to
fiber dosing and difference in IC50) was achieved against HSV-2 in vitro.
Additionally, TDF fibers demonstrated significantly enhanced efficacy against HIV1, relative to free TDF, after long-term release of 1 wk. Vaginal and cervical cells
exposed to TDF PLGA and PLCL fibers showed high viability, after up to 3 days
post-administration, demonstrating their safety in vitro. Finally, PLGA fibers
induced negligible and temporary increases (0–2 fold) in cytokine expression,
suggesting their potential for in vivo applications.
Comparing the attributes of PLGA and PLCL TDF EFs, PLGA appears to
be a more promising candidate compared to PLCL, based on its improved release
profile. However, as both formulations demonstrated efficacy against HIV-1 and
HSV-2 in vitro, future testing may reveal both fiber formulations to be equally
efficacious in vivo.
Using the information obtained from this work, we seek to further enhance
the efficacy and delivery duration of small molecule antivirals and biologics from
EFs by utilizing a variety of encapsulants and polymer blends. In particular, future
plans include fabricating formulations that co-deliver multiple active agents. Our
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hope is that these future fibers will provide more potent protection. We predict that
these, or similar electrospun fibers will confer long lasting and sustained protection
against both HIV-1 and HSV-2 infections.
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CHAPTER 3
PH-RESPONSIVE DELIVERY OF GRIFFITHSIN FROM ELECTROSPUN FIBERS
Introduction
Recently, polymeric electrospun fibers (EFs) have been investigated as a
new delivery platform for reproductive applications, demonstrating both ondemand

and

sustained

protection

against

HSV-2

and

HIV-1

infections75,84,86,87,101,161. However, one of the challenges of delivery vehicles,
including EFs, is that to provide adequate protection they must release
therapeutically relevant concentrations of active agents for the duration of use.
This often requires frequent administration and highly localized doses to maintain
adequate release for prolonged durations. While user adherence may be
increased by developing a product that necessitates less frequent application,
designing a dosage form that is efficacious regardless of administration time is
challenging. Many sustained-release formulations undergo a “burst” release
phase, where a significant fraction of active agent is released within the early hours
of delivery – regardless of whether this time frame is suitable for protection 38.
An alternative approach is to design a product that requires less frequent
dosing, by inducing the release of active agent only when needed, in response to
microenvironmental cues. This strategy has the potential to conserve active agent
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from unnecessary release, provide protection independently of administration
time, and deliver active agents directly to the target site of virus entry. One such
cue in the reproductive tract, increased pH, is associated with semen infiltration
peri- and post-coitus. While the “normal” vaginal pH ranges from 4.0 to 5.0,
exposure to semen (pH ∼ 7.5) increases the local pH to more neutral levels. We
expect a pH-responsive delivery vehicle that responds to increases in intravaginal
pH, will only release active agent when triggered by semen, while maintaining the
bioactivity and payload of encapsulated biologics under non-coital conditions.
While pH-responsive delivery has been used in a variety of drug delivery
applications79,263,277-281, thus far pH-responsive dosage forms are in the early
stages of development for delivery to the female reproductive tract (FRT) 83,280,282285.

Prior to the use of electrospun fibers for intravaginal applications, temperature

and pH sensitive hydrogels were developed to impart the dual advantages of
semen-triggered release and vaginal distribution and retention prior to
intercourse282. Hydrogels with pH-responsive properties have been shown to
release effective concentrations of antivirals. However, hydrogels tend to provide
more transient protection due to their propensity for leakage from the FRT.
Similarly, polymeric NP platforms comprised of poly(lactic-co-glycolic acid) (PLGA)
and S-100 Eudragit® blends were evaluated to provide pH-responsive release of
the antiretroviral reverse transcriptase inhibitors, tenofovir and TDF283. Increased
S-100 ratios resulted in decreased encapsulation efficiency, while conversely
providing improved pH-dependent release. Similar studies assessed the mucosal
delivery of pH-sensitive Eudragit S-100 NPs loaded with hydrophilic or
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hydrophobic molecules280, demonstrating retention of molecules within NPs under
acidic intravaginal pH and released upon exposure to more neutral pH conditions.
This study additionally demonstrated the uptake and biocompatibility of NPs in
vaginal cells280. Most recently, spray dried mucoadhesive and pH-responsive TFV
microspheres prepared from polymethacrylate salts were fabricated, resulting in
∼90% release within the first hour, while demonstrating biocompatibility and
mucoadhesivity to vaginal cells and porcine vaginal tissue284.
Relative to gel and NP delivery platforms, electrospun fibers have recently
emerged as an alternative intravaginal delivery platform that offer a durable
stationary reservoir of encapsulated agents. However, many of these studies have
focused on the delivery of antibiotics or ARVs, relative to new biologics280,283. One
of the first studies to investigate pH-responsive fibers for vaginal applications,
demonstrated that cellulose acetate phthalate (CAP) fibers highly incorporated the
reverse transcriptase inhibitors etravirine and TDF, and the hydrophilic dye
rhodamine83. The CAP polymer, itself a potent antiviral, is minimally soluble in
acidic conditions, and the addition of SSF rapidly dissolved the CAP fibers,
releasing the encapsulated drugs. While this quick degradation was attributed to
the natural (vs. synthetic) polymer chemistry, the fiber degradation raised concerns
over long-term structural integrity as well as corresponding protection, prompting
the development of fibers with improved mechanical properties. To address this
need, coaxial fibers, comprised of a polyurethane core and CAP shell layer, were
fabricated to provide pH-inducible release of rhodamine, while demonstrating
enhanced mechanical properties142. Finally, fibers comprised of Eudragit L-100
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encapsulating horseradish peroxidase and alkaline phosphatase were fabricated
using emulsion electrospinning286. These fibers modulated protein release in
response to pH, while preserving protein activity. In another study, pH-responsive
fibers comprised of poly(methacylic acid-co-methyl methacrylate), encapsulating
the ARVs, dapivirine and etravirine, were fabricated287. These fibers demonstrated
sustained-release of therapeutics within acidic conditions, while the fibers rapidly
dissolved in alkaline pH, to provide encapsulant release.
While a variety of pH-responsive platforms have demonstrated promise
against STIs, many of these platforms, inclusive of electrospun fibers, have
focused on the delivery of antibiotics or ARVs, relative to new biologics 150,153.
Recently, we and others have developed EFs as an efficacious platform to provide
sustained-delivery of antiviral drugs to the FRT75,84,86,87,101,161. Building upon this
work, the goal of this project was to develop and test pH-responsive EFs that
incorporate the antiviral lectin, GRFT. Griffithsin fibers were designed to address
the needs of an on-demand delivery system, while providing a delivery vehicle that
may reduce the frequency of daily administration. It is well known that poly(acrylic
acid) (PAA) has been used to fabricate a variety of pH-responsive dosage
forms288,289. Moreover, due to its carboxylic acid groups that are deprotonated
within acidic environments (here, vaginal), active agents are retained under slightly
acidic conditions. Conversely, in neutral and alkaline environments, the carboxylic
acid groups become ionized, inducing electrostatic repulsion, which results in fiber
swelling and agent release into the surrounding medium289. Additionally, PAA as
well as the polymer poly(n-butyl acrylate) (PBA) have been used to produce
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mucoadhesive

polymers,

demonstrated

in

buccal

delivery

and

other

applications290-295. Given these properties, we selected the copolymer, PBA-coPAA,

to

blend

with

known

sustained-release

polymers,

PLGA

and

methoxypolyethylene glycol (mPEG)-PLGA, to provide pH-dependent GRFT
release. We hypothesized that the encapsulated GRFT released from these pHresponsive fibers would retain antiviral properties relative to free GRFT and that
utilizing PBA-co-PAA fibers to deliver biological entry inhibitors, such as GRFT,
may prove useful to conserve the payload and activity of active agent when
needed.
Materials and Methods
Materials
Carboxyl-terminated poly(d, l-lactic-co-glycolic acid) (PLGA, 50:50, 0.55–
0.75 dL/g, 31–57 kDa MW) was purchased from LACTEL® Absorbable Polymers
(Cupertino, CA, USA). Methoxy poly(ethylene glycol)-b-poly(lactide-co-glycolide)
(mPEG-PLGA, 5,000:55,000 kDa) was obtained from PolySciTech® Akina Inc.
(West Lafayetter, IN, USA). Poly(n-butyl acrylate-co-acrylic acid) (PBA-co-PAA,
50:50, catalog number 19911-10), an alkali-soluble 20% latex in alcohol was
purchased from Polysciences Inc. (Warrington, PA, USA). Chemical solvents
including 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), dichloromethane (DCM), and
hydrochloric acid (HCl) were obtained from Fisher Scientific (Pittsburgh, PA, USA).
Sodium dodecyl sulfate (SDS) and MTT [3-(4,5-dimethylthiazol-2-yl)2,5diphenyltetrazolium bromide] were purchased from Sigma Aldrich (St Louis, MO).
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Griffithsin (MW 12.7 kDa) was produced by Kentucky BioProcessing LLC
(Owensboro, KY, USA) and was kindly provided by Dr. Kenneth Palmer (University
of Louisville). Fetal bovine serum (FBS) and 100× penicillin-streptomycin solutions
were purchased from VWR. Simulated vaginal fluid (SVF) and simulated semen
fluid (SSF) were prepared as described in246,296.
Cell Lines and Virus
Vaginal

keratinocyte

(VK2/E6E7),

endocervical

(End1/E6E7),

and

ectocervical (Ect1/E6E7) cell lines were used to assess fiber cytotoxicity (courtesy
of Dr. Kenneth Palmer, originally from ATCC, Rockville MD). VK2/E6E7 (VK2),
End1/E6E7 (End1), and Ect1/E6E7 (Ect1) are well-characterized immortalized cell
lines derived from normal human vaginal, endocervical, and ectocervical epithelia,
respectively. These cell lines were chosen as they are representative of the cell
types found within the female reproductive tract. VK2, End1, and Ect1 cells were
maintained in keratinocyte serum-free medium (KSFM) supplemented with
recombinant human epidermal growth factor (0.1 ng/mL), bovine pituitary extract
(50 μg/mL), calcium chloride (0.4 mM) (Thermo Fisher, Waltham, MA), with 1%
penicillin and streptomycin (100 μg/mL each). During cell trypsinization, plating,
and cell counting, cells were neutralized with Dulbecco’s Modified Eagle Medium:
Nutrient Mixture F-12 media (DMEM/F-12, 1:1, VWR) with 10% fetal bovine serum
(FBS), and 1% penicillin/streptomycin (100 μg/mL each).
TZM-bl cells, obtained from the National Institutes of Health AIDS Research
and Reference Reagent Program (ARRRP), were used to assess in vitro HIV-1
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infectivity. TZM-bl cells, previously designated JC53-bl (clone 13), are derived from
a HeLa cell clone engineered to express CD4, CCR5 and CXCR4. These cells
have a Tat-driven luciferase or E. coli β-galactosidase reporter system, under the
control of an HIV-1 long terminal repeat, permitting sensitive and accurate
measurements of infection247,248. TZM-bl cells were cultured in DMEM containing
10% FBS, 25 mM HEPES, and 50 μg/mL gentamicin. These cells are highly
permissive to infection by most strains of HIV-1, SIV and SHIV, including primary
or molecularly cloned viral isolates and molecularly cloned Env-pseudotyped
viruses.
The Env-pseudotype HIV-1 was produced in 293T/17 cells, using an
envelope (env)-expressing plasmid (CCR5-tropic clade A strain, Q769.h5) and an
env-deficient HIV-1 backbone vector (pNL4.3ΔEnv-Luc), both obtained from the
NIH AIDS Reagent Program (11884 and 3418). HEK-293T (human embryonic
kidney) cells were purchased from ATCC. Cells were maintained in MEM
supplemented with 10% FBS, and 1% penicillin and streptomycin (100 µg/mL
each).
Synthesis of Electrospun Fibers
Blank PLGA and mPEG-PLGA polymers (15% w/w) were dissolved in
0.6 mL HFIP overnight, while shaking at room temperature. Subsequent polymer
blends, comprised of varying PLGA:PBA-co-PAA polymer ratios (100:0, 90:10,
85:15, 80:20, and 75:25 w/w) were prepared as follows (Figure 3.1). Briefly, PLGA
polymers (15–30% w/w) were first dissolved in HFIP. Corresponding mass to mass
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ratios of PBA-co-PAA polymer were added to the PLGA polymer mixture and
allowed to solubilize overnight on a shaker at room temperature. Prior to
electrospinning, 140 μL of Tris-EDTA buffer (TE, pH = 7.4) was added to the
polymer solution and briefly vortexed.
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Figure 3.1 Schematic of mPEG-PLGA and PBA-co-PAA co-polymers and the fiber
fabrication process.
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For fibers incorporating GRFT, the GRFT stock solution was first
concentrated with a Spin-X® UF concentrator (10 kDa MWCO, Corning
Incorporated-Life Sciences, Oneonta, New York, USA) and resuspended to a
volume of 1 mL in TE buffer. For a 90:10 polymer blend, 144 mg of either PLGA or
mPEG-PLGA was weighed and added to 0.6 mL of HFIP. Immediately after, 80 µL
(16 mg) of PBA-co-PAA ethanol solution (20% w/v) was added to this mixture,
resulting in a polymer blend with a final concentration of 13.8% w/w
(polymer/solvent). After the polymers solubilized overnight, 140 μL (4.8 mg) of
GRFT solution (34.2 mg/mL) was added dropwise to the polymer mixture giving a
final electrospinning volume of 820 μL, with theoretical GRFT loading of 30 μg
GRFT/mg polymer. The solution was briefly vortexed and immediately
electrospun.
Five hundred microliters of PLGA:PBA-co-PAA and GRFT suspension was
aspirated into and electrospun from a 1 mL plastic syringe as previous
described87,161. Flow rates spanning (0.3–1.0 mL/h) were optimized over a range
of voltages (20–25 kV). The resulting fiber mat was collected on a rotating 4 mm
outer diameter stainless steel grounded mandrel located 10–20 cm from the
needle tip. All electrospinning processes were performed at room temperature (RT,
∼25 °C). Sample flow rate was monitored using an infusion pump (Fisher
Scientific, Pittsburgh, PA) while the voltage was applied using a high voltage power
supply (Spellman CZE 1000R). Final electrospinning conditions applied a voltage
of 25 kV, with a sample flow rate of 0.8 mL/h, with a distance of 20 cm, for the
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mPEG-PLGA:PBA-co-PAA 90:10 blend. After electrospinning, fibers were
removed from the mandrel and dried overnight in a desiccator.
Fiber Morphology
The morphologies of GRFT PLGA:PBA-co-PAA and mPEG-PLGA:PBA-coPAA blended fibers were evaluated using scanning electron microscopy (SEM)
(JSM-820 microscope, JEOL, Tokyo, Japan). Briefly, after drying, fibers were cut
into 5 mm pieces and placed on double-sided adhesive carbon tabs (Ted Pella,
Inc., Redding, CA, USA), which were then adhered to aluminum stubs. Samples
were coated with a thin gold alloy film using a Bio-Rad E5100 sputter coat system.
The coating process was operated at 20 mA for 90 s and images were captured at
an accelerating voltage of 8 kV. The average fiber diameter was determined by
analyzing SEM images in NIH ImageJ, and drawing line elements across a
minimum of 50 fibers per image. Statistical significance between fiber diameters
was determined using the Bonferroni post hoc t-test (p < 0.05).
Griffithsin Loading and Release
The amount of GRFT incorporated into each fiber was determined by
dissolving of 3–5 mg fiber pieces in 500 μL DCM, and adding 500 μL TE buffer to
extract GRFT. This extraction process was repeated twice by vortexing for 1 min
and centrifuging for 5 min at 13,000 rpm to fully extract GRFT. The TE buffer was
collected and analyzed using ELISA to determine GRFT loading. The
encapsulation efficiency (EE) was defined as the ratio of actual GRFT loading to
the theoretical loading (30 μg/mg).
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To quantify GRFT release from pH-responsive fibers under different in vitro
conditions, SVF (pH = 4.4), phosphate buffered saline (PBS, pH = 7.4), and
SVF:SSF (1:3, v/v, pH = 7.4) were used as eluates. The SVF:SSF mixture was
used to measure inducible GRFT release after exposure to semen-vaginal fluid
mixture296. Samples of GRFT PLGA:PBA-co-PAA and mPEG-PLGA:PBA-co-PAA
fibers were hole-punched with a Ribbel biopsy punch (7 mm diameter), resulting
in an approximate fiber mass of 10 mg. These fibers were immersed in 1 mL SVF
or PBS, in a shaker at 37 °C and 150 rpm. At pre-determined time points, the
release buffer was completely replaced with 1 mL of either fresh SVF or PBS. In
subsequent pH-dependent release studies, fibers were incubated in SVF for 24,
48, or 72 h. To create a pH “switch”, the SVF was replaced with either PBS or (1:3)
SVF:SSF to assess differences in GRFT release after a pH change. Fiber eluates
were collected and replaced at 1, 4, 24, 48, 72, 96, and 120 h after the initial PBS
or SVF:SSF “switch.”
The concentration of GRFT released was determined using an established
ELISA method. Briefly, Nunc Maxisorp ELISA plates were coated with 0.9 mg/mL
influenza virus hemagglutinin (diluted in 0.1 M PBS) overnight at 4 °C for use as a
coating buffer, which GRFT selectively binds to. The plate was washed three times
with PBS containing 0.05% Tween-20 (PBST) using an Immunowash plate washer
(Bio-Rad, Hercules, CA, USA). The wells were blocked by adding 3% (w/v) bovine
serum albumin in PBST at room temperature (RT) for 2–3 h to block non-specific
binding. A GRFT standard, loading extract and release eluates were added to the
wells for 1 h at room temperature. A 1:10,000 dilution of both a primary antibody
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goat anti-GRFT (provided by Dr. Nobuyuki Matoba, University of Louisville) and
secondary antibody rabbit anti-goat IgG-HRP (Sigma-Aldrich, St. Louis, MO, USA)
were added to the wells for another 1 h to detect bound GRFT. Colorimetric values
were derived using SureBlue Reserve TMB Peroxidase substrate (KPL,
Gaithersburg, MD, USA), and the reactions were stopped by 1 N H2SO4.
Absorbance was measured at 450 nm on a Synergy HT reader (BioTek, Winooski,
VT, USA). Results are shown as the cumulative amount of GRFT released per
mass fiber (μg/mg) and the cumulative release percentage, as a function of release
time. The encapsulation efficiency (EE) was defined as the ratio of actual GRFT
loading to the theoretical loading (30 μg/mg). All data are shown as the
mean ± standard deviation. All experiments were conducted in triplicate, with a
minimum of three independent experiments, unless otherwise noted.
Nuclear Magnetic Resonance Spectroscopy
For the quantification of the polymer composition, mPEG-PLGA, PLGA-coPAA, empty-fiber, and GRFT-loaded fiber were dissolved with fully deuterated
dimethyl sulfoxide for Nuclear magnetic resonance (NMR) spectroscopy. NMR
spectra of all the samples were obtained at a temperature of 298 K using a
600 MHz proton frequency spectrometer equipped with a triple resonance prodigy
probe (Bruker, Billerica, MA, USA). All the spectra were acquired with 2048
complex points and 4 number of scans and processed using TOPSPIN. Based on
the chemical structures of mPEG-PLGA and PBA-co-PAA, peaks in the spectra of
mPEG-PLGA and PBA-co-PAA were assigned to individual proton resonances.
These assignments were consequently used to identify resonances in the fiber
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spectra. Although severe overlapped resonances from mPEG moiety in mPEGPLGA and aliphatic moiety in PBA-co-PAA in the fiber spectra were observed,
protons attached to carbons of lactic and glycolic moieties in mPEG-PLGA and
proton in hydroxyl group in PBA-co-PAA could be unambiguously assigned to the
resonances at ∼5.0, ∼5.5, and ∼8.0 ppm, respectively (Supplemental Figure
3.1). After the assignments, the relative composition of moieties in mPEG-PLGA
were determined using integration of resonances in each spectrum and the
determined number of chains for lactic and glycolic moieties in mPEG-PLGA were
∼34 and ∼54, respectively and the chain number of acrylic acid in PBA-co-PAA
was ∼34. The relative ratio of mPEG-PLGA and PBA-co-PAA in the fiber were
determined as 1:0.1 using the integration of the peaks at ∼ 5.0, ∼5.5, and
∼8.0 ppm in the spectra of fibers (Supplemental Figure 3.1). Additional to the
resonances from the fiber, GRFT resonances were observed only in the GRFTloaded fiber (Supplemental Figure 3.1) that confirms that GRFT is incorporated
into the fiber using our protocol.

137

Supplemental Figure 3.1 NMR Spectrograph of GRFT Fibers.
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HIV-1 Pseudovirus-Based Neutralization Assay
The antiviral activity of GRFT loading extract and fiber release eluates was
measured relative to free GRFT, as a function of reduction in luciferase reporter
gene expression after a single round of infection with Env-pseudotyped virus
(CCR5-using clade A strain Q769.h5) in TZM-bl cells. The optimal virus dilution
was established to yield ≥ 100,000 relative luminescence units (RLU) after
infection. Assay stocks of molecularly cloned Env-pseudotyped viruses were
prepared by transfection of 293T cells and were titrated in TZM-bl cells as
previously described297. Briefly, all samples were diluted using serial dilutions
(ranging from no dilution to 1:10,000 with PBS to a final volume of 50 μL within a
96-well plate. One hundred microliters of TZM-bl cell solution (104 cells in DMEM
medium with 10 μg/mL DEAE-dextran) was subsequently added to each well,
followed by the addition 50 μL of HIV-1 pseudovirus virus dilution. Samples were
then incubated at 37 °C for 48 h. After the 48 h incubation, 100 µL culture medium
was carefully removed from each well. Luminescence was measured using the
Bright-Glo™ luciferase assay system (Promega Corporation, Madison, WI, USA)
by adding 100 µL Bright-Glo™ reagent solution to each well for 5 min. Plates were
read via luminescence by the Synergy HT reader (BioTek, Winooski, VT, USA). All
RLU values were corrected by subtracting the RLU of untreated/uninfected cells
from the sample RLUs (treated infected cells). The percent virus inhibition was
determined by normalizing the corrected RLUs of infected/treated cells to
corrected untreated/infected cells: % Infection = [(sample RLU − untreated
uninfected cells) ÷ (untreated infected cells –untreated uninfected cells)] × 100%.
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Antiviral activity is reported as the sample concentration at which RLUs compared
with virus control wells RLUs.
In Vitro Cytotoxicity
The in vitro cytotoxicity of mPEG-PLGA:PBA-co-PAA (90:10), relative to
free GRFT was evaluated in VK2, Ect1, and End1 cells using a colorimetric MTT
assay. Briefly, each cell line was seeded into 12-well plate at a density of 600,000
cells per well. Eluates from 1 and 10 mg GRFT mPEG-PLGA:PBA-co-PAA fibers,
suspended in 1 mL of media were incubated with the cells for 24, 48, and 72 h.
After each time point, 100 μL MTT solution (5 mg/mL) was added to each well
followed by incubation for 4 h at 37 °C. Lysis buffer (550 µL, 10% SDS in 0.01 M
HCl) was then added to each well for and incubated for 16 h. Absorbance readings
were performed at 570 nm. Ten percent DMSO was used as the positive control
for cytotoxicity, with blank fibers eluate-treated and untreated cells as negative
controls. All data are shown as the mean ± standard deviation.
Results
Fiber Morphology
The morphology and microstructure of PLGA and mPEG-PLGA fibers were
assessed with scanning electron microscopy (Figure 3.2). In addition, the
morphology of PLGA and PBA-co-PAA polymer fibers with blend ratios of: 100:0,
90:10, 85:15, 80:20 and 75:25 and mPEG-PLGA:PBA-co-PAA (90:10) fibers were
evaluated (Figure 3.3). As shown in Figure 3.2 and Figure 3.3, all formulations
provided well-defined fiber morphologies. The fiber diameters of the different
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polymer blends tested for pH-responsive release were assessed using ImageJ
software (NIH) (Table 3.1). The fiber diameters of the PLGA:PBA-co-PAA and
mPEG-PLGA:PBA-co-PAA (90:10) blends ranged from 204 to 407 nm. As the
initial PBA-co-PAA ratio increased, the average fiber diameter decreased;
however, only the 75:25 PLGA blend exhibited a statistically significant difference
relative to the other PLGA blends. There was no evident relationship between
polymer type, PBA-co-PAA ratio, and fiber diameter.
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Figure 3.2 SEM images of (A) PLGA and (B) mPEG-PLGA electrospun polymer
fibers that incorporate GRFT. The scale bar represents 2 μm.
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Figure 3.3 SEM images of different pH-responsive electrospun fiber blends that
incorporate GRFT. (A) PLGA:PBA-co-PAA (100:0, w/w); (B) PLGA:PBA-co-PAA
(90:10); (C) PLGA:PBA-co-PAA (85:15); (D) PLGA:PBA-co-PAA (80:20); (E)
PLGA: PBA-co-PAA (75:25); and (F) mPEG-PLGA:PBA-co-PAA (90:10). The
scale bar represents 2 μm.
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Table 3.1 pH-responsive fiber diameters measured from SEM images.
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Griffithsin Fiber Loading and Release Characterization
To determine the impact of polymer blend ratio on GRFT loading, the
extracts from 100:0, 90:10, 85:15, 80:20 and 75:25 PLGA:PBA-co-PAA and 90:10
mPEG-PLGA:PBA-co-PAA polymer blends were evaluated using an ELISA. Table
3.2 compares the actual amount of GRFT incorporated per milligram of fiber, to
the theoretical loading of 30 μg/mg. The encapsulation efficiency of active GRFT
in PLGA-only (100:0) EFs, measured via ELISA was over 90%, indicating the high
loading potential of these fibers. The 90:10, 85:15, 80:20 and 75:25 PLGA:PBAco-PAA blends exhibited GRFT encapsulation efficiencies of 62, 53, 51, and 80%,
respectively, while the 90:10 mPEG-PLGA:PBA-co-PAA fibers demonstrated 54%
loading efficiency. Similarly high GRFT loading was attained for both the PLGAonly and the 75:25 polymer blend, while GRFT loading of the other formulations
was statistically lower. Although statistical significance was observed between the
encapsulation efficiencies of different fiber formulations, there was no correlation
between GRFT loading and increased PBA-co-PAA ratio.
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Table 3.2 GRFT loading and encapsulation efficiency based on formulation.
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To initially assess the ability of fibers to release GRFT under different pH
conditions, the total cumulative release of GRFT from PLGA and mPEG-PLGA
fibers was measured during 72 h incubation in SVF (pH 4.4) or PBS (pH 7.4).
Although PLGA EFs demonstrated high GRFT encapsulation, negligible GRFT
release was observed from PLGA-only fibers in either SVF or PBS (Figure 3.4).
However, GRFT release from mPEG-PLGA fibers in SVF and PBS exhibited burst
release within the first 6 h (∼33 and 45% of total GRFT loading, respectively),
followed by minimal sustained-release during the remaining incubation period
(Figure 4.4). Based on these results, alternative polymer formulations were
investigated to improve GRFT release.
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Figure 3.4 In vitro release profiles of GRFT from mPEG-PLGA fibers. Negligible
GRFT release was detected from PLGA-only fibers (data not shown, release
coincides with x-axis). Cumulative release data is shown as a function of percent
total loading (solid circles) and mass released per mass of fiber (open squares).
Fibers were incubated in either SVF (solid lines) or PBS (dashed lines) for 72 h at
37 °C. Data are expressed as the mean ± SD of triplicate samples.
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In comparison to these initial release studies with PLGA and mPEG-PLGA
fibers, it was observed that blending PLGA with a pH-responsive polymer, PBAco-PAA, both enabled the formation of well-delineated fibers (Figure 4.3), and
provided enhanced GRFT release in PBS, relative to PLGA- or mPEG-PLGA-only
fibers (Figure 3.5). To mimic the more basic pH conditions of semen entry for pHresponsive applications, EFs were incubated in SVF for 24 h, and subsequently
“switched” to PBS (Figure 3.5). The same fiber formulations were also incubated
in PBS alone as a control. While unblended PLGA-only fibers (100:0) released
minimal amounts of GRFT, polymer blends containing increased PBA-co-PAA
(10–25% w/w), released more GRFT within the first 24 h in either PBS or SVF. Of
these blends, only the 90:10 PLGA:PBA-co-PAA blend exhibited increased GRFT
release in PBS only (relative to SVF), indicating its potential for pH-responsive
applications. In contrast, blends with increased PBA-co-PAA ratios (15, 20, and
25%) released GRFT in both PBS as well as SVF, deeming them less discerning
for a pH-responsive delivery platform.
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Figure 3.5 In vitro pH-responsive release profiles of GRFT from different
PLGA:PBA-co-PAA blended fiber formulations, each theoretically loaded with
30 μg GRFT/mg polymer. The cumulative release of GRFT from: (A) PLGA:PBAco-PAA (100:0, w/w); (B) PLGA:PBA-co-PAA (90:10); (C) PLGA:PBA-co-PAA
(85:15); (D) PLGA:PBA-co-PAA (80:20); and (E) PLGA: PBA-co-PAA (75:25) were
monitored at 37 °C. Fibers were initially incubated in SVF (pH = 4.5) for 24 h and
switched to PBS (pH = 7.4) for an additional 24 h. Release in PBS (pH 7.4) is
shown (without a switch) for comparison. A summary of GRFT release from all
blends in PBS is provided in (F). As the ratio of PLGA decreases, the cumulative
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amount of GRFT release increases. Release data are expressed as the mean ± SD
of triplicate samples.
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Based on these release results (Figure 3.4, Figure 3.5), it was
hypothesized that incorporating the properties of the 90:10 PLGA:PBA-co-PAA
blend with the increased hydrophilicity of mPEG-PLGA, may increase GRFT
release in more neutral conditions due to increased hydrophilicity, while retaining
GRFT loading at low intravaginal pH (e.g., SVF). To evaluate this, mPEGPLGA:PBA-co-PAA (90:10) fibers were formulated and incubated in SVF for either
24, 48, and 72 h. After 24, 48, and 72 h, the fibers were “switched” to PBS (Figure
3.6A) or simulated vaginal-semen fluid (SVF:SSF (1:3) w/w, pH 7.4)) (Figure
3.6B). The mPEG-PLGA:PBA-co-PAA blend provided negligible release of GRFT
in SVF after 24, 48, and 72 h, releasing only 0.27, 0.41, and 0.47 μg/mg GRFT
respectively. However, when switched to PBS, the blend exhibited a nearly thirtyfold increase in GRFT release, releasing 10–12 μg/mg (66–74%) over a
subsequent 120 h (Figure 3.6A). Moreover, within the first hour post-switch, the
fibers that were incubated for 24, 48, and 72 h in SVF released 6.2, 3.5, and 4.2 μg
GRFT/mg fiber, respectively. Similar release was observed when fibers were
switched from SVF to a more representative intravaginal environment of SVF:SSF
(1:3), with 1.3, 1.3, and 1.4 μg GRFT/mg fiber release 1 h post-switch from the 24,
48, and 72 h SVF incubations, respectively (Figure 3.6B). Overall, GRFT release
from fibers switched to SVF:SSF showed a lesser and more gradual release curve
relative to fibers switched to PBS. While fibers switched to PBS released
approximately 11 μg GRFT/mg fiber 24 h post-switch, fibers switched to SVF:SSF
released ∼5 μg GRFT/mg fiber within the same duration. Moreover, the PBS
switched fibers exhibited minimal release after 24 h, while the SVF:SSF switched
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fibers continued to release, resulting in a total of ∼7 μg GRFT released per mg
fiber, 72 h post-switch.
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Figure 3.6 In vitro pH-responsive release profiles of GRFT from mPEGPLGA:PBA-co-PAA (90:10, w/w) fibers. The cumulative release of GRFT is shown
as a function of mass released (A, C) and percent total loading (B, D). Fibers were
incubated in SVF for 24, 48, or 72 h. The media was subsequently “switched” to
(A, B) PBS or (C, D) SVF:SSF (1:3) mixture, and fibers were incubated for an
additional 72 h. Release values are expressed as the mean ± SD of triplicate
samples.
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HIV-1 Inhibition Studies
Based on the release results, mPEG-PLGA:PBA-co-PAA (90:10) GRFT
fibers were evaluated to provide pH-dependent protection against HIV-1 infection
in vitro. First, the activity of GRFT, extracted from electrospun fibers, was assessed
to determine whether GRFT is inactivated during electrospinning. Previous studies
have shown that harsh solvents and electric field used during the electrospinning
process may denature protein and decrease biologic activity 298,299. Therefore, the
inhibitory potential of extracted, relative to free GRFT, was tested against HIV-1
infection. Similar antiviral activity was observed between free GRFT and GRFT
extracted from mPEG-PLGA:PBA-co-PAA (90:10) fibers (Figure 3.7). Complete
protection against HIV-1 infection was achieved from undiluted fiber extracts (IC50
10.6 ng/mL) and free GRFT (15.5 ng/mL), with a dose-dependent decrease in
protection observed for both fiber extract and free GRFT dilutions.
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Figure 3.7 HIV-1 inhibition assays were conducted to assess the functional activity
of extracted GRFT after electrospinning into fibers, relative to free GRFT. GRFT
extracted from mPEG-PLGA:PBA-co-PAA (90:10) fibers demonstrates complete
efficacy against HIV-1 infection, and similar efficacy to free GRFT. The percent of
HIV-1 infected cells, relative to untreated cells, is shown as the mean ± SD of
triplicate samples, as a function of (A) eluate dilution or (B) GRFT concentration.
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To assess the inhibitory activity of GRFT fibers after an induced pH change,
mPEG-PLGA:PBA-co-PAA (90:10) fibers were incubated in SVF for either 24, 48,
or 72 h, followed by a switch to PBS or SVF:SSF, for an additional hour. After 1 h,
the eluates were collected and assessed in HIV-1 inhibition assays. As seen in
Figure 3.8A and B, despite different initial incubation periods in SVF (24, 48, or
72 h), GRFT maintained bioactivity and completely inhibited HIV-1 infection after
exposure to PBS. The IC50s for the 1 h PBS release eluates, after an initial 24, 48,
and 72 h in SVF were 28.3, 29.6 and, 23.5 ng/mL respectively. Similarly, complete
inhibition of HIV-1 infection was achieved from mPEG-PLGA:PBA-co-PAA fibers
that were switched to a more physiologically relevant environment of SVF:SSF
after the same durations (24, 48, 72 h) (Figure 4.8C and D). The IC50 values from
1 h post-switch SVF:SSF release eluates, were 23.2, 23.7, and 21.3 ng/mL
respectively. The IC50s of both PBS and SVF:SSF 1 h post-switch release eluates
were not statistically different, demonstrating that GRFT maintains bioactivity
regardless of incubation time.
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Figure 3.8 HIV-1 inhibition assays were conducted to assess the antiviral activity
of GRFT mPEG-PLGA:PBA-co-PAA (90:10) fiber release eluates against HIV-1
infection. GRFT mPEG-PLGA:PBA-co-PAA fibers were incubated in SVF for 24,
48, or 72 h. (A) After each time point, SVF was “switched” to PBS, and serial
dilutions of fiber eluates were collected to assess antiviral efficacy after 1 h in PBS.
(B) The percent of HIV-1 infected cells, relative to untreated cells, is shown as the
mean ± SD of triplicate samples. (C and D) The study was repeated with fibers
“switched” from SVF to SVF:SSF (1:3). The serial dilutions of GRFT release
eluates were evaluated against HIV-1 and IC50 values were calculated.
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In Vitro Safety
To determine the biocompatibility of pH-sensitive GRFT EFs, vaginal epithelial cell
lines: VK2, Ect1, and End1 E6/E7 were incubated with 1 and 10 mg/mL fibers in
vitro. As shown in Figure 3.9, all cell lines demonstrated greater than 95% cell
viability after 24, 48, and 72 h fiber administration, relative to untreated and DMSOtreated cells. There were no statistically significant differences noted in cell
viability, as a function of cell line or administration duration.
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Figure 3.9 In vitro safety evaluation of mPEG-PLGA:PBA-co-PAA (90:10) fibers
on cervicovaginal cell viability. (A) Ectocervical (Ect1/E6E7), (B) endocervical
(End1/E6E7), (C) and vaginal (VK2/E6E7) epithelial cells were incubated with
GRFT mPEG-PLGA:PBA-co-PAA fibers (1 and 10 mg/mL) for 24, 48, and 72 h and
assessed for cytotoxicity using the MTT assay. All cells had greater than 90%
viability, relative to untreated positive controls. Cell viability is expressed as the
mean ± SD of triplicate samples.
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Discussion
While previous work has demonstrated the potential to provide pHresponsive release of traditional antivirals, here we present a method to induce the
pH-responsive release of the antiviral lectin, GRFT. Griffithsin is a promising new
biologic for use against HIV-1, HSV-2, human papillomavirus, and a variety of other
viruses, due to its potent binding and antiviral activity61,62,71,300,301. Additionally,
GRFT has demonstrated stability and safety, prompting its development in clinical
trials. As such, we hypothesized that the incorporation of GRFT within an
electrospun fiber may provide an effective antiviral delivery vehicle to satisfy the
on-demand needs of virus entry inhibition. In this work we demonstrate that these
fibers provide pH-inducible release of GRFT while preserving GRFT activity and
payload for up to 3 days, prior to exposure to PBS or SVF:SSF solutions.
In our initial studies, fibers comprised of either PLGA or mPEG-PLGA
polymers were fabricated to provide sustained-release of GRFT. Based on the
biocompatibility of PLGA and its previous utilization in sustained-release
applications78, it was reasoned that similar sustained-release of GRFT may be
achieved. However, GRFT release from PLGA fibers was minimal, and
substantially below prophylactic needs, beyond 6 h application. We hypothesized
that the diminished release of GRFT from PLGA fibers may be attributed to the
isoelectric point of GRFT (pI = 5.4), facilitating GRFT adhesion to, or hydrophobic
interactions with, the negatively-charged PLGA polymer. In contrast, GRFT
release increased from the slightly more hydrophilic mPEG-PLGA fibers. Despite
slightly improved initial release, mPEG-PLGA fibers exhibited sub-optimal release
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at later time points, highlighting the need for an improved formulation that retains
GRFT under relevant intravaginal conditions, yet releases GRFT in response to
coital cues.
In combination with the challenges of obtaining sustained-release, one of
the issues with any sustained-release system, is that cargo is released under
temporal conditions that may not prophylactically (or therapeutically) necessitate
release. For more expensive and labile biologics, conventional sustained-release
platforms (not triggered by stimuli) may be inefficient to deliver active agent,
particularly an entry inhibitor like GRFT that should be present in high
concentration, to protect against virus entry and exposure. Moreover, from an
economic perspective, the premature release of biological molecules that have
shorter half-lives or are more expensive to produce may adversely impact overall
cost and feasibility. Given these considerations, we sought to develop a vehicle
that retains GRFT, and only releases GRFT upon exposure to the more neutral pH
conditions of semen infiltration. We hypothesized that this would be a desirable
option, given the role of GRFT as an entry inhibitor.
To test the pH-responsive properties, 100:0, 90:10, 85:15, 80:20, and 72:25
of PLGA:PBA-co-PAA GRFT fibers were evaluated. Increases in the length of
hydrophobic alkyl groups on acrylic acid, often result in increases in pKa, affecting
the pH of polymer switch302. In addition, pendant acidic groups are typically ionized
at a pH dependent on pKa, in neutral and alkaline solutions, and their induced
repulsion affects the physical properties of the polymer. Thus, the ionizable
carboxylic acid groups in both PBA and PAA increase solubility at neutral/basic
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pH288. In our studies, it was observed that increased ratios of PBA-co-PAA resulted
in increased GRFT release after exposure to PBS and SVF:SSF solutions. We
expect this trend is due in part to fiber swelling upon exposure to neutral PBS and
SVF:SSF solutions. We additionally observed that even small increases in the ratio
of PBA-co-PAA, relative to PLGA, resulted in increased release under both neutral
and acidic conditions. In fact, increased GRFT release corresponded with
increased ratio of PBA-co-PAA under acidic conditions, which was undesirable for
a pH-responsive application. The pKa values of PBA (7.4) and PAA (4.28), indicate
that the amount of PBA is driving this release, in both neutral (PBS, SVF:SSF) and
acidic (SVF) conditions. Of these selected formulations, the 90:10 blend exhibited
the most desirable pH-dependent release profile, and release in PBS and
SVF:SSF was improved by utilizing the more hydrophilic mPEG-PLGA fibers.
In addition to the pH-responsive properties imparted by PBA-co-PAA, PLGA
provides a biocompatible polymer that lends mechanical stability for use in
implants78. Moreover, it is well known that PLGA fibers specifically impart high
mechanical strength for a variety of applications, such as scaffolds303. Given these
favorable properties, blending with other polymers can add complementary
attributes304, here pH-responsive behavior. The anionic polymers PBA and PAA
have been applied to a variety of biomedical applications 305-311. Together, it was
anticipated that mPEG-PLGA and PBA-co-PAA may provide a stable mechanical
scaffold for administration and longevity in the FRT, while imparting properties that
enable prompt dissolution when needed. While not addressed in this immediate
work, we seek to assess the mechanical properties in addition to the
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mucoadhesivity often provided by blending with PBA or PAA 312. For long-term
applications, these features would be useful to provide immediate protection with
retention and subsequent release of GRFT.
In this work we show that pH-responsive fibers retain GRFT for up to 72 h
in SVF, suggesting that this platform may provide greater active agent stability and
tailored release for less frequent administration. In addition, we evaluated GRFT
release from fibers exposed to both PBS and SVF:SSF after initial incubation in
SVF. Fibers switched to PBS exhibited complete release of GRFT within the first
24 h (Figure 3.6), whereas fibers incubated in SVF:SSF exhibited a more gradual
release, for up to 72 h after SVF:SSF exposure. This difference in release may be
attributed to the increased viscosity and osmolality of simulated seminal fluid
relative to PBS296,313. The daily release of GRFT from fibers switched to SVF:SSF
was enough to provide protection throughout the 72 h post-switch incubation
period, indicating that these fibers may provide activity for up to 6 days
administration in the female reproductive environment. Moreover, previous studies
have shown that human semen may be present within the FRT for up to 72 h postcoitus, during which time multiple exposures to HIV-1 may occur. A platform that
provides pH-dependent release coupled with sustained short-term release postswitch may address the administration challenges of short- versus long-term (or
unknown) exposure. This platform demonstrates the ability to rapidly release
GRFT under pH conditions of semen exposure, while also preserving GRFT after
3 days in SVF, demonstrating exciting utility relative to traditional delivery
platforms.
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In addition to conserving GRFT payload and providing inducible release,
mPEG:PBA-co-PAA (90:10) EFs provided corresponding immediate and complete
protection against HIV-1 in vitro. Fiber eluates maintained antiviral activity against
HIV-1 after different incubation durations, demonstrating their potential utility for
administration every few days. Building upon this work, we expect to conduct more
prolonged release and efficacy studies in the future. Furthermore, the in vitro
release profiles indicate that the fibers retain GRFT for short duration, unlike
traditional sustained-release delivery platforms, which often exhibit an initial burst
release whether or not it is needed. This design feature may provide enhanced
protection relative to the administration of free GRFT alone or other traditional
delivery platforms, in which prematurely released GRFT may be shed with mucus,
or may be locally diluted when needed. Considering that GRFT acts as an entry
inhibitor by interacting with viral envelope proteins, the ability of this pH-responsive
platform to provide GRFT release immediately after exposure to SSF, may
increase the success rate of viral inhibition by releasing a timely localized
concentration of GRFT to inactivate virus.
In addition to relevant release times and efficacy, the design of intravaginal
delivery vehicles requires that safety and biocompatibility are considered early in
the development process. Particularly for GRFT, which has demonstrated
outstanding safety68,69, similar safety must be assessed with its integration in new
delivery vehicles. In our studies with vaginal epithelial cells, incubation with fiber
eluates resulted in greater than ∼95% cell viability after 1, 2, and 3 day exposure,
indicating the preliminary safety of these pH-responsive fibers. Future work will
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assess if these fibers induce inflammation or enhance cytokine production in in
vivo experiments.
Conclusions
Drug delivery systems in which active agent release can be tailored to
release in response to incoming stimuli are particularly promising for biologics that
may lose activity quickly and be expensive to produce. In this study, pH-responsive
fibers comprised of PLGA, mPEG-PLGA, and PBA-co-PAA polymer blends were
fabricated to provide pH-responsive release of GRFT. Of the formulations tested,
the mPEG-PLGA:PBA-co-PAA (90:10) blend provided the optimal release of
GRFT, exhibiting increased release under more neutral conditions while
maintaining minimal release in acidic SVF. In addition, fiber release eluates
provided immediate activity against HIV-1 infection while simultaneously retaining
GRFT activity. Furthermore, the release profiles demonstrated that fibers provided
pH-induced release for at least 72 h, further indicating the utility of this delivery
platform to preserve active agent for a minimum of 3–6 days post-administration.
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CHAPTER 4
RAPID RELEASE GRIFFITHSIN ELECTROSPUN FIBERS FOR USE AGAINST
SEXUALLY TRANSMITTED INFECTIONS
Introduction
In this study, our goal was to develop rapid-release electrospun fibers that
incorporate the biologic GRFT to provide on-demand dual-purpose protection
against HIV-1 and HSV-2 infections in vitro, and to demonstrate initial safety and
efficacy against HSV-2 infection in vivo. Rapid-release fibers, composed of
polyethylene oxide (PEO), polyvinyl alcohol (PVA), and polyvinylpyrrolidone (PVP)
were selected due to their established biocompatibility, mucoadhesivity, and rapid
dissolution in aqueous environments314-317. The ability of GRFT fibers to provide
complete protection against both HIV-1 and HSV-2 infections was demonstrated
in vitro. Furthermore, the efficacy of GRFT fibers was assessed in a murine model
of lethal HSV-2 infection, demonstrating that a single application of PEO, PVA, or
PVP GRFT fibers provided potent protection when administered 4 hr prior to
infection. In addition, histology and cytokine expression data, assessed from
murine reproductive tissues and vaginal lavages, demonstrated the preliminary
safety of rapid-release GRFT fibers in vaginal tissue.
Materials and Methods
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Materials.
PEO (600,000 MW), PVA (87-90% hydrolyzed, 30,000-70,000 MW), and
PVP (1,400,000 MW) were purchased from Sigma Aldrich (St Louis, MO). Organic
solvents including dimethyl sulfoxide (DMSO) were also purchased from Sigma
Aldrich. Cell culture media and reagents including Dulbecco's modified Eagle
medium (DMEM), minimum essential media (MEM), fetal bovine serum (FBS),
penicillin, streptomycin, and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) were purchased from VWR (Radnor, PA). Keratinocyte Serum Free
Media (KSFM) and gentamicin were purchased from Thermo Fisher (Hampton,
NH).
Cell Lines and Virus.
TZM-bl cells, obtained from the National Institutes of Health (NIH) AIDS
Research and Reference Reagent Program (ARRRP), were used to assess in vitro
HIV-1 infectivity. TZM-bl cells are engineered HeLa cells that express CD4, CCR5
and CXCR4 receptors and contain a Tat-driven luciferase gene, which is activated
by HIV-1 infection and permits sensitive and accurate measurements of infection.
TZM-bl cells are highly permissive to infection by most strains of HIV-1 and
molecularly cloned Env-pseudotyped viruses. TZM-bl cells were cultured in DMEM
containing 10% FBS, 25 mM HEPES, and 50 μg/mL gentamicin.
The Env-pseudotype HIV-1 was produced in house by transducing HEK293T/17 cells with both an envelope (env)-expressing plasmid (CCR5-tropic clade
A strain, Q769.h5) and an env-deficient HIV-1 backbone vector (pNL4.3ΔEnv168

Luc). Both plasmids were obtained from the NIH AIDS Reagent Program (Cat#
11884 and 3418). HEK-293T (human embryonic kidney) cells were purchased
from ATCC. Cells were maintained in minimum essential medium (MEM)
supplemented with 10% FBS, penicillin (100 µg/mL), and streptomycin (100
µg/mL).
To conduct HSV-2 plaque assays, Vero E6 cells and HSV-2 (4674) were
kindly provided by Dr. Kenneth Palmer from the University of Louisville. Cells were
maintained in MEM supplemented with 10% FBS, penicillin (100 µg/mL), and
streptomycin (100 µg/mL).
Finally, vaginal keratinocyte (VK2/E6E7), ectocervical (Ect1/E6E7), and
endocervical (End1/E6E7) cell lines were used to assess fiber cytotoxicity (all cells
courtesy of Dr. Kenneth Palmer, originally from ATCC, Rockville MD). VK2/E6E7
(VK2), Ect1/E6E7 (Ect1), and End1/E6E7 (End1) are well-characterized
immortalized cell lines derived from normal human vaginal, ectocervical, and
endocervical epithelia, respectively, which are representative of the cell types
found within the FRT. Cells were maintained in KSFM supplemented with
recombinant human epidermal growth factor (0.1 ng/mL), bovine pituitary extract
(50 μg/mL), calcium chloride (0.4 mM), and 1% penicillin and streptomycin (100
μg/mL each). During cell trypsinization, plating, and counting, cells were
neutralized with 1:1 DMEM:KSFM (with 10% FBS, and 1% penicillin/streptomycin
(100 μg/mL each)).
Rapid-Release Fiber Fabrication.
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Hydrophilic polymer solutions were fabricated by first weighing polymer into
a glass scintillation vial and incubating overnight in 1 mL of Milli-Q water. To create
PVA and PVP fibers with well-defined morphologies, 200 mg of either PVA or PVP
were added to 1 mL Milli-Q water (20% w/v solution), while PEO fibers were
fabricated by adding 50 mg of polymer to 1 mL Milli-Q water (5% w/v). Blank fibers
were electrospun with a mandrel-to-syringe distance of 20 cm, flow rate of 0.2 to
0.3 mL, and a voltage of 15 kV. The flow rate and voltage were changed to 0.2
mL/hr and 25 kV for 1 and 10% w/w (GRFT to polymer weight ratio) GRFT fibers.
Fiber Morphology.
The morphology of blank PEO, PVA, and PVP fibers, as well as 1% and
10% GRFT w/w PEO, PVA, and PVP fibers was assessed using scanning electron
microscopy (SEM). After electrospinning, fibers were dried for 24 hr in a desiccator,
cut into 5 mm pieces and placed on double-sided adhesive carbon tabs (Ted Pella
Inc., Redding, CA), which were adhered to aluminum stubs. The adhered fiber
pieces were sputter coated with a thin gold alloy film using a Bio-Rad E5100 sputter
coat system (Hercules, CA). The coating process was operated for 90 s at 20 mA.
Multiple SEM images were acquired using a Supra 35 SEM (Zeiss, Oberkochen,
Germany), with images captured under an accelerating voltage of 8 kV and using
an average magnification of 1,000 to 5,000x. The average fiber diameter was
determined with ImageJ software (NIH, Bethesda, MD), and a minimum of 50
fibers were assessed per image.
Fiber Characterization.
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To assess GRFT loading, PEO, PVA, and PVP fibers were weighed (3 to 5
mg) into separate 1.5 mL Eppendorf tubes, followed by the addition of 1 mL PBS.
After 1 to 2 min, the dissolved fiber solutions were vortexed and analyzed using
ELISA to quantify GRFT loading and encapsulation efficiency (defined as: [actual
loading ÷ theoretical loading] × 100).
The ELISA was conducted using 96-well Nunc Maxisorp plates as
previously described162. Briefly, plates were first prepared by coating wells with
100 µL of gp120 (250 ng/mL) in PBS, and incubating overnight at 4°C. Afterward,
the coating buffer was removed and 300 µL of blocking buffer, consisting of PBS
with 0.05% (v/v) Tween-20 (PBST) and 3% (w/v) bovine serum albumin, was
added to each well. Plates were incubated at room temperature for 2 hr and then
washed three times with PBST using a Multiwash III plate washer (Gardner
Denver, Milwaukee, WI). One hundred microliters of GRFT standards (ranging
from 0.2 to 120 ng/mL) and loading extracts were added to each well and incubated
for 1 hr at 37ºC. Dilutions of goat anti-GRFT primary antibody (1:10,000, provided
by Dr. Kenneth Palmer, University of Louisville) and rabbit anti-goat IgG-HRP
secondary antibody (1:20,000, Sigma-Aldrich) were added in volumes of 100 µL
and each incubated for 1 hr at 37ºC to detect bound GRFT. Finally, 100 µL of KPL
SureBlue TMB microwell peroxidase substrate (Sera Care, Milford, MA, USA) was
added to each well for 90 s, and the reaction was quenched with the addition of
100 µL of 1 N H2SO4 (Thermo Fisher, Waltham, MA). Plate absorbance was
measured at 450 nm on a Synergy HT reader (BioTek, Winooski, VT, USA). Data
were analyzed using Prism (GraphPad Software Version 6.0, La Jolla, CA).
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In Vitro HIV-1 Pseudovirus Inhibition Assay.
The antiviral activity of GRFT fibers against HIV-1 was measured using an
in vitro HIV-1 pseudovirus inhibition assay. As previously described75,161,162, HIV-1
inhibition was determined as a function of reduction in luciferase reporter gene
expression after a single round of infection in TZM-bl cells. The optimal virus
dilution was established prior to the experiments to yield ~100,000 relative
luminescence units (RLUs).
Briefly, 1% GRFT fibers (~3 to 5 mg) were first dissolved in sterile PBS,
followed by serial dilutions (1:2) with DMEM to a final volume of 50 μL within a 96well plate. TZM-bl cells (10,000 cells in 100 µL DMEM medium with 10 μg/mL
DEAE-dextran) were subsequently added to each well, followed by the addition of
50 μL of diluted HIV-1 pseudovirus. Cells were then incubated at 37°C for 48 hr.
Dilutions of free GRFT (stock concentration 50 µg/mL) ranging from 15 pg/mL to
120 ng/mL were similarly prepared for comparison.
After 48 hr, 100 µL culture medium was carefully removed from each well.
Luminescence was measured using the Bright-Glo luciferase assay system
(Promega Corporation, Madison, WI) by adding 100 µL Bright-Glo reagent solution
to each well for 5 min. Plates were read via luminescence by the Synergy HT
reader (BioTek). All RLU values were corrected by subtracting the RLU of
untreated/uninfected cells from the sample RLUs (treated/infected cells). The
percent virus inhibition was determined by normalizing the corrected RLUs of
treated/infected cells to corrected untreated/infected cells: % Infection = [(sample
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RLU

–

untreated/uninfected

cells)

÷

(untreated/infected

cells

–

untreated/uninfected cells)] × 100. The antiviral activity of GRFT fibers is reported
as the half maximal inhibitory concentration (IC50), which was calculated by
comparing the untreated/infected corrected control RLUs to the corrected RLU
values of sample dilutions.
In Vitro HSV-2 Plaque Assay.
HSV-2 plaque assays were conducted to evaluate the in vitro efficacy of
10% w/w GRFT fibers against HSV-2 infection as previously described161. Briefly,
Vero E6 cells were seeded at 600,000 cells/well in a 6-well flat bottom plate (50%
confluence) and grown for 24 hr to confluence. Prior to cell infection, 10% w/w
GRFT fibers (30 mg) were dissolved in 20 mL complete plating media (1% FBS
MEM). Once the cells were fully confluent, the growth media was removed and
replaced with 2 mL of GRFT fiber eluate dilutions, followed by HSV-2 infection
(3,000 PFU per well) 1 hr later. Free GRFT (2,000 µg/mL), corresponding to the
concentration necessary to provide complete HSV-2 inhibition, was used as a
positive control for inhibition, in addition to untreated/uninfected cells.
Untreated/infected cells, were used as a negative control of inhibition.
Subsequent to HSV-2 infection, plates were incubated for 48 hr at 37°C, all
media was removed, and cells were fixed with 1.5 mL methanol for 10 min.
Afterward, 0.1% crystal violet was applied for 30 min to stain the plaques. Finally,
plates were washed with Milli-Q water, and plaques were counted after drying.
Plaque numbers from experimental groups were normalized relative to the number
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of plaques in untreated/infected cells (~280-300 plaques per well). Samples were
analyzed in triplicate, and GraphPad Prism software was used to determine and
compare the IC50 values of GRFT fibers to free GRFT.
In Vitro Cytotoxicity.
Vaginal epithelial (VK2/E6E7), ectocervical (Ect1/E6E7), and endocervical
(End1/E6E7) cells were administered either blank or GRFT fibers to assess in vitro
safety. Cells were plated at a density of 50,000 cells/well in 96-well plates and
incubated in triplicate with 0.5 mg fiber pieces placed in the solution (2.5 mg/mL
final concentration). No treatment (media alone) and 10% DMSO were used as
positive and negative controls of cell viability, respectively. After 24, 48, and 72 hr,
20 µL of MTT reagent was added to the cells and incubated for an additional 4 hr,
followed by overnight lysis with the addition of 100 µL lysis buffer (10% sodium
dodecyl sulfate in 0.01 M hydrochloric acid). Absorbance measurements (570 nm)
were taken the following day. All sample absorbance values were normalized to
untreated cell absorbance to obtain percent viability.
In Vivo Efficacy against a Lethal Dose of HSV-2 Infection.
All in vivo experimental procedures were approved by the University of
Louisville’s Institutional Animal Care and Use Committee (IACUC 17135) prior to
testing. All animal studies were conducted using 5-week-old female BALB/c mice
(Jackson Laboratory, Bar Harbor, ME) to evaluate the efficacy and safety of GRFT
fibers. For efficacy studies, mice were administered either blank or GRFT fibers (5
mg) that were UV-sterilized for 15 s. Mice were subcutaneously injected with 3 mg
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Depo-Provera (Revive, Madison, NJ) to induce the diestrous stage of their cycle,
5 days prior to fiber administration.
To determine the efficacy of GRFT fibers against HSV-2 infection, mice
were administered a single dose of either GRFT PEO, PVA, or PVP fibers, or
control groups (n=20). Twenty-four hours after fiber administration, mice were
challenged with HSV-2 (20 µL, LD90 5,000 PFU). Untreated/infected mice were
used as positive controls for infection, while untreated/uninfected mice and
infected mice treated with free GRFT (20 µL of 1,000 µg/mL, 20 µg GRFT) served
as negative controls. Free GRFT doses were based on previous studies with
GRFT gels that were shown to provide in vivo protection against HSV-2 infection65.
Blank PEO fibers were administered as an additional control group in efficacy
studies. Mice were monitored daily for 14 days after HSV-2 challenge using an
established 4-point scale to monitor the progression of viral infection 69,318. Each
day, mice were weighed and examined for signs of neurological and epithelial
damage. After the two-week period following HSV-2 challenge, mice were
euthanized and Kaplan-Meier survival curves were generated. Log-ranked post
hoc tests were conducted to assess the statistical significance between groups.
In Vivo Safety.
To assess the safety of fiber administration, mice were similarly
subcutaneously injected with 3 mg of Depo-Provera, 5 days prior to fiber
administration. Afterward, UV-sterilized blank fibers (5 mg) were intravaginally
administered to mice under isoflurane anesthesia using sterile tweezers.
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Treatment groups included mice administered blank PEO, PVA, or PVP fibers,
while control groups included untreated mice, or mice treated with 20 µL free GRFT
in PBS (1,000 µg/mL) or 40 μL of Conceptrol gel. An additional sham control was
used to mimic fiber administration using tweezers alone. Mice were euthanized 24
or 72 hr after fiber administration and mouse reproductive tracts and vaginal
lavages were collected and stored at -80°C following euthanasia (n=3).
The structural integrity of collected reproductive tracts was evaluated using
histological analysis. First, tissue samples were washed with PBS, followed by
fixation with 4% paraformaldehyde. Samples were then embedded in a paraffin
block, and stained with hematoxylin and eosin (H&E). Sample cross-sections were
analyzed by a pathologist blinded to the treatment groups.
To determine cytokine levels after blank fiber administration, murine
reproductive tracts and vaginal lavages were assessed using a Luminex assay.
First, 20 µL of T-Per solution (Thermo Fisher) containing 1% Halt Protease Inhibitor
Cocktail (Thermo Fisher) was added per milligram of reproductive tissue.
Approximately 20 zirconia/silica beads (BioSpec Productions) were added to each
sample, followed by homogenization at 4,500x for 180 s using Precellys 24
homogenizer instrument (Bertin, France). Homogenized samples were cooled on
ice for 5 min, and centrifuged at 10,000 x g at 4°C for 5 min. Afterward, sample
supernatants were collected, aliquoted, and stored at -80°C for further study. Prior
to conducting the Luminex assay, interleukin-1 beta (IL-1β) levels were tested in
reproductive tissue samples using specific ELISA Ready-SET-Go! kits (Thermo
Fisher). Finally, Luminex assays were used to quantify the cytokine levels in
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collected mouse tissue and lavages. Cytokines including G-CSF, IFN-γ, IL-1α, IL1β, IL-2, IL-6, IP-10, MCP-1, MIP-1α, MIP1-β, MIP-2, and TNF-α were selected
based on previous studies that examined these markers for intravaginal
inflammation and damage65,69.
Statistical Analysis.
Unless otherwise noted, all in vitro experiments were conducted in triplicate,
with a minimum of 3 replicates per sample. Statistical analysis of samples
assessing fiber morphology, fiber characterization, in vitro assays, and in vivo
safety studies was performed by using one-way ANOVA with the Bonferroni post
hoc test (p < 0.05). For murine studies assessing viral efficacy, log-ranked post
hoc tests were conducted to assess statistical significance as a function of
treatment group and survival outcome.
Results
Fiber Size and Morphology.
The morphology of blank and GRFT PEO, PVA, and PVP fibers is shown in
Figure 4.1. All fibers demonstrated well-rounded fiber morphology with average
diameters ranging from 220 to 507 nm (Supplemental Table 4.1). The addition of
1% GRFT w/w to PEO and PVP fibers resulted in significantly decreased
diameters of 239 and 242 nm, while no statistical significance was observed
between blank PVA and 1% GRFT PVA fibers that shared similar diameters
regardless of GRFT incorporation. The addition of 10% w/w GRFT produced fibers
with diameters spanning 243 to 339 nm, demonstrating a statistically significant
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increase in fiber diameter for 10% w/w GRFT PVA and PVP fibers relative to 1%
w/w GRFT PVA and PVP fibers. However, PEO fiber diameters remained
unchanged with additional GRFT incorporation. Within similarly loaded GRFT
fibers, statistical significance in fiber diameter was observed between the 10%
GRFT PEO and PVA fibers, while no statistical significance was observed across
the 1% w/w GRFT formulations.
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Figure 4.1. Scanning electron microscopy (SEM) images of (A-C) blank, (D-F) 1%
w/w GRFT, and (G-I) 10% w/w GRFT fibers. (A) 5% PEO, (B) 20% PVA, (C) 20%
PVP blank fibers; (D) 5% PEO, (E) 20% PVA, (F) 20% PVP fibers incorporating
1% w/w GRFT; and (G) 5% PEO, (H) 20% PVA, (I) 20% PVP fibers incorporating
10% w/w GRFT. Scale bars represent 2 μm.
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Supplemental Table 4.1. Fiber diameters as a function of polymer formulation and
GRFT content. Statistical significance between different polymers with the same
GRFT loading is shown as *, while statistical significance between the same
polymer type with different GRFT loading is shown as

#

(p < 0.05). Statistical

significance was assessed using one-way ANOVA with the Bonferroni post hoc
test.

Fiber Formulation

Diameter (nm)

Blank PEO

507 ± 147

Blank PVA

249 ± 84*

Blank PVP

418 ± 137#

PEO 1% GRFT
PVA 1% GRFT

239 ± 53#
220 ± 59

PVP 1% GRFT

242 ± 57

PEO 10% GRFT

243 ± 95*

PVA 10% GRFT

339 ± 99#

PVP 10% GRFT

324 ± 79#
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Fiber Characterization.
GRFT loading was assessed using an ELISA (Figure 4.2). For 1% w/w
GRFT PEO, PVA, and PVP fibers, GRFT loading ranged from 7.4 to 9.7 µg
GRFT/mg fiber, exhibiting no statistical significance between formulations. For
10% w/w GRFT PEO, PVA, and PVP fibers, GRFT loading was 84.8, 69.6, and
62.4 µg GRFT/mg fiber, respectively, with PEO fibers demonstrating statistically
higher loading than PVP fibers. Correspondingly, the encapsulation efficiencies for
each fiber formulation ranged from 74.0 to 97.2%, and 62.4 to 84.2% for 1 and
10% GRFT fibers, respectively, demonstrating consistently high GRFT loading and
suggesting electrospinning compatibility between the polymer and lectin. There
were no observable trends between GRFT encapsulation efficiency and fiber
diameters.
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Figure 4.2. GRFT loading in different hydrophilic fiber formulations. Eluates from
GRFT fibers dissolved in PBS were used to determine GRFT loading via ELISA.
GRFT loading is expressed as the mean ± standard deviation of triplicate readings
of three independent fiber batches. Statistical significance between fiber
formulations with the same loading are shown (*p < 0.05).
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In Vitro HIV-1 and HSV-2 Inhibition from GRFT Fibers.
The dual-purpose antiviral activity of GRFT fibers was determined using
HIV-1 pseudovirus and HSV-2 plaque inhibition assays. For HIV-1 inhibition
studies, all fibers demonstrated complete and dose-dependent HIV-1 inhibition
(Figure 4.3A, B). The IC50 values for PEO, PVA, and PVP fibers administered 1
and 24 hr prior to infection ranged from 17.3 ± 7.2 to 26.7 ± 7.7 ng/mL, relative to
24.1 ±15.6 and 22.8 ± 12.2 ng/mL for free GRFT at 1 and 24 hr respectively (Table
4.1). No statistical significance was observed between the IC50 values of GRFT
PEO, PVA, and PVP fibers, suggesting no differences in efficacy based on polymer
type or as a function of administration time with respect to cell infection. Moreover,
similar inhibition values relative to free GRFT indicate that the electrospinning
process maintains the functional activity of GRFT.
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Figure 4.3. GRFT fibers demonstrate complete protection against in vitro HIV-1
and HSV-2 infections. Three independent batches of 1% w/w GRFT fibers were
assessed for their ability to inhibit HIV-1 infection. Fiber eluates were incubated
with cells (A) 1 hr and (B) 24 hr prior to HIV-1 infection. GRFT released from all
three fiber formulations achieved complete efficacy against HIV-1 infection, similar
to free GRFT. (C) In vitro HSV-2 plaque assays were performed using 10% w/w
GRFT fibers, which similarly achieved complete efficacy against HSV-2 infection
in vitro, similar to free GRFT. (D) Wells treated with GRFT fibers showed
decreased plaque sizes and numbers relative to (E) untreated (or blank fibertreated, data not shown) cells infected with HSV-2. The percent infection relative
to untreated/infected control groups for both HIV-1 and HSV-2 assays is shown as
the mean ± standard deviation of triplicate readings.
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Table 4.1. IC50 values from in vitro HIV-1 and HSV-2 infectivity assays. GRFT
eluates from rapid-release fibers were assessed against HIV-1 and HSV-2
infections, and compared to free GRFT using one-way ANOVA with the Bonferroni
post hoc test. Fibers demonstrated comparable activity relative to free GRFT. No
statistical significance between groups was observed in HIV-1 inhibition studies as
a function of fiber formulation or with respect to administration time. In HSV-2
plaque inhibition assays, GRFT PVA fibers demonstrated lower IC50 values relative
to other formulations and free GRFT-treated controls (p < 0.05). The average IC50
values are expressed as the mean ± standard deviation. Statistical significance
between GRFT PVA fibers and free GRFT is shown as (*p < 0.05).

Fiber Formulation 1 Hr HIV-1 IC50 (ng/mL) 24 Hr HIV-1 IC50 (ng/mL) 1 Hr HSV-2 IC50 (µg/mL)
PEO
PVA
PVP
Free GRFT

17.9 ± 5.4
26.7 ± 7.7
26.6 ± 2.7
24.1 ± 15.6

17.3 ± 7.2
21.7 ± 14.8
23.5 ± 14.1
22.8 ± 12.2
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22.0 ± 2.1
16.6 ± 0.9*
21.0 ± 2.4
25.5 ± 0.5

Plaque assays were used to assess the ability of GRFT fibers to inhibit
HSV-2 infection. Fibers containing a higher concentration of GRFT (10% w/w)
were evaluated, due to the increased concentration of GRFT needed to inhibit
HSV-2, relative to HIV-1 infection. GRFT PEO, PVA and PVP fibers demonstrated
equivalent protection against HSV-2 infection, relative to free GRFT (IC50 25.5 ±
0.5 µg/mL), with IC50s of 22.0 ± 2.14, 16.6, ± 0.92 and 21.0 ± 2.4 µg/mL (Figure
4.3C). No statistical significance in efficacy was observed between GRFT fibers
and free GRFT, except for PVA fibers, which showed a lower IC50 value relative to
free GRFT (p < 0.05, Table 4.1). Moreover, administration of all GRFT fiber
formulations resulted in decreases in both plaque number and size, relative to
untreated/infected controls (Figure 4.3D, E).
In Vitro Cytotoxicity.
To assess the cytotoxicity of rapid-release fibers, MTT assays were
conducted using VK2/, Ect1/, and End1/E6E7 cell lines. All cell lines, incubated
with 1 and 10% w/w GRFT fibers, demonstrated greater than 93% viability after
24, 48, and 72 hr fiber administration, relative to untreated cells (Figure 4.4). No
statistical significance in cell viability was observed as a function of polymer type
or GRFT loading.
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Figure 4.4 The cytotoxicity of PEO, PVA, and PVP fibers administered to vaginal
VK2/E6E7, Ect1/E6E7, and End1/E6E7 cells for (A) 24, (B) 48, and (C) 72 hr was
assessed using the MTT assay. Greater than 93% viability was observed across
all cell lines for all fiber formulations.
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In Vivo Efficacy against HSV-2 Infection.
The antiviral efficacy of rapid-release GRFT fibers was assessed in a
murine model of lethal HSV-2 infection (Table 4.2). A single dose of 10% w/w
GRFT fibers was intravaginally administered to female BALB/c mice, followed by
a single HSV-2 challenge with 5,000 PFU (LD90), 4 hr after fiber insertion (Figure
4.5A, B). Mice were evaluated daily for progression of HSV-2 infection for 14 d
post-infection (Figure 4.5C). Mice that were administered GRFT fibers (PEO, PVA,
or PVP) exhibited statistically significant decreases in HSV-2 infectivity, with 85,
95, and 100% survivability respectively, relative to untreated/infected controls (5%
survivability, p < 0.05). In addition, mice administered GRFT PEO, PVA, or PVP
fibers exhibited comparable protection against HSV-2 relative to free GRFT (p >
0.05), while blank PEO fibers imparted protection to 50% of the animals (p < 0.05).
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Table 4.2. GRFT doses administered in fibers or gel during in vivo HSV-2 infectivity
studies.
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Figure 4.5. Schematic timetable and Kaplan-Meier survival curves of in vivo HSV2 efficacy study. (A) Sequence of murine treatments during the course of the
efficacy study and (B) timeline of HSV-2 efficacy study. (C) GRFT fibers (10% w/w)
were assessed for their ability to protect mice against a lethal challenge (LD90) of
HSV-2 infection (n=20). All GRFT fiber formulations demonstrated strong
protection against HSV-2 infection, resulting in 85 to 100% murine survivability.
Blank fibers also demonstrated partial protection and showed significant
survivability (50%), relative to the untreated/infected control group. In contrast,
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untreated/infected mice demonstrated only 5% survivability. Statistical significance
between experimental groups is shown as (*p < 0.05).
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Another important finding from this study was the difference in infection
progression between untreated/infected mice and mice treated with GRFT fibers
(Figure 4.6). The first symptoms of HSV-2 infection in mice typically manifest 4 to
5 days post-infection, during which time mice exhibit symptoms of localized
swelling in the vaginal area and decreased hind leg mobility. After 5 to 8 days,
~75% of mice from the untreated/infected control group required euthanasia due
to the rapid progression and severity of infection. In contrast, all mice administered
GRFT fibers (PEO, PVA, or PVP) or free GRFT that exhibited symptoms, showed
decreased progression of infection relative to untreated/infected mice over the
same duration. The mice that did not survive infection despite pre-treatment with
GRFT fibers or free GRFT (representing up to 15% total mice, respectively)
exhibited a more gradual progression of infection, requiring euthanasia 7 to 10 d,
instead of 5 to 8 d post-infection. The prolonged duration of viral quiescence
suggests that GRFT may provide partial protection against infection for the few
mice that exhibited overt signs of infection. In comparison, the administration of
blank fibers showed no change in progression of HSV-2 infection in mice, relative
to untreated/infected controls. Finally, for the few infected mice treated with free
GRFT (1 of 20) or GRFT PVA fibers (2 of 20), initial symptoms disappeared near
of the end of the study. The decreased levels of infection in combination with the
more gradual progression demonstrate the ability of GRFT fibers to protect against
a lethal dose of HSV-2 after a single application.
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Figure 4.6 Griffithsin fibers protect mice against HSV-2 infection. Mice were
administered 10% w/w GRFT fibers 4 hr prior to HSV-2 infection (LD90). Mice were
evaluated and scored for progression of infection once daily for 14 d post-infection.
Infected mice were administered (A) PEO, (B) PVA, (C) PVP GRFT fibers, as well
as (D) free GRFT, or (E) no treatment. Mice administered GRFT fibers and free
GRFT exhibited decreased severity of infection, as well as more gradual
progression of infection, relative to untreated/infected animals.
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In Vivo Safety.
To assess the in vivo safety of rapid-release platforms, fibers were
intravaginally administered to mice, and reproductive tissue and vaginal lavages
were collected and analyzed 24 and 72 hr following administration.
Tissue samples were evaluated for possible edema of muscle, interstitial,
and epithelial tissue. In addition, untreated and blank fiber-treated cervical and
vaginal epithelia morphologies were compared, and assessed for possible
keratinization and goblet cell presence. A score ranging from 1 to 4 was used to
determine the severity of epithelial changes. Figure 4.7 shows images of tissues
collected 24 hr after fiber administration. Extracted tissues from untreated controls
demonstrated compact squamous and cervical epithelial tissue, with no evidence
of edema nor inflammation. Samples from tissues treated with blank PEO, PVA,
and PVP fibers showed similar morphology and normality, relative to untreated
controls (scores of 1 to 2). Furthermore, there was no increase in lymphocyte
accumulation in fiber-treated groups. Overall the tissues from blank fiber-treated
mice were comparable to tissues from untreated mice; however, one PVA-treated
sample exhibited increased levels of mucin secretion and neutrophil presence
(score 3), yet the vaginal and cervical epithelia were intact (Supplemental Figure
4.1A). Results from tissues collected after 72 hr administration were similar to 24
hr samples (images not shown).
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Figure 4.7. The in vivo safety of rapid-release fibers was assessed by
intravaginally administering fibers for 24 and 72 hr. Images depict H&E stained
tissues of murine reproductive tracts exposed (A) no treatment, (B) N-9 gel, (C)
and sham-treatment, as well as blank (D) PEO, (E) PVA, and (F) PVP fibers for 24
hr. There was no indication of tissue inflammation or epithelial disruption from fiber
administration, relative to untreated controls. Similar trends were observed for
tissue specimens assessed 72 hr post-administration (data not shown).
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Supplemental Figure 4.1. Images of H&E stained tissue outliers. (A) A blank PVA
fiber-treated tissue sample replicate demonstrated increased levels of mucin
secretion and neutrophil presence; however, no disruption of the vaginal or cervical
epithelium was observed. (B) In contrast, a replicate of N-9 treated tissue exhibited
inflammatory markers indicated by the presence of peripheral blood mononuclear
cells, goblet cell fusions, and epithelial disruption.
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For N-9 treated mice, a slight increase in neutrophil accumulation was
observed on the surface of the cervical squamous epithelium, relative to untreated
controls, indicating minor topical damage (score range 1 to 2). Murine tissue from
one N-9 treated mouse exhibited increased inflammation, due to the presence of
peripheral blood mononuclear cells, goblet cell fusions, and epithelial disruption,
resulting in a score of 3 (Supplemental Figure 4.1B). As for sham-treated mice,
there was a slight increase in neutrophil accumulation after 24 hr in most samples,
relative to untreated controls (score range 1 to 2), and one sham-treated replicate
was noted for widespread neutrophil accumulation, indicating tissue repair (score
3). These alterations present in both N-9 and sham-treated controls were not
observed in 72 hr tissue samples, perhaps indicating transitory damage.
Cytokine expression was assessed from murine FRTs and vaginal lavages
24 and 72 hr after blank fiber administration. Cytokine expression was compared
to untreated, N-9 treated, and sham-treated mice based on previously published
guidelines, in which a significant level of intravaginal inflammation results in a 2 to
5-fold increase in cytokine expression, relative to untreated controls69. Figure 4.8
summarizes the results from the cytokine analysis, indicating that blank fibers do
not induce pro-inflammatory or immune-regulatory cytokine expression. In fibertreated tissue and vaginal lavage samples, cytokine levels were found to be
comparable to tissue and washes collected from untreated control groups.
Cytokine expression was similar in both 24 and 72 hr samples, with 11 of 13
cytokines within a range of 2 to 5-fold expression of untreated controls. A few
exceptions were observed using the above criteria: vaginal lavages collected 24
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hr after PVA and PVP fiber administration demonstrated a 5-fold increase in IL-1α
expression, while vaginal tissue collected 24 hr after PEO administration
demonstrated elevated levels of MIP1-α and PVP MIP-2, relative to untreated
controls (p < 0.05). Additionally, vaginal tissue collected 72 hr after PEO fiber
administration demonstrated a 6-fold increase in MCP-1 and MIP-1α expression,
relative to untreated controls (p < 0.05). For sham-treated controls, which
simulated the administration method via tweezers only, increased cytokine
expression was observed in 24 hr tissue (MIP-2), 24 hr wash (IL-1β), and 72 hr
wash (IL-6, MCP-1), relative to untreated controls. N-9 treated samples
demonstrated an increase in MIP-2 expression in 72 hr wash samples only. Both
IP-10 and INF-γ were undetected in vaginal lavage or tissue samples.
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Figure 4.8. Cytokine expression from extracted murine tissue and vaginal lavages
collected (A, B) 24 and (C, D) 72 hr after fiber administration. Cytokine expression
was assessed concurrently with histology to determine the preliminary safety of
rapid-release fibers in a murine model. Mice treated with blank fibers expressed
similar cytokine levels relative to untreated controls, indicating that the presence
of fibers does not induce inflammation or an inflammatory response (*p < 0.05).

199

An ELISA, used to confirm IL-1β levels, showed similar results, in that blank
fibers induced negligible increases in cytokine expression relative to untreated
controls (p > 0.05).
Discussion
In this study, electrospun fibers composed of hydrophilic polymers were
evaluated as an alternative topical delivery platform to provide on-demand dualpurpose protection against HSV-2 and HIV-1 infections. GRFT PEO, PVA, and
PVP fibers demonstrated complete in vitro efficacy against both HIV-1 and HSV-2
infections and exhibited comparable safety to free GRFT and untreated cells when
tested in three vaginal cell lines. Furthermore, GRFT fibers were efficacious in an
in vivo HSV-2 infection model, and demonstrated preliminary safety by maintaining
macrostructural histology and similar cytokine expression, relative to untreated
mice. Moreover, fibers preserve the activity of incorporated GRFT and substantiate
the feasibility of electrospun fibers to provide an efficacious alternative platform for
the intravaginal delivery of Griffithsin.
The antiviral lectin GRFT has been shown to potently inhibit a variety of viral
infections, and has demonstrated particular promise in providing dual-purpose
protection against HIV-1 and HSV-2 infections65,66. To date, GRFT has been
primarily developed as a gel dosage form65; however, concerns surrounding gel
administration, such as leakage and suboptimal user adherence in clinical trials,
has prompted research into alternative delivery platforms. Other recent work has
begun to evaluate the use of fast dissolving inserts (FDIs) comprised of the gelling
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agents carrageenan, hydroxyethyl cellulose, and xanthan gum 73, for the delivery
of active agents GRFT and carrageenan. These inserts have shown promise in
providing on-demand release of agents, corresponding to immediate inhibition of
SHIV infection in macaque models and HSV-2 and HPV inhibition in murine
models. Another recent study examined the efficacy of poly(lactide-co-glycolide)
GRFT

nanoparticles

(NPs)319

that

co-encapsulate

the

ARV

dapivirine,

demonstrating synergistic protection against in vitro HIV-1 infections. While these
studies show the potential of alternative GRFT delivery platforms, they may also
be prone to challenges regarding leakage and ease of administration, prompting
the development of solid dosage form alternatives that may be easily and
discreetly administered to the FRT.
In this work, we envisioned a solid dosage form comprised of PEO, PVA, or
PVP polymers, due to their established mucoadhesivity, biocompatibility, and
hydrophilicity312,320. All three polymers have been used alone or in blends for drug
delivery applications, particularly for the delivery of proteins and biologics321-327. In
previous intravaginal delivery studies, mucoadhesive polymers were explored to
increase active agent retention312,320. Specifically, one study investigated the use
of PVA and PVP fibers to increase nanoparticle retention in the murine
reproductive tract215, finding that nanoparticles incorporated within fibers
demonstrated a 30-fold increase in retention relative to free NPs215. In addition,
their established biocompatibility, suggests their potential for translation,
particularly in the reproductive microenvironment. Finally, the hydrophilic
properties of

PEO, PVA, and PVP enable fiber fabrication using aqueous
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solutions, which can help to retain GRFT328 and potentially other biologic activity.
In future work we anticipate that the mucoadhesive properties of these polymers
will increase GRFT retention within the FRT, thereby enhancing efficacy at
potentially lower doses, relative to the administration of other dosage forms such
as gels or nanoparticles. Future studies will be conducted to assess how
mucoadhesion may enhance GRFT retention within the reproductive tract.
In these studies, the goal was to develop and preliminarily assess the safety
and efficacy of rapid-release GRFT fibers in a murine model of HSV-2 infection.
PEO, PVA, and PVP fibers all demonstrated high GRFT loading in both the 1 and
10% w/w GRFT formulations. These results are in agreement with other studies
that have used hydrophilic fibers to incorporate proteins and other hydrophilic
agents329,330. The high encapsulation efficiency of these fibers is attributed in part
to the favorable interactions between GRFT and polymers, specifically hydrogen
bonding via hydrophilic functional groups312. This high loading, and moreover the
preservation of GRFT activity, was further demonstrated in our in vitro efficacy
studies where GRFT fibers completely inhibited both HIV-1 and HSV-2 infections
in a dose-dependent manner, regardless of polymer formulation, and with similar
IC50 values relative to free GRFT.
Previous studies have shown that GRFT exhibits picomolar potency against
HIV-1, enabling 1% w/w GRFT fibers to completely prevent HIV-1 infection in vitro.
However, the decreased number of oligomannose N-linked glycans present on the
surface of HSV-2, necessitates a higher dose of GRFT65 and correspondingly,
GRFT fibers to prevent HSV-2 infection in vitro. Despite these differences in GRFT
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potency against HIV-1 and HSV-2, each fiber formulation provided complete, dualpurpose protection against in vitro infections.
Based on these successes, we sought to assess the efficacy and safety
after fiber administration in a murine model of HSV-2 infection. In these studies,
GRFT fibers were administered 4 hr prior to HSV-2 infection. This administration
time was based on surveys that studied female preference for topical delivery
platforms, showing that an “ideal” platform should provide convenient and discreet
administration, and can be applied hours prior to intercourse 331. In line with
previous studies testing GRFT gels65, all three GRFT fiber formulations provided
comparable or enhanced protection in efficacy (LD90) studies (85-100% survival),
relative to free GRFT (85% survival). Moreover, the few mice that became infected
showed decreased weight loss and overall slower progression of HSV-2
symptoms, relative to untreated/infected controls, indicating that GRFT fibers may
reduce the severity of symptoms and alter the course of infection. This trend of
reduced severity and delayed progression was also observed in previous in vivo
GRFT studies further validating the efficacy profile of GRFT fibers332.
Interestingly, blank fiber administration protected up to 50% of total mice,
relative to untreated/infected control mice, suggesting that physical fiber presence
alone may provide a significant level of barrier-like prevention against infections.
Previous studies by our group have demonstrated similar in vitro results,
suggesting that the fiber itself may act as a barrier to viral infection 75,87. Future
work seeks to better define the fiber characteristics that contribute to this inhibition
and utilize this information to improve fiber design. We hypothesize that fibers may
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be fabricated to serve as physical barriers to limit viral distribution within the FRT,
in addition to providing release of incorporated active agents.
Last, we acknowledge that regardless of the protection imparted by GRFT
fibers (or free GRFT), a small fraction of mice (averaging 1.3 and 3 mice of 20, for
GRFT fiber and free GRFT-treated mice, respectively) became infected. Previous
work has shown similar results, in which free GRFT significantly reduces the
incidence of infection, but may not impart complete protection within a sample
group65. Future work will assess dose-dependence and effects of different
administration times of GRFT fibers on in vivo prevention.
In addition to efficacy, it is critical that fibers are safe to administer and
minimize potential inflammatory responses333,334. All fiber formulations (PEO, PVA,
and PVP) exhibited preliminary safety in in vitro and in vivo experiments.
Histological analyses demonstrated the safety of these platforms in vivo, with the
majority of fiber-treated tissue showing no signs of cervical or vaginal epithelium
disruption, nor increased neutrophil accumulation relative to untreated controls.
Additionally, cytokine expression in fiber-treated mice tissues and vaginal lavages
demonstrated values within the normal range shown in previous studies,
confirming the biocompatibility of both polymers and GRFT69,335. Although cytokine
values from a few experimental and sham control group tissues were elevated
relative to untreated controls (as seen with increased levels of IL-1α in PVA and
PVP 24 hr vaginal lavages, and increased expression of MCP-1 and MIP-1 in PEO
72 hr tissue samples), we attribute these incidences of a single elevated cytokine
expression in samples to either vehicle administration or the inherent variability of
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in vivo studies. Previous studies have shown that inflammation is characterized by
the overexpression of multiple cytokines. For example, increased IL-1α
expression,

is

typically

associated

with

increased

TNF-α

or

IL-1β

expression186,336,337, therefore the singular overexpression of IL-1α in both PVA
and PVP 24 hr lavage samples may not be a sufficient indicator of inflammatory
response. Additionally, PEO 72 hr tissue samples demonstrated increased
expression of both MCP-1 and MIP-1, which causes increased localization of
neutrophils338-340; however, no increased neutrophil accumulation was observed in
histology samples during this time period.
In comparison to experimental groups, the sham-treated control group,
which used sterile tweezers to mimic the method of fiber administration, showed
similar cytokine profiles to blank fiber-treated tissue, with a slight increase in
neutrophil accumulation in some histological sample replicates. These results
suggest that this method of delivery may cause damage to the murine reproductive
tract. While previous studies used positive displacement pipettes to intravaginally
administer rolled-fibers, the amount of fiber administered with this method is
limited215. We believe the method of administration may be partially responsible
for the observed increased cytokine expression, as well as the increased
neutrophil accumulation seen in one of the blank PVA histology replicates
(Supplemental Figure 4.1A). Future studies, will be conducted using alternative
methods of fiber administration, to assess the impact of administration methods
and to more closely represent more commonly used tampon-like administration
packages.
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Concurrent with testing rapid-release GRFT fibers, N-9 gel was used as a
positive control in our in vivo safety studies65. However, histology samples showed
that a single administration of N-9 only marginally increased neutrophil
accumulation in tissue and no marked increase was observed in cytokine
expression, relative to untreated or blank fiber-treated mice (Supplemental
Figure 4.1B). Previous studies using N-9 gels have shown that a single
administration may result in transient damage within murine reproductive tissue,
with the highest severity 4 hr post-administration, followed by nearly complete
recovery after 24 hr341. This correlates with our in vivo efficacy results, in that mice
give a single application of N-9 gel show high HSV-2 infectivity, which may be due
to the time of viral administration corresponding to the time at which N-9 damage
is most prominent.
In these studies, we have fabricated rapid-release GRFT fibers to provide
on-demand protection against HIV-1 and HSV-2 infections, and have
demonstrated the preliminary safety of GRFT fibers. Our goal is to create a delivery
platform providing women an alternative viable solid dosage form that offers dualprotection against STI infections. Based on our cytokine work, future preclinical
studies will explore alternative administration methods to ensure that platform
administration does not enhance susceptibility to viral infection or cause off-target
effects. Additionally, future studies will examine the window of protection provided
by GRFT fibers by challenging with HSV-2 at different time points with respect to
fiber administration and assessing the dose-dependent response to fiber
administration. Moreover, we anticipate that GRFT fibers may enhance retention
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within the reproductive tract and in future work seek to study the retention and
pharmacokinetics of GRFT delivered from these fibers after different durations,
and how these concentration profiles relate to protection. Last, we anticipate that
these rapid-release fibers may be used as a foundation to develop sustainedrelease multilayered fibers, which may provide extended release, decreased
doses, and, potentially increased user adherence relative to existing delivery
platforms.
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CHAPTER 5
MULTIPURPOSE GRIFFITHSIN NANOPARTICLE-ELECTROSPUN FIBER
COMPOSITES AGAINST HIV-1 AND HSV-2 INFECTIONS
Introduction
A promising option to provide sustained topical delivery of GRFT may be
polymeric electrospun fibers (EFs), which have been developed for FRT
applications over the past decade342. Early studies showed that fibers comprised
of cellulose acetate phthalate provided pH-responsive release of tenofovir
disoproxil fumarate to inhibit HIV-1 infection in vitro83. In other studies, polymeric
fibers and fiber blends were fabricated to incorporate maraviroc, raltegravir, and
tenofovir, and demonstrated sustained-release of these agents for up to 10
days85,86,145,160,166. While these fiber platforms have demonstrated sustaineddelivery of ARVs for many applications, to date, no fiber-based platforms have
demonstrated the long-term delivery of biologics, such as GRFT, within the
FRT38,107-109,204,211.
In addition to electrospun fibers, polymeric nanoparticles (NPs) have been
explored for a variety of FRT applications, and have been used to incorporate
ARVs and other biologics (e.g., siRNA, antibodies)187,191,343-349. One of the key
strengths of NPs for FRT delivery is that they can distribute throughout the
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FRT186,349,350; however, NPs are often administered in gels or aqueous solutions,
resulting in decreased agent retention due to mucus clearance. To address this
challenge, we envisioned that a composite of nanoparticles and electrospun fibers
(NP-EF) may provide an alternative delivery platform that integrates the attributes
of each to prolong GRFT delivery. We hypothesized that multilayered fibers may
act as a NP reservoir to increase NP retention and modulate GRFT release.
Furthermore, in future work, we envision that this NP-EF composite platform may
incorporate and modulate the delivery of multiple active agents to provide longterm, multi-mechanistic, and synergistic protection against multiple types of viral
infections.
In previous work, our group developed pH-responsive and surface-modified
GRFT fibers that provided in vitro on-demand protection against HIV-1
infection75,162. The goal of this study was to design and evaluate a novel NP-EF
composite that incorporates GRFT to provide multipurpose and potentially longterm (> 1 month) protection against HSV-2 and HIV-1 infections. Here, NPs were
electrospun into fibers, composed of a polyethylene oxide (PEO), polyvinyl alcohol
(PVA),

or

polyvinylpyrrolidone

(PVP)

inner

layer,

surrounded

by

a

polycaprolactone (PCL) outer layer (Figure 5.1). We hypothesized that NP-EF
composites would provide sustained-release of GRFT and provide protection
against a lethal HSV-2 challenge in a murine model. Furthermore, we
hypothesized that the administration of NPs or NP-EFs would result in similar
cytokine expression and tissue macrostructure, relative to untreated murine
lavages and tissues. Importantly, the sustained-release of GRFT from NP-EF
209

composites was demonstrated for up to 90 days, and completely inhibited HSV-2
and HIV-1 in vitro. Furthermore, GRFT NP-EF composites and GRFT NPs
protected mice against a lethal HSV-2 challenge, suggesting that NP-EF
composites may serve as an alternative platform for women that seek long-term
dual-purpose prevention.
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Figure 5.1. (A) Schematic depicting the incorporation of NPs within hydrophilic
fibers to create multilayered NP-EF composites. Multilayered fibers consist of an
inner layer of hydrophilic polymer (here, PEO) that incorporates GRFT or C6 NPs,
and outer hydrophobic layers of PCL to tune GRFT release from the incorporated
NPs. (B) Schematic of NP-EF composites fabricated with varying outer layer
thicknesses to modulate GRFT release. The multilayered fiber acts as a NP
reservoir, conferring localized GRFT release from the composite.
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Methods and Materials
Polymers and Solvents
mPEG-PLGA (LG 50:50, 5,000 MW mPEG-50,000 MW PLGA) and PLGA
(50:50, 0.55-0.75 dL/g, 31-57k MW) were purchased from PolySciTech (Lafayette,
Indiana) and Lactel Absorbable Polymers (Cupertino, CA), respectively. Polymers
including PCL (80,000 MW), PEO (600,000 MW), PVA (87-90% hydrolyzed,
30,000-70,000 MW), and PVP (1,400,000 MW) were purchased from Sigma
Aldrich (St. Louis, MO). Trifluoroethanol (TFE) and dichloromethane (DCM) were
purchased from Thermo Fisher (Waltham, MA). Other chemicals, including
dimethyl sulfoxide (DMSO) and thiazolyl blue tetrazolium bromide (MTT) were
purchased from Sigma Aldrich. Griffithsin stock solution (12.0 mg/mL, in PBS) was
kindly provided by Kentucky Bioprocessing (Owensboro, KY).
Nanoparticle Synthesis
mPEG-PLGA and PLGA nanoparticles containing GRFT were synthesized
using the double emulsion solvent evaporation technique. First, 100 mg PLGA or
mPEG-PLGA were dissolved in 2 mL of DCM and incubated overnight. The next
day, the polymer solutions were vortexed, and 200 µL of GRFT stock solution (25,
50, or 100 mg/mL in PBS) was added dropwise to synthesize NPs with a theoretical
loading of 50, 100, or 200 μg GRFT/mg polymer. GRFT-polymer mixtures were
sonicated and added to 2 mL of 5% PVA solution, sonicated again, and
subsequently transferred to a beaker containing 50 mL of 0.3% PVA solution for 3
hr. The newly synthesized NPs were washed with Milli-Q water three times to
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remove residual PVA and solvent, followed by lyophilization and storage at -20°C
until use.
To assess NP loading within the NP-EF composite, Coumarin 6 (C6) NPs
were synthesized as previously described351-355. Briefly, C6 was dissolved in DCM
(15 µg C6/mg polymer or 15 mg C6 in 200 µL DCM), followed by the dropwise
addition of 200 µL to the 2 mL polymer/DCM mixture. Afterward, the fabrication
process of C6 NPs mirrored that of GRFT NPs, with sonication of the polymersolvent mixture, addition to 2 mL of 5% PVA solution, and subsequent transfer to
50 mL of 0.3% PVA solution for 3 hr.
NP Loading in Hydrophilic (Inner Layer) Fibers
Hydrophilic fibers, incorporating GRFT mPEG-PLGA NPs, were fabricated
by first adding PEO (5% w/w), PVA (20% w/w), and PVP (20% w/w) to scintillation
vials containing 1 mL Milli-Q water and were incubated overnight. Blank fiber
controls were electrospun with a mandrel-to-syringe distance of 20 cm, flow rate
of 0.25-0.60 mL/hr, and a voltage of 15-20 kV. To determine the loading capacity
of NPs within the fibers, C6 NPs were electrospun in fibers at 1, 2, 10, or 20% w/w
(NP/EF weight ratio). For GRFT NP-EF composites, PEO fibers were electrospun
with 1 or 20% w/w GRFT NPs. Electrospinning parameters were adjusted for
GRFT and C6 NP-EFs by changing the flow rate to 0.2 mL/hr and voltage to 2025 kV.
NP-EF Composite Synthesis
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Polycaprolactone (11% w/w or 152 mg/mL) was dissolved in 7 mL TFE and
incubated overnight. Different PCL solutions were electrospun using volumes of 1,
3, 5 or 7 mL to create composites with varying outer layer thicknesses. Similar
electrospinning conditions were used with the mandrel-to-syringe distance set to
15 cm, flow rate of 2.2 mL/hr, and voltage of 20 kV. Pre-massed NP-PEO fiber
sheets were placed on the freshly electrospun PCL layer and an additional PCL
layer was electrospun on top to create a PCL−(NP/PEO)−PCL multilayered
structure (Figure 5.1), and fibers were desiccated overnight prior to
characterization.
NP and NP-EF Composite Morphology
Scanning electron microscopy (SEM) was used to characterize the physical
structure and morphology of NPs, EFs, and NP-EF composites. Individual
hydrophilic and hydrophobic fiber layers as well as multilayered composites were
cut into 5 mm pieces and placed on double-sided adhesive carbon tabs (Ted Pella
Inc., Redding, CA, USA), which were then adhered to aluminum stubs.
Nanoparticles were similarly adhered to carbon tabs and all samples were sputter
coated with a thin gold alloy using a Bio-Rad E5100 sputter coat system (Hercules,
CA). Samples of composite cross sections were prepared by slicing composites
into 2 to 5 mm sections and adhering sections sideways to the aluminum stubs.
Sample images were acquired in triplicate using a Supra 35 SEM (Zeiss,
Oberkochen, Germany). Fiber and composite images were captured using an
accelerating voltage of 8 kV, with magnifications of 5,000- to 10,000x, while NP
images were captured with a voltage of 10 kV, and magnification of 20,000 to
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23,000x. The mean diameters of NPs and fibers were determined using ImageJ
software (NIH, Bethesda, Maryland), by measuring 50 line elements per SEM
image.
Quantification of GRFT NP, GRFT NP-EF, and C6 NP-EF Loading
The loading of GRFT in NPs and NP-EFs was assessed using an enzymelinked immunosorbent assay (ELISA). Griffithsin loading and encapsulation
efficiency (defined as [actual loading ÷ theoretical loading] × 100%) was
determined for NPs and NP-EF composites. To determine loading, GRFT NPs and
NP-EF composites (2 to 4 mg) were dissolved in 1 mL DCM, and vortexed for 30
s. Griffithsin was extracted from the DCM into 500 µL Tris-EDTA (TE) buffer,
vortexed, and centrifuged at 18,500 x g for 5 min. TE buffer was collected, and the
process was repeated to collect GRFT into a final volume of 1 mL. All extracts were
analyzed using ELISA as previously described162.
For the ELISA, 96-well Nunc Maxisorp plates were incubated overnight with
100 µL coating buffer (250 ng/mL gp120 in PBS). Coating buffer was removed
from the plates, and 300 µL blocking buffer (0.05% Tween-20 and 3% w/v bovine
serum albumin in PBS) was added to the wells for 2 hr. After incubation, the plates
were washed with PBST (0.05% Tween-20 in PBS) using a Gardner Denver
Multiwash III plate washer (Milwaukee, WI), and free GRFT standards (100 µL, 0.2
to 120 ng/mL) or sample extracts were added to each well. Plates were incubated
for 1 hr at 37ºC, followed again with a PBST wash. Dilutions of goat anti-GRFT
primary antibody (1:10,000, kindly provided by Dr. Kenneth Palmer, University of
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Louisville) and rabbit anti-goat IgG-HRP secondary antibody (1:20,000, Sigma
Aldrich) were subsequently added to each well in 100 µL volumes and incubated
for 1 hr at 37ºC to detect bound GRFT. After incubation, both antibody solutions
were rinsed and 100 µL of KPL SureBlue TMB microwell peroxidase substrate
(Sera Care, Milford, MA, USA) was added to each well for 90 s, followed by
quenching with 100 µL of 1 N H2SO4 (Thermo Fisher). Plate absorbance was
measured at 450 nm on a Synergy HT reader (BioTek, Winooski, VT, USA) and
data were analyzed using Prism (GraphPad Software, La Jolla, CA).
The loading of C6 NPs within NP-EFs was assessed via fluorescence. First,
C6 NP-EFs (2 to 4 mg) were dissolved in 1 mL DMSO, and vortexed for 1 min to
ensure complete composite dissolution. Composite dilutions were added (100 µL)
to 96-well plates. C6 NPs (3mg) were similarly dissolved in DMSO, and NP
dilutions were used to generate a standard curve (ranging 6 ng/mL to 100 µg/mL),
while dissolved blank NPs were used as background controls. Plates were read at
excitation and emission wavelengths of 443 and 494 nm using a Synergy HT
reader.
Quantification of GRFT Release from NPs and NP-EF Composites
The sustained-release of GRFT from NPs and NP-EF composites was
assessed for 30 and 90 d, respectively. GRFT PLGA and mPEG-PLGA NPs (3 to
5 mg) were aliquoted to 1.5 mL centrifuge tubes that contained 1 mL of simulated
vaginal fluid (SVF)246, while NP-EF composites were placed in 10 mL scintillation
vials and incubated in 3 mL SVF to ensure complete submersion. All samples were
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placed in a shaker at 37ºC and 150 rpm, and at specific time points, the SVF was
collected and replaced with fresh SVF. To collect NP release eluate, samples were
centrifuged at 18,500 x g at 4ºC for 10 min prior to supernatant collection.
Cell Lines and Virus
TZM-bl cells, obtained from the National Institutes of Health AIDS Research
and Reference Reagent Program (ARRRP), are engineered HeLa cells that
express CD4, CCR5 and CXCR4 receptors, and were used to assess in vitro HIV1 infectivity. TZM-bl cells are highly permissive to infection by most HIV-1 and
pseudovirus strains, and contain HIV-activated Tat-driven luciferase, allowing for
precise quantification of infection. TZM-bl cells were cultured in Dulbecco’s
Modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS), 25 mM
HEPES, and 50 μg/mL gentamicin (Thermo Fisher).
The Env-pseudotype HIV-1 was produced in house by introducing HEK293T/17 cells (ATCC, Rockville MD) with both an envelope (env)-expressing
plasmid (CCR5-tropic clade A strain, Q769.h5) and an env-deficient HIV-1
backbone vector (pNL4.3ΔEnv-Luc). Both plasmids were obtained from the NIH
AIDS Reagent Program (catalog# 11884 and 3418). Cells were maintained in
minimum essential medium (MEM) supplemented with 10% FBS, 1% penicillin
(100 µg/mL), and 1% streptomycin (100 µg/mL) (VWR Radnor, PA).
To assess HSV-2 infection in plaque assays, Vero E6 cells (African green
monkey kidney) and HSV-2 (4674) were kindly provided by Dr. Kenneth Palmer
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from the University of Louisville. Cells were maintained in MEM supplemented with
10% FBS, and 1% penicillin and streptomycin.
Finally, vaginal keratinocyte (VK2/E6E7), ectocervical (Ect1/E6E7), and
endocervical (End1/E6E7) cell lines were used to assess fiber cytotoxicity (all cells
courtesy of Dr. Kenneth Palmer, originally from ATCC, Rockville MD). VK2/E6E7
(VK2), Ect1/E6E7 (Ect1), and End1/E6E7 (End1) are well-characterized
immortalized cell lines derived from normal human vaginal, ectocervical, and
endocervical epithelia, respectively, and are representative of the cell types found
within the FRT. Cells were maintained in keratinocyte serum-free medium (KSFM)
supplemented with recombinant human epidermal growth factor (0.1 ng/mL),
bovine pituitary extract (50 μg/mL), calcium chloride (0.4 mM) (Thermo Fisher),
with 1% penicillin and streptomycin. During cell trypsinization, plating, and cell
counting, cells were neutralized with 1:1 DMEM:Nutrient Mixture F-12 media
(Thermo Fisher) with 10% FBS, and 1% penicillin/streptomycin.
In Vitro HIV-1 Inhibition
The activity of GRFT NPs and NP-EF composites against HIV-1 infection
was assessed using an in vitro HIV-1 inhibition assay as previously
described75,87,161,162. HIV-1 inhibition was determined as a function of reduction in
luciferase reporter gene expression after a single round of infection with
pseudotyped HIV-1 in TZM-bl cells. The optimal virus dilution (1:16) was
established to yield ≥ 96,800 relative luminescence units (RLUs). Briefly, GRFT
NP or NP-EF eluates were prepared in either PBS or DMEM (1.0 mg/mL), followed
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by 1:2 serial dilutions with DMEM to a final volume of 50 μL within a 96-well plate.
One hundred microliters of TZM-bl cells (10,000 cells in DMEM supplemented with
10 μg/mL DEAE-dextran) was added to each well, followed by the addition 50 μL
of HIV-1 pseudovirus dilution. Infected cells administered NPs or NP-EFs were
incubated at 37°C for 48 hr and compared to the inhibition obtained with free
GRFT-treated/infected (stock concentration 50 µg/mL), untreated/infected, and
untreated/uninfected control groups.
After 48 hr, 100 µL of culture medium was removed from each well.
Luminescence was measured using the Bright-Glo luciferase assay (Promega
Corporation, Madison, WI) by adding 100 µL Bright-Glo reagent solution to each
well for 5 min and recording relative luminescence units (RLUs, Synergy HT
reader, BioTek). All RLU values were corrected by subtracting the RLU of
untreated/uninfected cells from the RLUs of treated/infected cells. The percent
virus inhibition was determined by normalizing the corrected RLUs of
treated/infected cells to corrected untreated/infected cells with the following
formula: % Infection = [(sample RLU – untreated uninfected cells) ÷ (untreated
infected cells – untreated uninfected cells)] × 100%. The antiviral activity is
reported as the half maximal inhibitory concentration (IC50) and was calculated by
comparing the sample luminescence intensity to the luminescence intensity from
untreated/infected controls.
In Vitro HSV-2 Inhibition
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HSV-2 plaque assays were conducted to determine the in vitro efficacy of
GRFT mPEG-PLGA NPs against HSV-2 infection. Briefly, Vero E6 cells were
seeded at a density of 600,000 cells/well in a 6-well flat bottom plate and grown
for 24 hr to complete confluence. Prior to cell infection, ~20 mg of GRFT NPs were
added to 20 mL complete plating media (1% FBS MEM). Once the cells were fully
confluent, the growth media was removed and replaced with 2 mL dilutions per
well of GRFT NPs, followed by the introduction of HSV-2 (10 µL containing 3,000
PFU per well) after 1 hr of treatment. Free GRFT (2,000 µg/mL) corresponding to
the concentration needed to provide complete inhibition and untreated/infected
cells, were used as negative and positive controls of HSV-2 infection.
Untreated/uninfected cells were used as additional negative controls.
After HSV-2 infection, plates were incubated for 48 hr at 37°C. After
incubation, media was removed, cells were fixed for 10 min with 1.5 mL of
methanol, stained with crystal violet (0.1% crystal violet in 80:20 water: ethanol
solution), and incubated for 30 min. Finally, plates were washed with Milli-Q water,
dried, and plaques were counted. Plaque numbers from experimental groups were
normalized to the number of plaques in untreated/infected cells (~280-300
plaques). Samples were analyzed in triplicate, and GraphPad Prism software was
used to determine and compare the half maximal inhibitory concentration IC50
values of GRFT NPs to free GRFT.
In Vitro Cytotoxicity
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Vaginal epithelial (VK2/E6E7), ectocervical (Ect1/E6E7), and endocervical
(End1/E6E7) cells were incubated with either blank NPs, blank NP-EFs, GRFT
NPs, or GRFT NP-EF composites to assess the in vitro cytotoxicity of GRFT
delivery platforms. Cells were plated at a density of 50,000 cells/well in 96-well
plates and incubated in triplicate with either 0.5 or 1 mg/mL NPs in media.
Composites were tested by incubating cells with 0.5 mg NP-EF pieces (2.5 mg/mL
in media). No treatment (media alone) and 10% DMSO were used as positive and
negative controls of cell viability, respectively. After 24, 48, and 72 hr incubation,
20 µL of MTT reagent was added to the cells and incubated for an additional 4 hr.
Cells were lysed overnight with 100 µL lysis buffer (10% sodium dodecyl sulfate in
0.01 M hydrochloric acid). Absorbance values were measured at 570 nm the
following day and normalized to untreated cell absorbance to obtain percent
viability.
In Vivo HSV-2 Efficacy
All in vivo experiments were approved by the University of Louisville’s
Institutional Animal Care and Use Committee (IACUC-17135) prior to testing.
Animal studies were conducted using 5-week-old female BALB/c mice (Jackson
Laboratory, Bar Harbor, ME) to evaluate the efficacy of mice to HSV-2 infection
after administration of GRFT NPs and NP-EF composites (n=20). For these
studies, mice were subcutaneously injected with 3 mg Depo-Provera (Revive,
Madison, NJ) 5 days prior to vehicle administration to induce the diestrous stage
of their cycle. All materials administered to mice were UV-sterilized for 15 s prior
to use. Mice were administered 0.5 mg blank or GRFT NPs diluted in sterile PBS
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(20 µL of 25 mg/mL) or 20% w/w GRFT NP-EF composites (5 mg) under isoflurane
anesthesia. Untreated/uninfected mice and mice treated with 20 µg free GRFT (20
µL of 1,000 µg/mL) served as negative

controls of

infection, while

untreated/infected mice served as a positive control for infection. Blank mPEGPLGA nanoparticles were administered as an additional control group in efficacy
studies. A single challenge of HSV-2 LD90 (here, 5,000 PFU, HSV-2(4674) was
given 24 hr after vehicle administration, followed by 14 day observation using an
established 4-point scale to monitor infection progression69,252,318. Each day, mice
were weighed and examined for neurological and epithelial damage. The study
concluded 14 d after HSV-2 challenge, mice were euthanized, and survival was
assessed. Kaplan-Meier survival curves were generated from the data, followed
by log-ranked post hoc tests to assess the statistical significance between groups.
In Vivo Safety
Additional studies were conducted to evaluate the safety of blank NPs and
NP-EF composites in vivo. NPs and NP-EFs were UV-sterilized for 15 s, and
intravaginally administered to mice under isoflurane anesthesia, at the same doses
(0.5 and 5 mg, respectively) that were evaluated in the efficacy study. Control
groups included uninfected mice that were untreated, treated with 20 µL free GRFT
in PBS (1,000 µg/mL), or treated with 40 μL of N-9 gel. An additional “sham” control
was used to evaluate the effects of tweezer administration alone. Mice were
euthanized after 24 or 72 hr of vehicle administration (n=3 per time point) and
reproductive tracts and vaginal lavages were collected and stored at -80°C
following mouse euthanasia.
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The structural integrity of the murine reproductive tracts was evaluated with
histology. Collected tissue samples were washed with PBS, and subsequently
fixed with 4% paraformaldehyde. The uterine horns, uterine body, and vagina were
resected, fixed in 10% formalin, embedded in paraffin and sliced and stained with
hematoxylin and eosin (H&E) for histological examination. Similarly, tissue
samples and vaginal lavages were collected and analyzed for cytokine expression.
The histology of sample cross-sections was assessed by a pathologist blinded to
treatment groups.
Cytokine expression from murine reproductive tracts and vaginal lavages
was determined using Luminex assays. First, 20 µL of T-Per solution (Thermo
Fisher) containing 1% Halt Protease Inhibitor Cocktail (Thermo Fisher) was added
per 1 mg of reproductive tissue. Approximately 20 zirconia/silica beads (BioSpec
Productions) were added to each sample, followed by homogenization at 4,500x
for 3 min (Bertin, France). Homogenized samples were cooled on ice for 5 min,
and centrifuged at 10,000 x g at 4°C for 5 min. Sample supernatants were
collected, aliquoted, and stored at -80°C for further study. Prior to Luminex
analysis, interleukin 1 beta (IL-1β) levels were tested in the reproductive
specimens using specific ELISA Ready-SET-Go! kits (Thermo Fisher) to confirm
cytokine concentration ranges prior to the Luminex assays. Luminex assays were
subsequently used to quantify cytokine levels, including G-CSF, INF-γ, IL-1α, IL1β, IL-2, IL-6, IP-10, MCP-1, MIP-1α, MIP1-β, MIP-2, and TNF-α from murine
tissues and lavages. These cytokines were selected for assessment based on
intravaginal inflammatory markers quantified in previous studies65,69.
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Statistical Analysis
Unless otherwise noted, all in vitro experiments were conducted in triplicate,
with 3 replicates per sample. Statistical analysis of samples for delivery vehicle
morphology, loading, in vitro assays, and in vivo safety studies was performed by
using one-way ANOVA with the Bonferroni post hoc test (p < 0.05). For murine
efficacy studies, log-ranked post hoc tests were conducted to determine statistical
significance as a function of treatment group and survival outcome.
Results
Nanoparticle Characterization
PLGA and mPEG-PLGA NPs were synthesized with 50, 100, or 200 μg
GRFT per mg polymer. NPs were assessed for morphology, total GRFT loading,
and sustained-release. The morphology and diameter of GRFT NPs, relative to
blank NPs, were evaluated using SEM (Figure 5.2) and ImageJ software
(Supplemental

Figure

5.1).

All

NP

formulations

possessed

spherical

morphologies, with diameters ranging from 72 to 131 nm. Blank nanoparticles
demonstrated the largest diameters, with average PLGA and mPEG-PLGA NP
diameters of 118 and 128 nm respectively. The addition of 50 µg/mg GRFT to
PLGA and mPEG-PLGA NPs decreased NP diameters to 97 and 102 nm,
respectively, while the addition of 100 µg/mg GRFT resulted in average diameters
of 131 and 78 nm. The smallest PLGA and mPEG-PLGA NP diameters (72 and
74 nm), were achieved with the addition of 200 µg/mg GRFT. Overall the
incorporation of GRFT corresponded to a decrease in NP diameter.
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Figure 5.2 Scanning electron microscopy images of (A) blank, (B) 50, (C) 100, and
(D) 200 µg/mg GRFT PLGA NPs, and (E) blank, (F) 50, (G) 100, and (H) 200
µg/mg GRFT mPEG-PLGA NPs. Scale bars represent 100 nm.
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Supplemental Figure 5.1. Characterization of the average diameter of blank and
GRFT NPs. NP diameters were determined using SEM and ImageJ software.
Statistical significance between groups represented by *(p < 0.05).
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The loading of GRFT in PLGA and mPEG-PLGA NPs is shown in Table
5.1. The addition of 50, 100, and 200 µg GRFT/mg PLGA NPs resulted in 23.6 ±
1.4, 42.4 ± 3.1, and 77.8 ± 4.6 µg GRFT/mg PLGA respectively, while mPEGPLGA NPs demonstrated consistently higher total GRFT loading of 49.6 ± 1.9,
63.6 ± 15.1, and 171.1 ± 21.5, for each formulation, respectively.
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Table 5.1. Griffithsin loading in mPEG-PLGA and PLGA NPs. Griffithsin extracts
from NPs were assessed using ELISA. Increased theoretical loading resulted in
increased actual loading. Three NP batches were fabricated for each formulation,
with GRFT loading expressed as mean ± standard deviation of triplicate readings
of each NP batch. Statistical significance was assessed using one-way ANOVA
with the Bonferroni post hoc test.
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During NP release studies, an initial burst release was observed from both
PLGA and mPEG-PLGA NPs through one week, followed by minimal GRFT
release from 1 to 4 wk (Figure 5.3). Increased release was seen from mPEGPLGA NPs, relative to PLGA NPs, with 66.5 and 38.6 µg/mg GRFT released from
200 µg/mg mPEG-PLGA and PLGA NPs within 4 wk. Finally, as expected, the
amount of GRFT release corresponded to the amount of GRFT loading for both
polymers, with 200 µg/mg mPEG-PLGA NPs releasing the most GRFT over 4 wk.
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Figure 5.3. The cumulative release of GRFT from mPEG-PLGA and PLGA NPs
shown as (A) total GRFT release or (B) the percent of total loading. Increased
amounts of GRFT were released from mPEG-PLGA NPs relative to PLGA NPs,
and total release corresponded with GRFT loading for each formulation. Release
values are shown as the mean ± standard deviation of three independent NP
batches.
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Nanoparticle-Electrospun Fiber Composite Characterization
Studies were conducted to assess the maximum loading that could be
attained by adding C6 NPs to PEO, PVA, and PVP inner layer fibers. Fibers were
loaded with 1, 2, 10 and 20% w/w NP/fiber, resulting in high NP incorporation,
regardless of and corresponding to, theoretical loading (Table 5.2). The
encapsulation efficiency of maximally-loaded NP-fiber composites (20% w/w) was
97, 65, and 46% for PEO, PVA, and PVP, respectively. Based on these results,
PEO was selected as the hydrophilic layer for the multilayered composite.
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Table 5.2. Coumarin-6 NP loading in PEO, PVA, and PVP NP-EF composites.
Dilutions of NP-EF composites, dissolved in DMSO, incorporating 10, 20, 100, or
200 µg/mg C6 NPs were evaluated by measuring fluorescence. Three composite
batches were fabricated for each formulation, with C6 loading expressed as mean
± standard deviation of triplicate readings of each NP batch. Statistical significance
was assessed using one-way ANOVA with the Bonferroni post hoc test.

Fiber Formulation

PEO

PVA

PVP

Theoretical Loading
NP/EF (µg/mg)

Actual Loading
NP/EF (µg/mg)

Encapsulation
Efficiency (%)

10
20
100
200
10
20
100
200
10
20
100
200

10.5 ± 1.2
15.8 ± 1.2
77.6 ± 23.0
194.6 ± 11.3
7.4 ± 0.5
13.4 ± 1.2
86.0 ± 4.0
130.4 ± 42.0
9.1 ± 1.1
9.2 ± 1.1
68.3 ± 7.2
147.2 ± 16.3

105 ± 11
78.9 ± 3.9
77.6 ± 23.0
97.3 ± 6.0
74.3 ± 4.3
67.3 ± 7.2
86.8 ± 4.9
65.2 ± 22.4
91 ± 11.0
46.0 ± 6.2
68.3 ± 7.2
71.1 ± 8.2
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Based on NP loading in the hydrophilic layer, multilayered PCL-PEO-PCL
composites that incorporated 1 or 20% w/w mPEG-PLGA GRFT NPs (200 µg/mg
GRFT) were fabricated. As shown in Figure 5.4, both PEO (inner) and PCL (outer)
layers maintained fiber morphology and integrity. Subsequent loading studies
showed that 58 ± 8 and 56 ± 8% of GRFT NPs were incorporated from 1 and 20%
NP w/w loaded multilayered NP-EFs.
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Figure 5.4. Scanning electron microscopy images of GRFT NP-EF composites
taken from (A) inner layer PEO fibers (5% w/w) that incorporate 20% w/w blank
mPEG-PLGA NPs, (B) outer layer PCL fibers, and (C) a cross-sectional image of
an NP-EF composite. Scale bars for panels A and B represent 2 µm, while the
scale bar in panel C represents 20 µm.
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Sustained-release studies were conducted to assess GRFT release from
NP-EF composites with varying outer layer thicknesses corresponding to 1, 3, 5
and 7 mL volumes. First, release was measured from composites that contained
1% w/w GRFT NPs (Figure 5.5A, B). All formulations, regardless of thickness,
exhibited an initial burst release through ~72 hr, followed by sustained-release of
GRFT for up to 90 d. Overall, increasing the PCL outer layer thickness resulted in
decreased GRFT release. After 90 d, the total GRFT released from fibers was 81,
67, 54, and 57 ng/mg for 1, 3, 5 and 7 mL composites respectively.
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Figure 5.5. Cumulative release of GRFT from multilayered GRFT NP-EF
composites. The cumulative release of GRFT from multilayered mPEG-PLGA NPEF composites formulated with 1% w/w NP loading, with different outer layer
thicknesses shown as (A) total GRFT release or (B) percent of total loading.
Subsequent release studies evaluated the cumulative release of GRFT from
mPEG-PLGA NP-EF composites formulated with 20% w/w NPs shown as (C) total
GRFT release or (D) percent of total loading. Overall, GRFT release increased
from composites with thinner shells. Griffithsin release values are shown as the
mean ± standard deviation of three independent NP-EF batches.
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Based on the release results, composites that incorporated 20% w/w GRFT
NPs with 1 and 3 mL PCL outer layers were fabricated. After 90 d, the total GRFT
released was 11 and 9 µg/mg (53 and 45% total release) for the 1 and 3 mL NPEF composites (Figure5. 5C, D). Release profiles showed similar trends to 1%
NP-EFs in that there was a noticeable burst release during the first 72 hr; however,
decreased release was observed through week 4, while increased GRFT release
was observed between weeks 4 and 8.
In Vitro Viral Inhibition Studies
Both mPEG-PLGA GRFT NPs and NP-EF composites were assessed in
vitro against HIV-1 and HSV-2 infections. Dilutions of GRFT NPs and eluates from
20% w/w NP-EF composites were administered to TZM-bl cells 1 and 24 hr prior
to viral infection. GRFT NPs demonstrated complete dose-dependent inhibition
against HIV-1 at both time points (Figure 5.6A, B). Furthermore, the IC50 of GRFT
released from NPs was comparable to free GRFT. Additionally, GRFT released
from NP-EF composites demonstrated comparable efficacy relative to free GRFT,
achieving complete protection (> 98%) after 1 and 24 hr administration. The IC 50
values of GRFT NPs, GRFT NP-EFs, and free GRFT were 51.1 ± 2.3, 35.6 ± 7.1,
21.5 ± 5.3, after 1 hr and 36.1 ± 6.8, 29.7 ± 18.1, and 20.8 ± 6.7 ng/mL after 24 hr
administration. All platforms demonstrated statistically similar IC 50 values to free
GRFT, with the exception of 1 hr GRFT NPs, which showed a statistically higher
IC50 value relative to both 1 and 24 hr free GRFT. These results indicate that
incorporation of GRFT in either NPs or NP-EFs composites maintains antiviral
activity.
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Figure 5.6. Results from in vitro HIV-1 inhibition and MTT toxicity assays. Three
independent batches of GRFT NPs and NP-EF composites were assessed for their
ability to inhibit HIV-1 infection. Nanoparticles or composite eluates were incubated
with cells (A) 1 hr and (B) 24 hr prior to HIV-1 infection. GRFT released from both
platforms exhibited complete HIV-1 inhibition at both 1 and 24 hr, relative to free
GRFT. The cytotoxicity of the maximum dose of GRFT NPs and NP-EFs used in
the in vitro assays was administered to vaginal VK2/E6E7, Ect1/E6E7, and
End1/E6E7 cells for (C) 24, (D) 48, and (E) 72 hr was assessed using the MTT
assay. Greater than 94% viability was observed in all cell lines for all NPs and NPEF formulations.
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In Vitro Safety Studies
Prior to in vivo studies, both blank and GRFT NPs and NP-EFs were assessed for
cytotoxicity in VK2/, Ect1/, and End1/E6E7 cells using MTT assays. All cell lines
demonstrated greater than 94% viability after 24, 48, and 72 hr incubation with
samples, relative to untreated controls (Figure 5.6C-E).
In Vivo Efficacy Studies
The efficacy of GRFT NPs and GRFT NP-EF composites was assessed
within a murine model of lethal HSV-2 infection. Delivery platforms were
intravaginally administered to female BALB/c mice, followed by a single challenge
of HSV-2 (LD90, 5,000 PFU) 24 hr later (Fig. 5.7A, B, Table 5.3). Mice were
monitored for 14 d post-infection, and Kaplan-Meier survival analyses were applied
to generate survival curves (Fig. 5.7C). Mice administered GRFT NPs or GRFT
NP-EF composites showed statistically significant decreases in HSV-2 infection
(70 and 80% survivability, respectively), relative to the untreated/infected control
group (5% survivability, p < 0.05). Additionally, GRFT NPs exhibited statistically
similar protection to free GRFT (85% survivability), whereas GRFT NP-EFs
demonstrated a slight decrease in protection, relative to free GRFT controls (p <
0.05). Additionally, the administration of blank NPs provided a significant level of
protection against HSV-2 (35% survival), relative to GRFT NPs, GRFT NP-EFs,
and untreated/infected controls (p < 0.05).
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Figure 5.7. Schematic, timetable, and results of in vivo HSV-2 efficacy study. (A)
Sequence of murine treatments and (B) administration schedule from HSV-2
efficacy study. (C) Kaplan-Meier survival curves from HSV-2 in vivo efficacy study.
GRFT platforms were assessed for their ability to protect mice against a lethal
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challenge (LD90) of HSV-2 infection (n=20). Both GRFT NPs and NP-EF
composites demonstrated comparable protection (70% and 80%, respectively)
relative to free GRFT (85%), and demonstrated a significant increase in protection
relative to untreated/infected controls (5% survival). Additionally, blank NPs were
found to decrease viral infection and protect 35% mice after 14 d, *p < 0.05.
Furthermore, mice were evaluated and scored for progression of infection once
daily for 14 d post-infection. Infected mice administered (D) no treatment, (E) free
GRFT, (F) GRFT NPs or (G) GRFT NP-EFs exhibited decreased severity of
infection and more gradual progression of infection, relative to untreated/infected
animals.
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Table 5.3. Dosing regimen of GRFT NPs, GRFT NP-EFs, and free GRFT
administered in in vivo studies.

Formulation Name

Amount of Vehicle
Administered per Mouse

Total GRFT Administered
Based on Loading (µg)

GRFT NPs

20 µL of 25 mg/mL PBS

63

GRFT NP-EFs

5 mg

71

0.1% w/v GRFT Solution

20 µL in PBS

20
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In addition to preventing HSV-2 infection, the mice treated with GRFT NPs,
GRFT NP-EF composites, or free GRFT that became symptomatic, demonstrated
delayed onset of symptoms and a more gradual progression of infection, relative
to the untreated/infected control group (Figure 5.7D-G). In the untreated/infected
control group, the first symptoms of HSV-2 infection typically manifest 4 to 5 d postinfection, during which time mice exhibit localized vaginal swelling and decreased
hind leg mobility. After 5 to 8 d, ~75% of mice from the untreated/infected control
group required euthanasia due to the rapid progression and severity of infection.
In contrast, mice exposed to free GRFT or GRFT delivery platforms showed
decreased progression of symptoms within the same duration. Mice that did not
survive HSV-2 challenge despite GRFT pre-treatment, exhibited a more gradual
progression of infection, requiring euthanasia 7 to 10 d instead of 5 to 8 d postinfection, suggesting that GRFT may provide partial protection at these doses for
the few mice that exhibited overt signs of infection. No differences were observed
in the progression of HSV-2 infection after administration of blank NPs, relative to
the untreated/uninfected control group (data not shown).
In Vivo Safety Studies
To assess the in vivo safety of these delivery platforms, blank NPs and NPEF composites were intravaginally administered to uninfected mice, and
reproductive tissue and vaginal lavages were collected and analyzed 24 and 72 hr
following administration.
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Tissue samples were evaluated for edema of muscle, interstitial, and
epithelial tissue. In addition, the macrostructure of untreated and vehicle-treated
cervical and vaginal epithelia were compared, and assessed for potential
keratinization and goblet cell presence. A score ranging from 1 to 4 was used to
determine the severity of epithelial changes. Images of tissues collected 24 hr after
vehicle administration are shown in Figure 5.8A-E. Extracted tissues from
untreated controls demonstrated compact squamous and cervical epithelial tissue,
with no evidence of edema nor inflammation. Similarly, tissues treated with blank
NPs or NP-EF composites showed similar morphology and normality, relative to
untreated tissue (scores of 1 to 2). Furthermore, no increase in lymphocyte
accumulation was observed in these groups. Overall the tissues from vehicletreated mice were comparable in morphology to tissues from untreated mice.
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Figure 5.8. The safety of NPs and NP-EF composites was assessed by
administering platforms to murine reproductive tracts for 24 and 72 hr. H&E stained
tissues of murine reproductive tracts exposed to (A) no treatment, (B) shamtreatment, (C) blank NPs, and (D) blank NP-EF composites for 24 hr. No indication
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of tissue inflammation or epithelial disruption was observed after NP or NP-EF
administration, relative to untreated controls. Additionally, cytokine expression was
evaluated from extracted murine tissue and vaginal lavages collected (E, F) 24 and
(G, H) 72 hr after vehicle administration. Cytokine expression was assessed using
previously published criteria, with acceptable safety values within a 2 to 5-fold
range of expression in the untreated control group. Statistical analysis was used
in addition to evaluate possible increased cytokine expression in both tissue and
vaginal lavage samples.

Mice treated with blank NPs or NP-EF composites

expressed similar cytokine levels relative to untreated controls, with no cytokine
levels demonstrating over 5-fold increase relative to untreated controls, indicating
that the presence of either platform does not induce inflammation or immune
response. Statistical significance between untreated controls and other groups
represented by * (p < 0.05).
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For N-9 treated mice, a slight increase in neutrophil accumulation was
observed at the surface of the cervical squamous epithelium, relative to untreated
controls, indicating minor topical damage (score range 1 to 2). One N-9 treated
sample exhibited increased inflammation, due to the presence of peripheral blood
mononuclear cells, goblet cell fusion, and epithelial disruption, resulting in a score
of 3 (data not shown). However, the alterations observed in the N-9 control
replicate were not observed in any 72 hr N-9 treated tissue controls, indicating
transitory damage.
Finally, cytokine expression was assessed in collected murine tissues and
vaginal lavages 24 and 72 hr after blank NP and NP-EF administration. Cytokine
expression from blank NP or NP-EF treated mice was compared to levels in
untreated mice, as well as to N-9 and sham-treated control groups. Cytokine
expression was evaluated based on previously published guidelines, in which a
significant level of intravaginal inflammation results in a 2 to 5-fold increase in
cytokine expression, relative to untreated controls69. Cytokine expression from
extracted vaginal tissue and vaginal lavages is shown in Figure 5.8F-I, indicating
that both blank NPs and NP-EFs are non-inflammatory. In both collected vaginal
tissue and lavage samples treated with blank NPs and NP-EF composites,
cytokine levels were comparable to untreated negative controls (p > 0.05). This
trend was exhibited both 24 and 72 hr post-administration, with no statistical
significance in cytokine expression between most untreated and blank fibertreated groups. The only exceptions observed were in tissues that had been
administered NPs for 72 hr, which demonstrated decreased cytokine levels of both
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MIP-1β and TNF-α, and 72 hr wash samples from the NP-EF treated group, which
showed increased IL-6 expression, relative to the untreated group. For shamtreated controls, which simulated the administration method via tweezers only,
increased cytokine expression was observed in 24 hr tissue (MIP-2), 24 hr wash
(IL-1β), and 72 hr wash (IL-6, MCP-1), relative to untreated controls. The N-9
treated group demonstrated an increase of MIP-2 in 72 hr wash samples only.
Increased TNF-α expression is typically associated with increased IL-1α, IL-1β,
and IL-2 expression, whereas increased MIP-1β is associated with increased
neutrophil accumulation, neither of which were observed in NP-treated tissue
samples337,338,340. Additionally, increased IL-6 expression alone is not indicative of
inflammation, but is overexpressed with TNF-α and IL-1α under conditions of
localized inflammation, which were not observed in NP-EF treated mice356.
Therefore, we attribute the increased expression of IL-6, MIP-1β and TNF-α to
variability in samples, and not inflammation, as our delivery platforms did not elicit
increased the expression of multiple cytokines. An ELISA, used to confirm IL-1β
levels, showed similar results, showing that both blank NP and NP-EF composites
induced negligible increases in cytokine expression, relative to untreated controls
(p > 0.05).
Discussion
During the past decade, Griffithsin has been studied for its activity against
a variety of viruses, including HSV-2 and HIV-163,65,66, and has demonstrated an
outstanding in vivo safety profiles, with no induction of inflammatory or cytokine
responses. Given these successes, recent work has focused on exploring GRFT
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delivery in topical dosage forms to provide on-demand delivery options in
preventing viral infections. Toward these efforts, recent work evaluating GRFT gels
has shown in vivo efficacy against both HIV-1 and HSV-2. Moreover, other studies
demonstrated the efficacy of GRFT fast dissolving inserts (FDIs) in vivo73,74. In
these studies, both gels and inserts released GRFT within 4 hr to protect mice
against a lethal dose of HSV-2 infection65,73. Furthermore, previous work in our
group has developed pH-responsive and surface-modified fibers that incorporate
GRFT for short-term protection against HIV-1 infections75,162. While these
technologies may provide on-demand protection, to date, vehicles have not been
developed that provide long-term (here, > 72 hr) biologic or GRFT delivery options.
Delivery platforms that provide sustained-release may enable less frequent
administration to provide an effective and practical long-term prevention strategy
that is less reliant on user adherence.
To

achieve

long-term

prevention,

multilayered

nanoparticle-fiber

composites were developed in this study to provide a dual-purpose sustainedrelease platform against HSV-2 and HIV-1 infections. Previous studies for other
applications (e.g., chemotherapy, antibacterial) have demonstrated the potential
of multilayered fibers alone to provide spatially-specific release, where specific
layers incorporate active agents, and other layers are tailored to delay or tune
release177-182,184,357. These architectures provide unique advantages relative to
traditional

uniaxial

fiber

architectures,

particularly

for

sustained-release

applications. Multilayered fibers comprised of distinct hydrophilic and hydrophobic
polymer layers have combined the advantages of both polymer types to highly
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incorporate small hydrophilic drugs or biologics, resulting in better tunability of
release357. Given these attributes, parallel to these NP-EF composite studies, free
GRFT was incorporated into multilayered fibers with shell thicknesses similar to
the NP-EF composites. Although shell thickness did delay release from
multilayered fibers, complete GRFT release from all fibers was observed within 72
hr (Supplemental Fig 5.2), which may be attributed to the pore sizes of PCL shell
layers and the lack of NPs to further modulate release (Figure 5.4B).
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Supplemental Figure 5.2. The cumulative release of GRFT from multilayered
fibers with different outer layer thicknesses shown as (A) total GRFT release or (B)
percent of total loading. Increased GRFT release was observed from multilayers
with thinner shells, although complete release was observed in all samples after
72 hr. Griffithsin release values are shown as the mean ± standard deviation of
three independent NP-EF batches.
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While multilayered electrospun fibers alone (without NPs) have been
previously studied to provide the sustained-release of hydrophilic agents177-182,184,
NP-EF composites have been less extensively studied to prolong delivery 198,206209.

In one proof-of-concept study, multilayered fibers alone comprised of a PCL

shell and a PEO inner layer were fabricated to provide sustained-release of the
small hydrophilic dye rhodamine B for up to 15 days 358. By increasing the shell
thickness by a factor of 4, release was extended up to 25 days, with thicker outer
layers providing close to zero-order release profiles, relative to fibers with thinner
outer layers. More recently, hydrophilic, rapid-dissolve NP-EF single-layered
composites have been designed to enhance agent retention within the murine
reproductive tract215. Hydrophilic PVA and PVP fibers incorporating rhodamine B
or etravirine PLGA NPs were fabricated and intravaginally administered to mice. It
was found that composite dissolution within murine tissue was slower, relative to
in vitro release studies, due to the decreased wettability within the murine
reproductive tract, which contributed to the prolonged release of both rhodamine
B and etravirine. The intravaginal retention of rhodamine was 30-fold higher 24 hr
after composite administration (~50% total dose present) relative to administration
of free NPs (1.5% total dose), in addition, detectable amounts of rhodamine were
present within the reproductive tract for up to 72 hr. Additionally, etravirine released
from NP-EF composites demonstrated a 12-fold increase in concentration after 72
hr composite administration (44% total dose), relative to free NP administration
(1.2% total dose). For both rhodamine B or etravirine PLGA NPs, durations longer
than 24 hr post-administration showed a significant fraction of freely administered
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NPs (~99%) absent from the murine reproductive tract, due to high mucus
clearance. In contrast, NP-EF composites provided short-term release of both
compounds and improved rhodamine and etravirine retention over the course of
72 and 120 hr, respectively. Although this study demonstrated only short-term
release (up to 120 hr) using readily dissolvable NP-EF composites, it demonstrates
the potential of nanoparticle-fiber composites to prolong active agent release,
relative to the administration of free NPs. While NP encapsulation within
hydrophilic polymers such as PVA and PVP may improve NP retention for
durations less than one week, we hypothesized that the incorporation of
hydrophobic polymers in more complex multilayered architectures may
significantly extend release profiles of active agents compared to using to fibers or
NPs alone.
In this work, combining the unique advantages of electrospun fibers and
nanoparticles, resulted in extended GRFT release (up to 90 d) from multilayered
nanoparticle-fiber composites, relative to PLGA and mPEG-PLGA NPs, which
released GRFT within one week. GRFT NP-EFs demonstrated long-term release,
particularly from the formulation that incorporated a lower concentration of NPs
(1% w/w). Based on these results, GRFT NP-EF composites incorporating 20%
w/w GRFT NPs were fabricated and assessed for sustained-release. Although a
greater amount of GRFT release was demonstrated in the 20% w/w composites,
compared to 1% NP-EFs, higher burst release was observed in the 20% w/w
composites, with negligible release between weeks 1 and 4. However, both 1 and
20% formulations demonstrated extended GRFT release from wk 5 through wk 9,
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which was attributed to NP and EF degradation. Future studies may evaluate other
polymer types or polymer blends in the outer layer to further tailor GRFT sustainedrelease profiles. Additionally, outer layer thickness provided some modulation of
GRFT release, but additional options such as electrospinning conditions affecting
fiber micromorphology such as pore size, may provide further tunability of release.
Moreover, the overall multilayered fiber architecture, including the number of
discrete fiber layers, may be changed to further adjust GRFT release. Finally, the
differences between in vitro models of release and the reproductive tract must be
considered as well. The decreased wettability within the FRT, may prolong release
of agents from composites, to in vitro models215.
In addition, to addressing the need for sustained-release delivery, another
benefit of composite platforms is that both NPs and fibers can preserve the activity
of encapsulants. While GRFT has been shown to retain activity in a variety of
physiological environments, including human semen and blood68,73,162,359, studies
have shown that GRFT is susceptible to oxidation, specifically the 78th amino acid
residue (methionine), which may impact its long-term stability360,361. Moreover,
studies evaluating

GRFT-containing FDIs showed that GRFT was initially

susceptible to thermal shear and compression stresses, in addition to oxidation
during conventional FDI fabrication processes, requiring specialized fabrication in
order to provide stability for incorporated GRFT74. Similar to these specialized
FDIs, electrospun fibers have been shown to preserve the stability of incorporated
proteins80,362,363. In particular, previous work has shown that incorporated agents
released from fibers provided enhanced long-term in vitro efficacy relative to free
254

agents, due to fibers preserving encapsulant

activity357. Moreover, the

incorporation of hydrophilic polymers can improve biologic encapsulation and
maintain protein integrity and activity, relative to more hydrophobic polymers that
often require harsh organic solvents during fabrication.
In line with previous observations regarding NPs and fibers, multilayered
NP-EFs were also shown to preserve the activity of incorporated GRFT. The
results from in vitro HIV-1 inhibition assays demonstrated that GRFT released from
either NPs or NP-EF composites provided comparable antiviral activity relative to
free GRFT. These results are in agreement with previous studies that evaluated
free GRFT and GRFT incorporating pH-responsive and surface-modified fibers,
demonstrating a high degree of stability and retention of functional activity 75,162.
Similar results are shown here, suggesting that multilayered composites maintain
the structure and corresponding functional activity of GRFT. More importantly,
composites provided similar inhibition of in vivo HSV-2 infections relative to free
GRFT. Future work with composites seek to optimize GRFT and GRFT NP
loading, and will potentially evaluate the co-delivery of multiple active agents with
different mechanisms of action, to reduce doses required to provide dualprotection.
While this study sought to translate the antiviral properties of GRFT NPs
and composites to in vivo applications, GRFT NPs and NP-EF composites were
initially evaluated using an HSV-2 challenge model 24 hr following vehicle
administration. This challenge time was selected to evaluate the initial potential of
these vehicles to provide complete protection relative to other GRFT-based on255

demand platforms currently under evaluation. Both GRFT NPs as well as GRFT
composites provided potent protection against infection, similar to free GRFT.
Moreover, for the few mice that were infected, GRFT reduced the infection severity
and disease course, which is in line with previous studies that evaluated the in vivo
efficacy of GRFT gels62. Another observation from the efficacy study was that
blank platforms provided modest levels of protection against viral infection relative
to untreated/infected controls (35% survivability). This confirms previous in vitro
studies from our group that have shown that polymer presence alone can serve as
a physical barrier to virus infection75,87. In future work, we may evaluate different
shapes and sizes of composites, in line with a dose-optimization study to provide
a more detailed characterization of this delivery platform.
In addition to investigating dose response and evaluating the potential of
composites to act as a physical barrier of protection, intravaginal retention active
agents released from topical delivery vehicles could be explored further. In other
studies that evaluated GRFT and carrageenan gels, efficacious GRFT
concentrations were detected in murine models 8 hr following initial administration,
despite in vitro FDI dissolution occurring within 1 min73. These studies attributed
epithelial-bound GRFT to the high concentrations present for hours after vehicle
dissolution. In addition to the decreased wettability of the delivery platforms
presented here, we hypothesize that GRFT and even vehicle binding may further
extend the GRFT retention within the reproductive tract. Although examining the
pharmacokinetics of GRFT released from multilayered composites in murine
reproductive tissue was beyond the scope of this work, future studies will explore
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how intravaginal retention relates to the long-term protection imparted by
multilayered composites against single or multiple challenges of HSV-2 at different
times with respect to composite administration. Based on the release studies
presented here, we anticipate that GRFT composites will maintain efficacious
levels of GRFT on the order of weeks to months, depending on fiber dose and NP
loading, and will demonstrate long-term efficacy against both HIV-1 and HSV-2
infections.
Finally, the safety of nanoparticles and multilayered composites were
assessed in both in vitro and murine models. These safety studies were conducted
to evaluate potential toxicity or inflammation caused by the administration of these
delivery platforms, representing an important criteria of topical delivery platforms.
Previous work has shown that increased cytokine expression within the female
reproductive tract is associated with an increased risk of HIV-1 acquisition, which
may negate any protective attributes of a delivery platform 364. Results from
cytotoxicity and histology studies showed that blank and GRFT NPs and NP-EF
composites demonstrated safety and biocompatibility. Furthermore, cytokine
expression levels from vaginal lavages and tissues exposed to NP and NP-EFs
were within a 2 to 5-fold range of levels in untreated controls, indicating the
preliminary safety of these delivery platforms69. These results were anticipated,
given the established safety profiles of the selected polymers, the encapsulant
GRFT, and our previous observations with electrospun fibers and NPs individually.
Conclusion
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In this study, multilayered NP-EF composites that incorporate the antiviral
lectin GRFT were fabricated to provide dual-protection against HIV-1 and HSV-2
infections. Composites demonstrated high loading of GRFT NPs and achieved
sustained-release of GRFT, over a duration of 90 d, dependent on GRFT NP
loading within the NP-EFs. Both NPs and NP-EF composites inhibited HIV-1
infection in vitro and moreover, these vehicles demonstrated protection against a
lethal dose of HSV-2 infection in a murine model. Overall these platforms
demonstrated preliminary safety and efficacy in vivo, suggesting the potential of
these new composite platforms as an alternative sustained-delivery dosage form
to provide dual-protection against HIV-1 and HSV-2 infections.
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CHAPTER 6
OVERALL DISCUSSION AND CONCLUSION
In these studies, electrospun fibers, composed of different polymer types
and fiber architectures were fabricated to deliver the antiviral lectin GRFT or the
antiretroviral TDF. The overall goal was to create topical delivery platforms that
would provide dual-purpose protection against both HIV-1 and HSV-2 infections.
Additionally, these platforms were designed to overcome challenges associated
with other topical delivery platforms, such as transient release, as well as to
provide an alternative dosage form for women in providing protection. Ultimately,
the objective is to translate the success of these fiber formulations into effective
dosage forms that provide efficacious, discreet, and convenient protection against
STIs for women.
Studies have shown that HSV-2 infection increases the susceptibility to HIV1 infection by 2 to 4-fold2,3. Hence, there is a pressing need to provide dualpurpose protection against both HIV-1 and HSV-2 infections. Additionally, women
are disproportionately impacted by the HIV pandemic, necessitating strategies
focused on new alternatives for female-applied protection365.
The development of active agents that provide multipurpose protection
against HIV-1 and HSV-2 is a potential solution. There are dozens of therapeutics
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available to treat either HIV-1 or HSV-2; however only a fraction of these have the
ability to prevent both infections55,366. Currently, Truvada® is the only oral tablet
FDA-approved to prevent HIV-1 infections27. One of the two active agents in the
tablet, TDF, has shown activity against HSV-2, albeit with decreased efficacy
relative to HIV-1. However, other traditional antivirals, such as valaciclovir,
foscarnet, and raltegravir, also have the potential to provide dual-purpose
protection367-369. However, these agents are concurrently used in treatment
regimens, raising the risk of antiviral resistance and potentially rendering
preventative strategies using these molecules ineffective.
Recently, new classes of antiviral biological agents have been discovered
that possess potent antiviral activity. Polysaccharides including carrageenan or the
proteins, of cyanovirin-N and scytovirin, have all shown promising activity against
HIV-1300,370-372. However, the lectin GRFT, originally derived from a species of red
algae has demonstrated potent activity within the picomolar range against HIV-1
and other viruses, relative to other biologic candidates 66. Moreover, unlike other
tested biologics, GRFT has been shown to be safe and biocompatible, and to
induce negligible immune response or inflammation68,69.
Concurrent with the development of new active agents, efforts have focused
on oral and topical pre-exposure prophylaxis (PrEP) to prevent viral infections. For
oral PrEP, Truvada is the only oral tablet that is FDA-approved to prevent HIV-1
infection. However, efficacy is dependent on strict user adherence, and side effects
have been reported with long-term use373,374. Additionally, many of the new
antiviral biologics lack oral bioavailability, excluding their use for oral PrEP. Topical
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PrEP, where dosage forms are directly administered to the FRT, may reduce the
occurrence of side effects relative to oral PrEP, and improve biologic delivery.
However, the dosage forms commonly used to administer biologics, such as gels,
films, or fast dissolving inserts, may be challenged with providing prolonged
protection or achieving acceptable user adherence29. Several topical PrEP delivery
platforms, such as gels and films, have showed disappointing results in clinical
trials, due to low user adherence29,219,375. Although biologics such as GRFT have
been successfully incorporated into gels and fast dissolving inserts to impart in
vivo antiviral protection, to date there is no delivery platform that extend the release
of GRFT within the FRT for longer than 72 hr65,73.
In response to these challenges, this work sought to develop polymeric
electrospun fibers to deliver TDF and GRFT for different temporal administration
strategies. The wide diversity of polymers available for electrospinning,
electrospinning parameters, and the different fiber architectures available allows
for a variety of fibers types to be fabricated76,109,114,376. In these studies, fibers
comprised of PLGA polymers were covalently surface-modified with GRFT, to act
as a stationary viral trap. Results from in vitro HIV inhibition assays demonstrated
that GRFT surface-modified fibers completely inhibited HIV-1, and that fibers alone
reduced infection. Next, fibers composed of polymer blends were developed to
provide pH-responsive release of GRFT. In addition, fibers comprised of
hydrophilic polymers were fabricated to provide rapid-release of GRFT against
both HIV-1 and HSV-2 infections. All rapid-release formulations were shown to
highly incorporate GRFT and to provide complete protection against both
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infections in vitro, while maintaining comparable in vivo protection relative to free
GRFT. Finally, multilayered composites demonstrated the sustained-release of
GRFT and corresponding potent antiviral activity against HSV-2 in vivo.
Conclusion and Future Work
During the course of these studies, target product profiles (TPP) were
established for GRFT NPs, fibers, and NP-EF composites (Table A 1, Table A 2).
These profiles defined the acceptable and ideal properties as criteria by which to
measure these platforms, with for example, providing sustained-release of
efficacious GRFT concentrations for at least one month. Other goals included
providing in vitro anti-HIV-1 activity and in vivo safety and efficacy against HSV-2
infection. In these studies, the selected GRFT platforms provided complete in vitro
inhibition of HIV-1 infection and more importantly, in vivo protection against HSV2 challenge at an LD90 dose. Furthermore, our in vivo safety studies confirm the
preliminary safety of GRFT rapid-release EFs, NPs, and NP-EF composites,
demonstrating the potential of these dosage forms for intravaginal application.
In accordance with the established TPPs, one of the first delivery criteria
was that delivery vehicles would release GRFT concentrations that were
efficacious against both HSV-2 and HIV-1 infections. Although these platforms
failed to provide daily release of GRFT (600 ng/mL and 39 µg/mL for HIV-1 and
HSV-2 respectively), these values were initially determined primarily from in vitro
GRFT studies in completely preventing infections. Upon further evaluation, these
values may not reflect the actual GRFT dose required to prevent infections in vivo,
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based on the efficacy of our delivery platforms assessed within HSV-2 murine
models of infection. Despite the decreased GRFT release relative to initial TPP
requirements, GRFT delivery platforms provided comparable protection against a
LD90 of HSV-2 infection. In agreement with our observations, other studies that
assessed GRFT FDIs demonstrated that GRFT is retained within the reproductive
tract due to the interactions between the tissue and lectin73,74. Furthermore, it was
found that efficacious concentration of GRFT would be retained for several days,
lowering the required daily release of GRFT. Additionally, the amount of GRFT
released in vivo is dependent upon the amount of fiber intravaginally delivered. In
line with our own observations and other’s work, future studies evaluating NPs and
NP-EF composites will assess if these platforms will provide extended protection
against multiple challenges of in vivo HSV-2 infection.
In addition to providing GRFT release, the TPPs established the
requirement that our GRFT delivery platforms must demonstrate acceptable safety
profiles. Our in vivo and in vitro work have demonstrated the preliminary safety
profiles of all delivery platforms. MTT analysis demonstrated that all platforms
provided over 95% viability of vaginal cell lines. Additionally, no histological
abnormalities were noted in murine tissues incubated with blank platforms.
Although individual cytokines expression levels in some samples showed over a 2
to 3-fold increase relative to untreated controls, this was not observed with multiple
cytokines, indicating negligible inflammatory response. However, further studies
will be required to assess the safety of platforms, such as evaluating peripheral
blood mononuclear cells (PMBCs) following intravaginal administration.
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Despite the success of these platforms, more work is required to assess the
safety and efficacy of these platforms. First, in vivo murine models could be used
to assess GRFT release, retention, and distribution within the reproductive tract as
a function of administration time. Previous studies evaluating FDI and gel murine
intravaginal retention found that GRFT released from these platforms was retained
for longer durations in vivo than in vitro release studies suggested65,73. This
disparity between release profiles has been attributed to the decreased wettability
of the reproductive tract, resulting in delayed release of agents from platforms and
increased retention of GRFT. Hence, the increased GRFT retention may translate
to these platforms providing increased durations of protection against viral
infections, than estimated from in vitro release studies. To validate this hypothesis,
future studies may assess GRFT concentration in both reproductive tissue and
vaginal lavages at selected timepoints following GRFT platform administration. To
accomplish this, platforms incorporating fluorescently-labeled GRFT could be
utilized, with murine reproductive tracts imaged for quantification of localized
fluorescence at selected timepoints. We hypothesize that our GRFT platforms, in
particular the GRFT NPs and NP-EF composites, will demonstrate prolonged
retention and release, relative to the results observed during in vitro release
studies.
Concurrent with assessing the retention and distribution of GRFT from
delivery platforms is to evaluate the window of protection imparted by GRFT
delivery vehicles. Our initial in vivo studies evaluated the efficacy of rapid-release
and sustained-release delivery platforms 4 hr and 24 hr after administration,
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respectively. Immediate future work can assess if GRFT platforms protect against
extended HSV-2 challenges, such as 1 wk, 1 month, or longer durations following
platform administration. Additionally, multiple challenges of HSV-2 may be
administered to assess if platforms provide protection in circumstances of multiple
exposures to virus.
In addition to expanding the evaluation of these platforms against HSV-2
infection, other efficacy studies may assess the impact that multiple active agents
with different mechanisms of action incorporated in fibers or NP-EF composites,
may have on the dose needed to prevent HSV-2 infection. Although GRFT shows
potent activity against HIV-1, it is less efficacious against HSV-2, demonstrating a
1000-fold higher IC50 for HSV-2, relative to HIV-1. Future formulations may
incorporate other active agents tailored against HSV-2 (and HIV-1) infections, in
addition to GRFT, to improve the dual-purpose utility of these platforms. We
hypothesize that by incorporating additional active agents, future GRFT platforms
will demonstrate synergistic efficacy against both HIV-1 and HSV-2 infections.
During our in vivo HSV-2 efficacy studies, it was found that blank EFs and
NPs

alone

imparted

partial

protection

against

infection,

relative

to

untreated/infected controls. Previous studies in our group have shown that the fiber
structure itself can act as a barrier to viral particles, and inhibit cell entry. Future in
vivo experiments may evaluate this property in order to enhance antiviral
protection of delivery platforms. A potential experimental setup could determine
how different fiber or composite structures (without active agent) could inhibit or
prevent the spread of seminal fluid in murine models. Using seminal fluid
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containing fluorescent compounds mimicking viral particles or fluorescentlylabeled sperm, different fiber architectures could be assessed in mice to minimize
virus transport throughout the reproductive tract. We hypothesize that fiber
structures, in addition to providing release of incorporated agents, can be
fabricated to as a physical barrier to virus distribution in tissue, imparting further
protection.
Although we anticipate success of these platforms in providing sustainedrelease protection against viral infections, additional preclinical studies are
required to fully ascertain the potential safety risks associated with administration
of intravaginal delivery platforms, such as evaluating off-target effects and
correlating with GRFT concentration and distribution in the reproductive tract.
Previous safety studies with GRFT have demonstrated an outstanding safety
profile, revealing that GRFT does not induce inflammation nor toxicity following
subcutaneous or intravaginal administration. Although, intravaginal administration
of GRFT gel in murine models results in GRFT distribution throughout the
reproductive tract, including the uterine horns, it is considered unlikely for GRFT
to absorb systemically. Similar results were observed in tests assessing polymers
that comprising both EFs and NPs215, however, further testing will be required to
validate the safety of our platforms. We hypothesize that our delivery platforms will
continue to exhibit acceptable safety profiles in future studies that examine the
pharmacodynamics and pharmacokinetics of released GRFT.
Lastly, we anticipate the need for additional studies to confirm the safety of
these delivery platforms. Previous studies examining microbicide candidates, such
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as N-9, showed that traditional safety studies failed to reveal the gel’s cytotoxic
properties, which enhanced the risk of viral acquisition, and exposed the need for
further studies. A virus susceptibility study, run with the proper positive controls
can be investigated to validate the complementary histological and cytokine
studies conducted to date. Compounds known to increase viral susceptibility, such
as N-9 and benzalkonium chloride, will be administered as positive controls of
toxicity and inflammation. We hypothesize that GRFT delivery platforms will not
enhance the risk of HSV-2 acquisition, but that the positive controls will enhance
susceptibility.
Based on our criteria and future studies, multilayered composites
demonstrated the most promising potential for long-term GRFT release of the
platforms examined. The composites provided GRFT release for up to 90 d, and
were designed to overcome the challenge of high mucus clearance within the FRT.
However, it was noted that only 50% of incorporated GRFT released from NP-EF
composites. Future studies will be necessary to account for the lack of complete
release during the 90 d period. It is possible that residual GRFT may be
noncovalently bound to the composite scaffold structure. Established extraction
methods may be used to separate GRFT protein from polymeric scaffolds. Another
possibility for low GRFT recovery is that GRFT was released completely, but was
unable to be quantitated due to denaturation or alteration. Quantification of eluate
samples from composite release studies can be analyzed using liquid
chromatography-mass spectrometry to account for possible denatured or
covalently modified GRFT compounds. Although GRFT has been characterized as
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highly stable and the high loading of rapid-release GRFT fibers results indicate
that the electrospinning process does not affect the activity or structure of GRFT,
further analysis will be required to validate the stability of incorporated GRFT from
NP-EF composites.
Finally, in future work, the composite architectures may be more finely
tailored to modulate active agent release. Altering polymer choice, electrospinning
conditions, or the number of fiber layers, all have the potential to tune GRFT
release from multilayered composites. Additionally, the shape and size of
composites may be revisited to better serve user preference and needs.
Concurrent with experimental composite alterations, mathematical modeling may
be employed to better predict the release kinetics of agents from fiber delivery
platforms. Previous work has shown the capacity of in silico modeling in predicting
TDF release from PLGA fibers. By accounting for parameters involved in agent
release, in silico models can complement and expedite the optimization of agent(s)
release. This optimization may be helpful for composites, in which the fabrication
of these complex structures is dependent upon dozens of interdependent
parameters.
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APPENDICES
FABRICATION AND CHARACTERIZATION OF GRIFFITHSIN-MODIFIED FIBER
SCAFFOLDS FOR PREVENTION OF SEXUALLY TRANSMITTED INFECTIONS
Introduction
During the past two decades, EFs have been extensively used in the fields
of drug delivery and tissue engineering108. Often, biocompatible polymers are
selected to easily translate to therapeutic applications. To fabricate polymeric EFs,
the selected polymer is dissolved in an organic solvent or aqueous solution,
depending on the degree of polymer hydrophobicity 377. Active agents of interest
are then added to the solvent or aqueous solution prior to the electrospinning
process. The polymer solution is then aspirated into a syringe and slowly ejected
while subject to an electrical current. This process typically results in polymer fibers
with sheet or cylindrical macrostructures (Figure A.1), and fiber diameters ranging
from the micro- to nano-scale80. For most therapeutic applications, active agents
are incorporated within the fibers during the electrospinning process and are
released from the fiber via diffusion and subsequent fiber degradation. The rate of
degradation or release may be altered by using different types of polymers or
polymer blends to establish a desired release profile, imparting unique chemical
and physical properties376, and promoting the encapsulation of virtually any
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compound. As such, EFs have proven beneficial to the delivery of small molecule
drugs and biological agents including proteins, peptides, oligonucleotides, and
growth factors80,110,183.
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Figure A.1 The macroscale morphology of electrospun fibers. The electrospun
fibers shown were fabricated using a 4 mm (cylinder) and 25 mm (sheet) diameter
mandrel, respectively.
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In the field of STI prevention, EFs have been recently used to incorporate
and provide sustained- or inducible-release of antiviral agents38,83-87,101,160,166,378.
In one of the earliest studies, pH-responsive fibers were developed to release
active agents in response to environmental changes within the female reproductive
tract (FRT), as an on-demand method of protection against HIV-183. Since, other
studies have investigated polymer blends comprised of polyethylene oxide (PEO)
and poly-L-lactic acid (PLLA), to evaluate the tunable release of antiviral and
contraceptive agents for HIV-1 prevention and contraception in vitro86. Additional
studies have demonstrated the feasibility of EFs to provide the following: prolonged
release of small molecule antivirals87, strong and flexible mechanical properties379,
3-D delivery architectures380, inhibition of sperm penetration86, and the ability to
merge with other delivery technologies378. Finally, previous work has evaluated
polymeric fibers for the sustained-delivery of antiviral agents against common coinfective viruses, HSV-2 and HIV-187. In this study, polymer fibers provided
complementary activity to antiviral delivery by retaining their structure for up to 1
month and providing a physical barrier to viral entry. From these results, it was
observed that EFs may be used to both physically and chemically hinder virus
infection.
While tunable release properties make polymeric EFs an attractive delivery
platform for microbicide delivery, EFs have been developed in other applications
to serve as surface-modified scaffolds376. EFs have been used to mimic the
morphology of the extracellular matrix (ECM), often acting as scaffolds to improve
cellular regeneration381, and enhance their utility in tissue engineering211,382. Fibers
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comprised of polymers such as poly-ε-caprolactone (PCL) and PLLA have been
surface-modified with growth factors and proteins after electrospinning to impart
ECM-like properties including increased cellular adhesion and proliferation 383,384.
Additionally, antimicrobial surface-modified EFs have been evaluated to prevent
the growth of specific pathogenic bacteria385,386. Due to this versatility and the
ability to induce biological effects, EF technology continues to expand across a
variety of fields to provide multi-mechanistic functionality. Yet, despite their utility
in a diversity of applications, surface-modified fibers have only recently been
explored in the microbicide field75.
In parallel with the development of new delivery technologies to prevent and
treat STIs, novel biological therapeutics have been developed. One of the most
promising microbicide candidates is the adhesive antiviral lectin, GRFT66.
Originally derived from a species of red algae, GRFT has demonstrated activity as
a potent inhibitor of HIV-1, HSV-2, SARS, as well as Hepatitis C virus62-65,67,70. In
fact, among biologically-based inhibitors, GRFT has one of the most potent antiHIV activities, inactivating HIV-1 almost immediately upon contact66, while
maintaining stability and activity in the presence of culture media from vaginal
microbes for up to 10 days69. More recently, a 0.1% GRFT gel was shown to
protect mice against intravaginal HSV-2 challenge, making it a promising
candidate for the first line of protection against both HSV-2 and HIV-165,387. For
HIV-1 specifically, GRFT inhibits infection by physically binding gp120 or terminal
mannose N-linked glycan residues on viral envelope surfaces to prevent entry61,387390.

This inhibition is highly potent, with IC50s approaching 3 ng/mL62. In addition to
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inhibiting HIV-1 infection, studies have also shown that GRFT protects against
HSV-2 infection by inhibiting the cell-to-cell spread of the virus65. In all cases,
GRFT has been shown to be adhesive to viral particles, while demonstrating high
resistance to denaturation. Last, GRFT has demonstrated synergistic activity with
combinations of Tenofovir (TFV) and other antivirals72, making it feasible and likely
beneficial to co-administer with EFs. The potent properties of GRFT make it an
excellent biologically-based antiviral candidate, in which delivery may be
enhanced with EF technology.
Utilizing this knowledge of the adhesive and innate antiviral properties of
GRFT, a polymeric fiber scaffold was designed, that integrates these properties to
provide the first layer of virus entry inhibition75. Finding inspiration in the way that
cervicovaginal mucus hinders virus transport primarily through mucoadhesive
mucin interactions, we hypothesized that by using EFs as a scaffold and covalently
modifying the surface with GRFT, a high density of surface-conjugated GRFT
would debilitate and inactivate virus at its entry point391-393. Here EFs were
developed as a stationary scaffold to provide a protein-based, viral adhesiveinactivating barrier platform. We sought to combine the potent antiviral properties
of GRFT with a biocompatible, modifiable, and durable polymer platform, to create
a novel virus "trap."
To achieve these goals, fibers comprised of PLGA were electrospun, and
EDC-NHS chemistry was used to subsequently modify the EF surface with GRFT.
PLGA served as a model polymer due to its extensive use in electrospinning 394,
combined with its biocompatibility and cost-effectiveness. Additionally, surface
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modification exploits the large surface area of EFs, and provides a useful
alternative that can be combined with encapsulation to maximize fiber utility88.
Unlike traditional encapsulation methods where only a portion of GRFT is available
(and only transiently present in the FRT), surface modification may enable GRFT
to maintain maximum bioactivity during the entire duration of treatment.
Furthermore, the incorporation of hydrophilic compounds such as proteins, by
traditional electrospinning methods, may result in lower encapsulation efficiencies
and loss of protein activity362. Therefore, GRFT surface-modified fibers may offer
a promising alternative delivery method that can be used alone or in combination
with electrospinning to enhance protection against STI infection.
Protocol
Preparation and Fabrication of the Electrospun Fiber Scaffold
CAUTION: All work with solvents or polymer solutions should be performed in a
chemical fume hood. Refer to material safety datasheet of each reagent before
starting the protocol.
1. To electrospin a 3 mL 15% w/w PLGA polymer solution, weigh 720 mg of 50:50
poly(lactic-co-glycolic acid) (PLGA; 0.55 to 0.75 dL/g, 31-57 kDa) into a 10 mL
scintillation vial. The volume of the solution is based on the typical batch size used
in current studies.
NOTE: The polymer mass to add to a given volume of solvent must be calculated
by first determining the density of the solvent used to dissolve the polymer. The
density of the solvent Hexafluoro-2-propanol (HFIP) is 1.59 g/mL. Thus, the weight
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of solvent, based on a volume of 3.0 mL HFIP needed, is 4.8 g (3.0 mL x 1.59
g/mL). For a 15% w/w fraction of PLGA to HFIP, 720 mg PLGA must be added to
3.0 mL HFIP (0.15 x 4,800 mg = 720 mg). The advantage of using a % w/w
polymer/solution, rather than % w/v, is that this provides a defined weight of the
final solution. This defined weight enables more accurate solvent replacement, in
the case of solvent evaporation during step 1.3.
2. Add 3.0 mL HFIP to the glass scintillation vial containing PLGA (from step 1.1)
using a serological glass pipette. Cover the vial with plastic film, then measure and
record the vial mass.
3. Incubate the polymer suspension overnight at 37 °C to ensure complete
dissolution of the polymer. If any solvent evaporates, decreasing the vial mass,
add HFIP until the vial reaches its original mass in step 1.2.
4. After incubation, prepare the electrospinning apparatus (Figure A.2A). Although
a mandrel of any size may be used, here a rotating 25 mm outer-diameter stainless
steel mandrel was used as the collector.
NOTE: A larger mandrel diameter will decrease the fiber thickness, given the same
volume of electrospinning solution.
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Figure A.2 Electrospinning apparatus. (A) The collecting mandrel where the liquid
jets of polymer deposit, and (B) the full electrospinning setup.
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5. Aspirate the polymer solution into a 3 mL syringe.
6. Connect a blunt 18-gauge, ½ inch needle tip to the syringe and dispense the
excess solution (typically 0.25 mL) to remove empty headspace in the needle tip.
7. Place the syringe on a syringe pump and set the instrument flow rate to 2.0
mL/h.
NOTE: This flow rate was previously optimized based on polymer viscosity for this
formulation.
8. Connect the power source to the syringe needle and electrospin the polymer
solution using a voltage of +27 kV. The distance between the needle and collector
should be set to approximately 25 cm (Figure A.2B.
CAUTION: The electrospinning process creates a solvent vapor. Use a fume hood
or an enclosed apparatus (Figure A.2) to remove the harmful vapor.
9. Once the entire solution is electrospun, turn off the power source and allow the
mandrel to spin for an additional 30 min to fully evaporate solvent.
10. Turn off the rotating mandrel collector, and use a razor blade to cut the fiber
from the mandrel. Use the blade to gently peel the fiber from the mandrel.
11. Collect the electrospun PLGA fiber into a labeled Petri dish, and place in a
desiccator overnight to remove residual solvent.
Surface-modification of Fibers with GRFT
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1. Prepare solutions of phosphate-buffered saline (PBS) and 2-(N-morpholino)
ethanesulfonic acid (MES buffer). Prepare PBS by dissolving 8 g NaCl, 0.2 g KCl,
1.44 g Na2HPO4, and 0.24 g KH2PO4 in 1 L of ultrapure water. Similarly, dissolve
19.52 g MES (free acid, MW 195.2) and 29.22 g NaCl in 1 L of ultrapure water, to
prepare MES buffer. Ensure the final pH of each solution is between 7.2 - 7.5 and
5.0 - 6.0, respectively, using a pH meter.
2. Prepare individual working solutions of EDC (2 mM) and NHS (5 mM). Remove
the EDC and NHS from the freezer and allow them to equilibrate to room
temperature before weighing. Weigh 4 mg of EDC into a 1.5 mL microcentrifuge
tube. Weigh 6 mg of NHS into another microcentrifuge tube. Add 1 mL MES buffer
to each tube. Vortex both tubes vigorously to ensure the reagents are fully
dissolved.
3. Prepare a solution of hydroxylamine by weighing 70 mg into a 50 mL conical
centrifuge tube.
4. Add 20 mL PBS to the hydroxylamine and vortex to dissolve.
5. Mass out an appropriate amount of PLGA fiber into a 15 mL conical centrifuge
tube. Typically, 75 mg of fiber is used for each reaction batch.
6. Add 8 mL of MES buffer to the 15 mL tube.
7. Add 1 mL each of the EDC and NHS solutions prepared earlier to the tube. The
final volume of the solution should be 10 mL. The final concentrations of EDC and
NHS should be 0.4 mg/mL and 0.6 mg/mL, respectively.
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8. Close and seal the 15 mL tube with plastic film and place on a rotator to allow
the solution to be gently inverted for 15 min at room temperature (Figure A.3B).
This step activates the carboxyl groups on the polymer to allow for covalent
modification with the GRFT protein (Figure A.3A).
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Figure A.3 Schematic of EF modification with GRFT using EDC-NHS chemistry.
(A) Carboxyl groups on the PLGA EF react with NHS in the presence of EDC to
form amine-reactive esters, which will subsequently form stable amide bonds with
the primary amines of GRFT. (B) Two milligram fiber disks or pieces are cut and
incubated in 8 mL of MES buffer with 2 mL of EDC/NHS reagent and rotated for
15 min.
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9. After activation, carefully quench the reaction by adding 14 μL of βmercaptoethanol to the tube. Invert the tube several times to ensure complete
mixing.
CAUTION: β-mercaptoethanol is highly toxic and should only be used in a
chemical fume hood.
10. Discard the supernatant and rinse the PLGA fiber twice, with 10 mL of PBS, to
remove any remaining β-mercaptoethanol.
11. After rinsing, add an appropriate amount of GRFT stock solution to the tube.
For example, a 5 nmol GRFT/mg fiber would require 6.35 μL of GRFT stock
solution (from a 10 mg/mL stock) per mg of fiber. Thus a 75 mg fiber sample would
require 476.25 μL of 10 mg/mL GRFT stock solution.
NOTE: GRFT fibers with theoretical loadings of 0.05, 0.5, and 5 nmol GRFT per
mg fiber were fabricated.
12. Add enough PBS to bring the final volume to 8 mL, close and invert the tube
to ensure thorough mixing.
13. Seal the tube with plastic film and place on a rotor again, this time for 2 h.
14. After the 2 h incubation, quench the reaction by adding 2 mL of hydroxylamine
solution into the 15 mL centrifuge tube. Per manufacturer instructions, the final
concentration of hydroxylamine during the quenching reaction should be 0.7
mg/mL.
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15. Mix the solution well and discard the supernatant. Rinse the surface-modified
PLGA fiber twice with 10 mL ultrapure water to remove any unconjugated GRFT.
16. Transfer the fiber to a Petri dish and place inside of a desiccator until the fiber
is completely dry. Transfer the Petri dish to 4 °C for storage.
SEM Characterization of GRFT Surface-modified Fibers
1. Place a strip of double-sided carbon tape on an SEM specimen mount. Label
the bottom of the specimen mount with the sample identifying information using a
permanent marker.
2. Cut three samples from one surface-modified fiber and place them on separate
specimen mounts. The thickness of each sample is approximately 0.5 mm.
3. Sputter coat the samples using electron-induced particle deposition from a gold
plate. Sputter coat for 90 s, at 2.4 kV.
NOTE: The sputter coat time may vary depending on equipment parameters,
including voltage and amperage.
4. Image the samples at 8 kV with a magnification ranging from 1,000 to 5,000X.
Extraction of GRFT from Surface-modified Fibers
1. Mass out 2 mg of fiber in triplicate into 1.5 mL microcentrifuge tubes.
2. Add 1 mL dimethyl sulfoxide (DMSO) to the tube, then vortex and incubate for
1 min at room temperature to completely dissolve the fiber.
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3. After incubation, dilute a 10 μL aliquot of the DMSO-fiber solution from step 4.2,
at least 100-fold in Tris-EDTA (TE) buffer (pH = 8.0).
4. Store samples at -20 °C until loading characterization with ELISA.
Measuring GRFT Desorption from Fibers
1. To assess the amount of GRFT released or desorbed from the fiber, weigh 5 10 mg of surface-modified fiber and place in a microcentrifuge tube. Record the
fiber mass in each tube.
2. Add 1 mL of an appropriate solution that mimics the physiological environment
(e.g., PBS, TE buffer, simulated vaginal fluid (SVF), etc.) to each sample.
3. Incubate the samples for 1 h on a rotating shaker at 200 rpm, 37 °C.
4. After incubation, remove approximately 1 mL of TE buffer containing the
desorbed GRFT from the vial, and aliquot to cluster tubes. Store at -20 °C until
protein quantification.
5. Transfer the sample to a new microcentrifuge tube, add 1 mL of fresh buffer
solution to the fiber within the microcentrifuge tube, and incubate until the next time
point.
6. Typical time points used to measure release include: 1, 2, 4, 6, 8, 24, 48, 72 h,
and 1 wk. Negligible desorption was observed in these studies after 4 h.
Quantification of GRFT Extraction and Desorption via ELISA
1. Coat a 96-well ELISA plate with 0.1 mL of HA (10 μg/mL) per well as previously
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described395. Seal the plate with plastic film and incubate overnight at 4 °C (Figure
A.4).
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Figure A.4 Schematic illustrating GRFT quantification using ELISA. A 96-well
immunoplate is coated with gp120 or HA to capture and immobilize GRFT. Primary
antibodies against GRFT, secondary antibodies linked to horseradish peroxidase,
and ELISA substrate are sequentially added to quantify GRFT.
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2. Remove the coating buffer, and add 0.3 mL blocking buffer (2 - 3% bovine serum
albumin (BSA) in PBS with 0.05% polysorbate 20) to each well. Incubate the plate
for at least 2 h at room temperature.
3. After incubation, rinse the plate 3 times with 1x PBS with 0.1% polysorbate 20
(PBS-P). After rinsing, dispense 0.1 mL of sample, standard, or PBS as negative
control into the respective wells. Incubate the plate again for 1 h at room
temperature.
4. Rinse the plate 3 times again with PBS-P. After rinsing, add 0.1 mL of primary
antibody (goat anti-GRFT antiserum) into each well and incubate for at least 1 h at
room temperature. Typically, the primary antibody solution is diluted by 1:10,000
in PBS.
5. After incubating the samples with primary antibody rinse the plates again 3 times
with PBS-P. Add 0.1 mL of secondary antibody (horseradish peroxidase (HRP)conjugated rabbit anti-goat IgG) to each well and incubate for 1 h at room
temperature. The secondary antibody solution is diluted by 1:10,000 in PBS.
6. Wash the plate 3 times. Add 0.1 mL TMB 2-peroxidase substrate to each well.
Monitor color development (approximately 2 min), then add 0.1 mL H2SO4 (1 N)
to quench the reaction. Read plate at 450 nm on a plate reader.
7. Average the background OD values (wells which only receive PBS), and
subtract this from the experimental groups.
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Representative Results
Fiber morphology has a significant effect on the ability of surface-modified
EFs to provide protection against viruses. Although electrospinning is a convenient
and straightforward procedure, non-optimized polymer formulations may result in
irregular fiber morphology (Figure A.5). Alterations in electrospinning conditions
that result in the formation of beaded or amorphous mat-like morphologies, are
often caused by solvent polymer incompatibility, low polymer viscosity, flow rate,
or other electrospinning conditions. The resulting variations in fiber structure can
result in different release profiles for drug-incorporated fibers or inconsistencies in
conjugation efficacy, altering the fibers ability to physically or chemically hinder
virus penetration. The PLGA EFs fabricated using the described electrospinning
conditions should result in distinct fiber morphologies with diameters ranging
between 1.5 and 2.8 μm (Figure 3.6). To determine fiber morphology and
diameter, EFs should be examined with SEM prior to other characterization or
modification steps.
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Figure A.5 Effects of solvent choice on PLGA EF morphology. (A) The 15% w/w
PLGA EFs in HFIP displayed desirable thread-like morphology. (B) The 15% w/w
PLGA EFs in chloroform and dimethylformamide, failed to form due to non-optimal
solvent choice or polymer concentration (viscosity). (C) The 15% w/w and (D) 20%
w/w PLGA EFs in TFE demonstrate the importance of polymer viscosity. Beads
formed in the formulation with lower polymer concentration (C), while increasing
the polymer concentration (solvent viscosity) resulted in well-defined fiber
morphology (D). Note, Figure 3.5B was taken at a lower magnification to show the
mat-like morphology. Scale bars = 10 µm.
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Figure A.6 SEM images and fiber diameters of bare and GRFT-modified EFs. (A)
Bare PLGA EFs and PLGA EFs surface-modified with (B) 0.05 nmol, (C) 0.5 nmol,
and (D) 5 nmol of GRFT per mg of fiber. Scale bars = 10 µm. (E) Diameters of
unmodified and GRFT-EFs. Error bars represent the mean ± SEM. No statistical
difference was observed between the diameters of unmodified and GRFT-modified
fibers. Figure A.6E has been adapted from Grooms et al.75
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SEM images of blank, 0.05, 0.5, and 5 nmol GRFT fibers showed no
significant differences in fiber morphology (Figure A.6A-D), indicating that GRFT
modification has no effect on fiber morphology. To determine the average diameter
of each EF formulation, a minimum of 50 random measurements were taken per
field of view from the SEM images diameters of the EF formulations were
measured and calculated in ImageJ, as shown in Figure A.6E. All EF formulations
had similar average diameters around 1.9 μm, demonstrating the consistency of
unmodified fiber fabrication process across batches.
To determine the amount of GRFT conjugated to the EFs, GRFT-EFs were
dissolved in DMSO, followed by a 100-fold dilution in TE buffer, to extract GRFT
from the fiber. The quantity of GRFT conjugated per mg of fiber was quantified
using ELISA. For each modification density (0.05, 0.5, and 5 nmol GRFT per mg
fiber), ten replicates were evaluated. For the 5, 0.5, and 0.05 nmol GRFT/mg EF
modifications, each EF had 373, 165, and 42 ng GRFT per mg of EF, resulting in
conjugation efficiencies of 0.6, 4.2, and 6.9%, respectively. These results
demonstrate that GRFT-EFs conjugated with higher theoretical surfacemodification density, result in more GRFT conjugated to the fiber (Figure 3.7A).
However, there was an inverse correlation with the resulting conjugation
efficiency75
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Figure A.7 Quantity of GRFT conjugated to and desorbed from GRFT-modified
EF. (A) The quantity of GRFT conjugated to each mg of EF fiber increases with
increased GRFT reactant concentration. (B) The quantity of GRFT released from
each mg of fiber is shown for the 0.05, 0.5, and 5 nmol formulations after 1, 2, and
4 h incubation in SVF. Error bars represent the mean ± SEM. This figure has been
adapted from Grooms et al75.
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To assess the amount of GRFT covalently conjugated to the fiber surface
relative to that adsorbed, GRFT-EFs were incubated in SVF to determine the
amount of GRFT released. Within the first 4 h, 113, 25, and 10 ng of GRFT per mg
EF was detected in SVF for the 5, 0.5, and 0.05 nmol theoretical modification
concentrations, respectively. These values correspond to 30%, 41%, and 24% of
the amount of GRFT conjugated to 5, 0.5, and 0.05 nmol GRFT-EFs. After 4 h,
negligible GRFT was detected in the release eluate for all three formulations.
GRFT release after 1, 2, and 4 h is shown in Figure 3.7B. Taken together, these
data indicate that the majority of GRFT is covalently bound to the EFs, and that
the surface-adsorbed GRFT is released within the first 4 h.
Discussion
Due to their porous structures and large surface areas, EFs have found a
variety of applications in healthcare, one of which includes serving as therapeutic
delivery vehicles. Drugs and other active agents can be incorporated within EFs
for tunable delivery, while biologics and chemical ligands can be conjugated to the
fiber surface for cell-specific targeting396 or biosensing102. Here the fabrication of
GRFT surface-modified PLGA EFs, as a delivery scaffold to prevent HIV-1
infection, is described. GRFT-EFs were synthesized by electrospinning, providing
the advantages of low cost and high production rate relative to other fiber
production methods88,102.
Critical Steps in the Protocol
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The formation of EFs is critically dependent on the properties of polymer
solution, in particular the solution or solvent viscosity397. The factors that affect the
viscosity of a polymer solution include polymer molecular weight, polymer
concentration, and the type of solvent used. The solution or solvent viscosity is
typically adjusted by changing the ratio of polymer to solvent, to obtain the desired
polymer concentration. With each fabrication, the volume must be maintained
during overnight incubation to maintain the proper polymer-to-solvent ratio
(viscosity). At sufficiently high polymer concentration, the polymer molecules
entangle in the solution during the electrospinning process to produce fibers.
During the electrospinning process, a bead will form at the spinneret tip and if there
is sufficient polymer entanglement, liquid jets will erupt from this point at a critical
voltage and accelerate in whip-like fashion toward the collecting mandrel398.
Solvent evaporation will then lead to jet thinning, producing threads of fiber as they
deposit on the collecting mandrel. Once synthesized, EFs should be analyzed by
SEM to verify proper morphology and consistent fiber diameter. The presence of
beaded EFs may be the result of low solution viscosity399, exceedingly high applied
voltage256, polymer feed rate400, or a combination of all three factors. If this is
observed, polymer concentration should be increased and the applied voltage and
feed rate should be adjusted, to attain fiber-like morphology.
To conjugate proteins to the EF surface, here PLGA carboxyl groups were
reacted using EDC-NHS carbodiimide crosslinking chemistry401. During the
modification process, fibers are briefly incubated with EDC in the presence of NHS
which results in the conversion of carboxylates into semistable, amine-reactive
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esters. During the two-step conjugation process, it is critical that the buffers used
during each step have the optimal pH, noted in the manufacturer's instructions, to
ensure maximum conjugation efficiency. The half-life of NHS esters ranges from
four to five hours at neutral pH and dramatically decreases in more basic
conditions402. Thus, the first reaction should be performed in MES buffer at pH 5 6 and the activated fibers should then be transferred to a PBS buffer (pH 7.2 - 7.5)
for subsequent and immediate reaction with GRFT. It is also important that EDC is
inactivated by the addition of 2-mercaptoethanol and sufficiently rinsed from the
fibers after carboxylate activation. This will help prevent protein activation by EDC
and self-crosslinking during the second reaction, which may reduce conjugation
efficiency.
Modifications and Troubleshooting
Although our previous work demonstrated the efficacy of a variety of GRFTmodified fibers against HIV-1 infection, certain process alterations may be
considered to customize EF morphology or to improve GRFT (or other protein)
conjugation efficiency or fiber yield75. In particular, the EF surface area may be
increased by decreasing the fiber diameter, to enable a greater surface area for
conjugation. Previous studies have shown that reducing polymer concentration
and viscosity produces smaller fiber diameter403,404. However, this approach is
limited by the formation of beaded fibers when the concentration is below the
threshold value. To decrease fiber diameter without changing solution viscosity,
dual-solvent systems can be utilized to reduce the surface tension, or salts may
be added to increase solution conductivity256,399. Both methods will enable greater
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stretching of the electrospinning jets which may produce smaller fiber diameters.
In addition, lower molecular weight polymers may be used to fabricate smaller
diameter fibers. Decreasing fiber diameter also provides the added advantage of
generating smaller pores, potentially making EFs more effective as a barrier to
virus penetration, for microbicide-based applications405. Finally, it was observed
that humidity can affect EF yield. At higher humidity, the yield tends to decrease
due to the formation of fibers with unusual macro-morphology. Installing a humidity
control system within the electrospinning chamber could therefore facilitate
producing EFs with consistent yields, if this presents a challenge to fabrication.
To improve GRFT conjugation efficiency, investigating the selection and
location of functionalizable groups may also be considered. For example, if the
primary amines of the protein of interest are located near the interior of the threedimensional protein structure, steric hindrance may prevent activated carboxyl
groups on EFs from interacting with primary amines, thereby decreasing the
likelihood of the reaction. This challenge may be overcome by amino acid
substitution of the protein to generate a primary amine group closer to the protein
surface. However, as GRFT and other proteins depend on the specific activity of
its binding sites for functionality, alterations in protein conformation should be
thoroughly tested in functional assays prior to conjugation.
Limitations
A major limitation of GRFT surface modification is the potential for low
conjugation efficiency using carbodiimide crosslinking chemistry. If the antiviral
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protein of interest has a high IC50, a low conjugation efficiency may not provide
sufficient protection (in these applications) against virus infection. However, for
GRFT (or other modified) EFs, proteins and active agents that are not covalently
bound to EFs may still adsorb to the surface. These adsorbed agents offer the
potential to complement the activity of conjugated GRFT, by transiently increasing
the localized concentration available for virus binding. In this example, desorbed
GRFT may bind to HIV-1 virions that do not directly contact EFs, and may provide
an alternative mechanism of protection with the first 4 h of (pericoital)
administration. Thus, both conjugated and surface-adsorbed GRFT may contribute
to providing uniform protection against STIs.
Despite the protection conferred from both protein conjugation and
desorption, other surface-modification strategies with potentially higher efficiency
might be pursued. For example, PLGA terminated with amines instead of carboxyl
groups could be used to conjugate activated GRFT. Alternatively, a different
surface-modification strategy may be utilized to improve EF-protein conjugation
efficiency. Nanofibrous membranes composed of EFs have been functionalized
with avidin via carbodiimide crosslinking chemistry406. Biotinylation or addition of a
Strep-tag (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) through recombination may enable
the modified protein to form strong and extremely stable non-covalent interaction
with avidin EFs. While non-covalent, the avidin-biotin linkage is the strongest noncovalent bond, with femtomolar affinity, likely resulting in stable conjugation to the
fiber surface. For any surface-modification strategies, steric hindrance should be
considered to maximize conjugation efficiency.
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Lastly, we envision that surface-modified EFs will offer an alternative
strategy to active agent encapsulation to provide complementary modes of
protection. One consideration with combining encapsulation and surfacemodification technologies on a single EF platform will be reducing the premature
release of active agents during the surface-modification process. For surfacemodification reactions that require relatively long incubation time in aqueous
solution, a significant percentage of the active agents loaded could be lost due to
polymer hydrolysis.
Significance of the Method with Respect to Existing and Alternative Methods
In previous work, we observed that unmodified blank EFs were able to
inhibit HIV-1 infection by ~38% when placed in a transwell insert above infectible
cells75.

This

observation

combined

with

the

biocompatibility,

web-like

microstructure, and tortuosity of EFs, in parallel with the observed potent antiviral
and adhesive properties of GRFT, prompted the development of the surfacemodified EFs described here.
Relative to other delivery technologies currently employed in microbicide
applications, EFs have a wide range of potential applications due to their
architecture and capacity for customization. In other work, the fibrous morphology
of EFs has enabled them to deliver active agents, and to mimic the ECM, making
them suitable scaffolds for tissue engineering. EFs have also been surfacemodified to enhance biocompatibility and enhance sustained-release407,408.
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To enhance biocompatibility or deliver agents that function through specific
binding activity, numerous methods exist that allow for the attachment of
compounds to the surfaces of EFs such as plasma treatments, wet chemical
methods, and surface graft polymerizations362. In the case of GRFT which
specifically bind to the viral glycoproteins of HIV-1, the wet chemical method of
EDC-NHS is the most optimal due to the ability to penetrate fibers deep within the
mesh while also preserving GRFT functionality362. GRFT immobilized to EFs can
then be delivered in a durable formulation to the FRT and provide immediate
protection against HIV-1 infection.
Compared to the existing strategy of encapsulating therapeutics within EFs
to inhibit STIs, covalent conjugation offers the distinct advantage of increasing the
potential avidity between GRFT and HIV-1 virions. By immobilizing GRFT to EFs
through surface-modification, highly localized concentrations of GRFT can be
achieved, which increase the opportunity for multivalent binding with HIV-1. In
addition, EF-immobilized GRFT, relative to free GRFT in solution, may prevent the
depletion of the GRFT pool by hindering cell internalization. Moreover, due to the
unique mechanism of action of GRFT as a stable and adhesive entry inhibitor,
covalent surface conjugation enables surface-modified EFs to provide a physical
barrier to virus penetration, in addition to potent antiviral properties.
Future Applications of this Method
The utilization of surface-modification for delivery presents the opportunity
to integrate multiple active agents within a single EF platform. In the future, we
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seek to develop a multipurpose technology (MPT) where a variety of active agents
may be encapsulated within and conjugated to EFs. These MPTs may be designed
to confer protection against a wider range of pathogens by incorporating
therapeutics with different mechanisms of action. By utilizing both the surface and
interior of EFs to deliver active agents with different mechanisms of action, the
potential of EFs to protect against virus infection will be maximized.
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Target Product Profile
Table A 1. GRFT Electrospun Fibers Target Product Profile
GRFT Electrospun Fibers Target Product Profile
Formulation Properties
Minimum Acceptable
Ideal Result
Result
Primary Purpose*
To
fabricate
GRFT To
fabricate
GRFT
encapsulated electrospun encapsulated electrospun
fibers that will provide fibers that will provide
sustained release of GRFT sustained release of GRFT
for one week to one month. for up to one month.
Furthermore, the released Furthermore, the released
GRFT
will
provide GRFT will provide complete
protection against both protection against both
HSV-2 and HIV-1 in vitro as HSV-2 and HIV-1 in vitro as
well as HSV-2 in vivo well as HSV-2 in vivo
against a single challenge. against multiple challenges.
In Vitro Target Population TZM-bl, Vero, VK2, Ect, TZM-bl, Vero, VK2, Ect,
End.
End.
In Vivo Target Population
BALB/c female mice.
BALB/c female mice.
In Vitro Treatment Duration Test 1 day to 1 month Test 1 day to 1 month
eluates.
eluates.
In Vivo Treatment Duration Test single dose of fibers.
Test single dose of fibers.
In Vivo Delivery Mode
Intravaginal administration Intravaginal administration
for murine model.
for murine model.
In Vivo Regimen
One administration for the One administration for the
entire duration.
entire duration.
Dosage for In Vitro
3-10 mg of GRFT fiber for in 3-10 mg of GRFT fiber for in
vitro studies. Minimum vitro studies. Minimum
release is 600 ng/mL per release is 600 ng/mL per
day against HIV-1 409,410, day against HIV-1409,410,
while at least 19-39 µg/mL while at least 19-39 µg/mL
is required for HSV-265,71.
is required for HSV-265,71.
Dosage for In Vivo
4-5 mg of GRFT fiber for in 4-5 mg of GRFT fiber for in
vivo studies. Minimum vivo studies. Minimum
release is 600 ng/mL per release is 600 ng/mL per
day against HIV-1409,410, day against HIV-1409,410,
while at least 19-39 µg/mL while at least 19-39 µg/mL
is required for HSV-265,71.
is required for HSV-265,71.
In Vitro Efficacy
Greater than 90% reduction Greater than 90% reduction
in HIV-1BaL infectivity for up in HIV-1BaL infectivity for up
to 1 week eluates.
to 1 month eluates.
50-90% reduction of cell to At least 90% reduction of
cell spread (via plaque cell to cell spread (via
counts).
plaque counts).
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In Vivo Efficacy

In Vitro Risk/Side Effects

In Vivo Risk/Side Effects

Stability

HSV-2: 5,000 PFU/20µL
(LD90). Single dose of fibers
provides greater than 90%
protection for at least one
week.
Greater than 80% viability
(MTT assay) in cell lines
after 3 day culture.
No
histopathological
aberrations in the FRT from
exposure to GRFT fibers.
No more than a 2-3 fold
difference in cytokines
(GM-CSF, IFN-γ, IL-1α, IL1β, IL-6, CCL-2, TNF-α)
after exposure to GRFT
EFs68.
Most (>50%) incorporated
GRFT is stable for 1 month.

HSV-2: 5,000 PFU/20µL
(LD90). Single dose of fibers
provides greater than 90%
protection for for up to one
month.
Greater than 80% viability
(MTT assay) in cell lines
after 3 day culture.
No
histopathological
aberrations in the FRT from
exposure to GRFT fibers.
No more than a 2-3 fold
difference in cytokines
(GM-CSF, IFN-γ, IL-1α, IL1β, IL-6, CCL-2, TNF-α)
after exposure to GRFT
EFs68.
All incorporated GRFT is
stable for 1 month.

Primary Purpose
Minimum Acceptable Result
The primary purpose of using polymeric electrospun fibers as delivery
vehicles is to provide sustained-release of the antiviral Griffithsin (GRFT) for one
month. Additionally, both the incorporated and released GRFT will maintain its
bioactivity and by extension antiviral properties. Acceptable fiber formulations will
release enough GRFT to significantly protect against both HIV-1 as well as HSV2 throughout a week’s duration. Furthermore, GRFT release from fibers should
continue for an entire month.

Ideal Result
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The ideal result would meet all of the specifications listed above, releasing
enough GRFT to completely prevent HIV-1 or HSV-2 infection for the entire one
month duration.
In Vitro Target Population
Minimum Acceptable Result
These fibers will be assessed in vitro against both HIV-1 and HSV-2
infection. To assess against HIV-1 infection TZM-bl cell lines will be used in an
HIV-1 inhibition assay. These cell lines are an accepted cell model to assess the
therapeutic efficacy against HIV-1 infection. Eluates from GRFT EFs at various
time points during the one month period will be evaluated.
For HSV-2 infection, plaque assays using Vero E6 cell lines will be used.
Vero E6 is a widely used and accepted model to determine viral infection. For both
HIV-1 and HSV-2 assays, the minimum acceptable result will be a significant
decrease in infection within a 1 week duration. In addition, a decrease of cell-tocell spread will be assessed in our HSV-2 studies. Finally, VK2/E6E7, Ect1/E6E7,
and End/E6E7, cell lines will be used to assess cytotoxicity. An acceptable result
is that cells in contact with GRFT EFs exhibit 80-97% viability.
Ideal Result
The ideal result is that electrospun fibers completely inhibit HIV-1 and HSV2 infections while maintaining full viability of selected cell lines.
In Vivo Target Population
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Minimum Acceptable Result
BALB/c female mice will be used for these studies. This mouse type is an
acceptable model for studies involving HSV-2 infection.
Ideal Result
Same as minimum acceptable result (MAR).
In Vitro Treatment Duration
Minimum Acceptable Result
Any fabricated fiber incorporating GRFT must release GRFT throughout
the entire 1 month duration. However, the MAR is therapeutically relevant GRFT
release during the first week of release.
Ideal Result
Any fabricated fiber incorporating GRFT must release enough of the
antiviral to completely inhibit viral infection throughout the entire 1 month. Our ideal
result is that therapeutically relevant concentrations of GRFT are released during
the entire one month.
In Vivo Treatment Duration
Minimum Acceptable Result
Our in vivo studies are to be conducted for 1 month.
Ideal Result
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Same as MAR.
Delivery Mode
Minimum Acceptable Result
Fibers will be delivered intravaginally to assess a new topical antiviral
delivery vehicle that will be administrated within the female reproductive tract.
Ideal Result
Same as MAR.
Regimen
Minimum Acceptable Result
One administration for the entire 1 month duration.
Ideal Result
Same as MAR.
In Vitro Dosage
Minimum Acceptable Result
For GRFT released from fibers, a daily release of 600 ng/mL is required to
provide an IC90 against HIV-1 infection409,410. In regard to HSV-2 infection,
literature mentions several IC50 values for GRFT dependent on cell type (19, 4.5,
and 72 μg/mL for Vero E671, Caski65, and VK2/E6E765 respectively). However,
GRFT mainly acts to prevent the cell-to-cell spread of HSV-2 infection with IC50
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values of 4.5 and 72 μg/mL65. As for IC90, GRFT concentrations of 39 and 335
μg/mL were required to prevent of cell-to-cell spread65. Thus, for HSV-2, a GRFT
daily release of at least 19-39 μg/mL will be required in our in vitro studies using
Vero cell lines.
This release should also be enough to significantly decrease HIV-1
infection. To provide an IC90 against HIV-1 for one entire week, a fiber will have to
release a total of at least 4.2 µg/mL of GRFT in total. For in vitro testing, a 3 mg
fiber sample with a loading of 1.4 µg/mg is needed to provide an IC90 against HIV1 infection for 1 week (assuming complete release during this period). For HSV-2,
to provide at least an EC50 for one week in Vero cells, a 3 mg fiber sample must
have a loading of 45 µg/mg (135 µg) of GRFT. To provide an IC90 against HSV-2,
a 3 mg sample must load 91 µg/mg (273 µg) of GRFT.
Ideal Result
For GRFT released from fibers, we anticipate a daily release of 600 ng/mL
for 1 month duration to provide an IC90 against HIV-1. This would require a fiber to
release a total of 18 µg of GRFT during this duration. For a 3 mg fiber sample, the
total loading would require a loading of at least 6 µg/mg (assuming full release
after one month). As for HSV-2, 570 µg of GRFT would need to be released to
provide an IC50 against HSV-2 for one month, requiring a loading of (190 µg/mg)
from a 3 mg EF sample. To provide an IC90 against HSV-2 the entire one month
duration, a 3 mg EF sample must load 390 µg/mg (1.17 mg) of GRFT.
In Vivo Dosage
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Minimum Acceptable Result
For GRFT released from fibers, a daily release of 1 μg/μL (0.1% wt/vol)
would be required to provide protection against HSV-2 within a mouse model65.
This daily release must be extended for at least one week.
Ideal Result
For GRFT released from fibers, we anticipate a daily release of 3 μg/μL
(0.3% wt/vol) for 1 month duration to provide an EC90 against HSV-2 infection
within a mouse model. This would require a fiber to release a total of 1.8 mg of
GRFT during this duration. For a 10 mg fiber sample, the total loading would
require a loading of at least 180 µg/mg (assuming full release after one month).
In Vitro Efficacy
Minimum Acceptable Result
For HIV-1 in vitro testing, the minimal result acceptable would be at least a
90% decrease of infection during a 1 week period. In regard to HSV-2, a decrease
in plaque formation is ideal; however, a 50-90% reduction in cell-to-cell spread of
HSV-2 is required.
Ideal Result:
The ideal result would be that collected daily or weekly eluates collected
from fibers demonstrate a 90% decrease of both HIV-1 and HSV-2 infections.
These eluates will be collected for up to one month.
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In Vivo Efficacy
Minimum Acceptable Result
Fibers provide 90% protection against a single challenge with HSV-2 (LD90)
for 1 week.
Ideal Result
Fibers provide 90% protection against a single challenge with HSV-2 (LD90)
for 1 month.
In Vitro Risk/Side Effects
Minimum Acceptable Result
An acceptable result would be cells in contact with GRFT EFs exhibiting 70100% viability. These viability values are from the JFHE grant proposal.
Ideal Result
Ideally, we would want no cytotoxicity expressed from contact from fibers.
In Vivo Risk/Side Effects
Minimum Acceptable Result:
From literature, GRFT is biocompatible and does not induce inflammation68.
Furthermore, our selected polymers share the same attributes in safety. Therefore,
the administration of GRFT fibers should not induce toxicity or lead to increased
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cytokine expression. Histopathological grading should reflect a lack of
inflammation.
Ideal Result
Same as MAR.
Stability
Minimum Acceptable Result
GRFT has shown remarkable stability409. Therefore, there should not be
any decrease of activity shown form released GRFT. We predict that encapsulated
GRFT will retain activity for the entire 1 month duration. However, since the amount
of GRFT encapsulated within fibers will be more than necessary to provide IC90, a
decrease of activity can be tolerated. For our purposes, a decrease of at most 50%
will be tolerated.
Ideal Result
Ideally, we would want all incorporated and released GRFT to maintain
bioactivity for the entire duration.
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Table A 2. GRFT Nanoparticle Target Product Profile
GRFT Nanoparticle Target Product Profile
Formulation Properties
Minimum Acceptable
Ideal Result
Result
Primary Purpose*
To fabricate encapsulated To fabricate encapsulating
GRFT NPs that will provide GRFT NPs that will provide
sustained release of GRFT sustained release of GRFT
for up to one month. for up to one month.
Furthermore, the released Furthermore, the released
GRFT and will provide GRFT and will provide
significant
protection complete
significant
against both HSV-2 and protection against both
HIV-1 in vitro as well as HSV-2 and HIV-1 in vitro as
HSV-2 in vivo.
well as HSV-2 in vivo.
In Vitro Target Population TZM-bl, Vero, VK2, Ect, TZM-bl, Vero, VK2, Ect,
End.
End.
In Vivo Target Population
BALB/c female mice.
BALB/c female mice.
In Vitro Treatment Duration Test 1 day to 1 month Test 1 day to 1 month
eluates.
eluates.
In Vivo Treatment Duration Test single dose of NPs.
Test single dose of NPs.
Delivery Mode
Intravaginal administration Intravaginal administration
for murine model.
for murine model.
Regimen
One administration for the One administration for the
entire duration.
entire duration.
Dosage for In Vitro
2-5 mg for in vitro studies. 2-5 mg for in vitro studies.
Minimum release is 600 Minimum release is 600
ng/mL per day against HIV- ng/mL per day against HIV1409,410, while at least 19-39 1409,410, while at least 19-39
µg/mL is required for HSV- µg/mL is required for HSV65,71
.
265,71.
Dosage for In Vivo
4 mg in 20 μL for in vivo 4 mg in 20 μL for in vivo
studies. Minimum release studies. Minimum release
is 600 ng/mL per day is 600 ng/mL per day
against HIV409,410, while at against HIV409,410, while at
least 19-39 µg/mL is least 19-39 µg/mL is
required for HSV-265,71.
required for HSV-265,71.
In Vitro Efficacy
Greater than 90% reduction Greater than 90% reduction
in HIV-1BaL infectivity for up in HIV-1BaL infectivity for up
to 1 wk eluates.
to 1 month eluates.

In Vivo Efficacy

50-90% reduction of cell to
cell spread (via plaque
counts).
HSV-2: 5,000 PFU/20µL
(LD90). Single dose of NPs
provides greater than 90%
protection for at least one
week.
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At least 90% reduction of
cell to cell spread (via
plaque counts).
HSV-2: 5,000 PFU/20µL
(LD90). Single dose of
provides greater than 90%
protection for at least one
month.

In Vitro Risk/Side Effects

In vivo Risk/Side Effects

Stability

Greater than 80% viability
(MTT assay) in cell lines
after 3 day culture.
No
histopathological
aberrations in the FRT from
exposure to GRFT NPs. No
more than a 2-3 fold
difference in cytokines
(GM-CSF, IFN-γ, IL-1α, IL1β, IL-6, CCL-2, TNF-α)
after exposure to GRFT
NPs68.
Most (>50%) incorporated
GRFT is stable for 1 month.

Greater than 80% viability
(MTT assay) in cell lines
after 3 day culture.
No
histopathological
aberrations in the FRT from
exposure to GRFT NPs. No
more than a 2-3 fold
difference in cytokines
(GM-CSF, IFN-γ, IL-1α, IL1β, IL-6, CCL-2, TNF-α)
after exposure to GRFT
NPs68.
All incorporated GRFT is
stable for 1 month.

Primary Purpose
Minimum Acceptable Result
The primary purpose of using polymeric nanoparticles (NPs) as mobile
delivery vehicles is to provide sustained-release of the antiviral griffithsin (GRFT)
for one month. Additionally, both the incorporated and released GRFT will maintain
its bioactivity and by extension antiviral properties. Acceptable NP formulations will
release enough GRFT to significantly protect against both HIV-1 as well as HSV2 throughout a week’s duration. Furthermore, GRFT release from NPs should
continue for an entire month.
Ideal Result
The ideal result would meet all of the specifications listed above, releasing
enough GRFT to completely prevent HIV-1 or HSV-2 infection for the entire one
month duration
In Vitro Target Population
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Minimum Acceptable Result
These NPs will be assessed in vitro against both HIV-1 and HSV-2 infection.
To assess against HIV-1 infection TZM-bl cell lines will be used in an HIV-1
inhibition assay. These cell lines are an accepted cell model to assess the
therapeutic efficacy against HIV-1 infection. Eluates from GRFT NPs at various
time points during the one month period will be evaluated.
For HSV-2 infection, plaque assays using Vero E6 cell lines will be used.
Vero E6 is a widely used and accepted model to determine viral infection. For both
HIV-1 and HSV-2 assays, the minimal acceptable result will significantly decrease
in infection within a 1 week period. A decrease of cell-to-cell spread will be
assessed during the HSV-2 studies. Finally, VK2/E6E7, Ect1/E6E7, and End/E6E7
cell lines will be used to assess cytotoxicity. An acceptable result is that cells in
contact with GRFT NPs exhibit 80-97% viability.
Ideal Result
The ideal result is that NPs completely inhibit HIV-1 and HSV-2 infections
while maintaining full viability of selected cell lines.
In Vivo Target Population
Minimum Acceptable Result
BALB/c female mice will be used for these studies. This mouse type is an
acceptable model for STI studies.
Ideal Result
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Same as minimum acceptable result (MAR).
In Vitro Treatment Duration
Minimum Acceptable Result
NPs incorporating GRFT must release GRFT throughout the entire 1 month.
Ideal Result
GRFT NPs release enough of the antiviral to completely inhibit viral infection
throughout the entire 1 month.
In Vivo Treatment Duration
Minimum Acceptable Result
Our in vivo studies are to be conducted for 1 month.
Ideal Result
Same as MAR.
Delivery Mode
Minimum Acceptable Result
NPs will be delivered intravaginally using PBS to assess a new topical
antiviral delivery vehicle that will be administrated within the female reproductive
tract.
Ideal Result
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Same as MAR.
Regimen
Minimum Acceptable Result
One administration for the entire 1 month duration.
Ideal Result
Same as MAR.
In Vitro Dosage
Minimum Acceptable Result
For GRFT released from nanoparticles, a daily release of 600 ng/mL is
required to provide an IC90 against HIV-1 infection. As for HSV-2 infection, a daily
release of 19-39 µg/mL would be required to provide an EC50 for Vero cell lines71.
This release should also be enough to significantly decrease HIV-1 infection. To
provide an IC90 against HIV-1 for one entire week, NPs will have to release a total
of at least 4.2 µg/mL of GRFT for one week. For in vitro testing, a 2 mg with a
loading of 2.1 µg/mg is needed provide an IC90 against HIV-1 infection for 1 week
(assuming complete release during this period). For HSV-2, to provide at least an
EC50 for one week, a 2 mg of NPs must have a loading of 66 µg/mg (135 µg) of
GRFT. To provide an IC90 against HSV-2, a 2 mg NP sample must load 136 µg/mg
(273 µg) of GRFT.
Ideal Result
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For GRFT released from nanoparticles, we anticipate a daily release of 600
ng/mL for 1 month duration to provide an IC90 against HIV-1. This would require
NPs to release a total of 18 µg of GRFT during this duration. For a 2 mg NP sample,
the total loading would require a loading of at least 9 µg/mg (assuming full release
after one month). As for HSV-2, 570 µg of GRFT would need to be released to
provide an IC50 against HSV-2 for one month, requiring a loading of (285 µg/mg)
from a 2 mg NP sample. To provide an IC90 against HSV-2 the entire one month
duration, a 2 mg NP sample must load 585 µg/mg (1.17 mg) of GRFT.
In Vivo Dosage
Minimum Acceptable Result
For GRFT released from NPs, a daily release of 1 μg/μL (0.1% wt/vol) would
be required to provide protection against HSV-2 within a mouse model65. This daily
release must be extended for at least one week.
Ideal Result
For GRFT released from NPs, we anticipate a daily release of 3 μg/μL (0.3%
wt/vol) for 1 month duration to provide an EC90 against HSV-2 infection within a
mouse model. This would require a fiber to release a total of 1.8 mg of GRFT
during this duration. For a 4 mg NP sample, the total loading would require a
loading of at least 450 µg/mg (assuming full release after one month).
In Vitro Efficacy
Minimum Acceptable Result
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For HIV-1 in vitro testing, the minimal result acceptable would be at least a
90% decrease of infection during a 1 week period. In regard to HSV-2, a decrease
in plaque formation is ideal; however, a 50-90% reduction in cell-to cell-spread of
HSV-2 is required.
Ideal Result
The ideal result would be that daily or weekly eluates collected from GRFT
NPs demonstrate a 90% decrease of both HIV-1 and HSV-2 infections. These
eluates will be collected for up to one month.
In Vivo Efficacy
Minimum Acceptable Result
GRFT NPs provide 90% protection with a single challenge against HSV-2
(LD90) for 1 week.
Ideal Result
GRFT NPs provide 90% protection against a single challenge with HSV-2
(LD90) for 1 month.
In Vitro Risk/Side Effects
Minimum Acceptable Result
An acceptable result would be cells in contact with GRFT NPs exhibiting
80-100% viability.
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Ideal Result
Ideally, we would want no cytotoxicity expressed from contact from
nanoparticles.
In vivo Risk/Side Effects
Minimum Acceptable Result
Same as EFs.
Ideal Result
Same as EFs.
Stability
Minimum Acceptable Result
Same as EFs.
Ideal Result
Ideally, we would want all incorporated and released GRFT to maintain
bioactivity.
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LIST OF ABBREVIATIONS
ACV – Acyclovir
AIDS – Acquired immunodeficiency syndrome
ARRRP – AIDS Research and Reference Reagent Program
AZT – Azidothymidine
BSA – Bovine serum albumin
C6 – Coumarin 6
CCR5 – Chemokine receptor 5
CD4 – Cluster of differentiation 4 receptor
CG – Carrageenan
CXCR4 – Chemokine receptor type 4
D – Day
DCM – Dichloromethane
DMEM – Dulbecco`s modified Eagle media
DMSO – Dimethyl sulfoxide
EC90 – 90% maximal response
ECM – Extracellular matrix
EDC – 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
EE% – Encapsulation efficiency
EFs – Electrospun fibers
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ELISA – Enzyme-linked immunosorbent assay
ENV – Envelope glycoprotein
FBS – Fetal bovine serum
FDA – Food and Drug Administration
FDI – Fast dissolving insert
FRT – Female reproductive tract
GRFT – Griffithsin
HAART – Highly active antiretroviral therapy
H&E – Haemotoxylin and Eosin
HFIP – Hexafluoro-2-propanol
HIV-1 – Human immunodeficiency virus
HSV-2 – Herpes simplex virus
IC50 – The half maximal inhibitory concentration
IVR – Intravaginal ring
KFSM – Keratinocyte serum-free media
LC/MS – Liquid chromatography–mass spectrometry
LD10 – Lethal dose 10%
LD90 – Lethal dose 90%
MEM – Minimal essential medium
MES – 2-ethanesulfonic acid
mPEG-PLGA – methoxy poly(ethylene glycol)-b-poly(lactide-co-glycolide)
MTT – 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
N-9 – Nonoxynol-9
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NHS – N-Hydroxysuccinimide
NIH – National Institutes of Health
NNRTIs – Non-nucleoside/nucleotide reverse transcriptase inhibitors
NP-EFs – Nanoparticle-Electrospun Fiber composites
NPs – Nanoparticles
NRTI – Nucleoside/nucleotide reverse transcriptase inhibitors
PAA – Poly(acrylic acid)
PBA – Poly(n-butyl acrylate)
PBS – Phosphate-buffered saline
PBS-T – Phosphate-buffered saline Tween 20
PCL – Polycaprolactone
PEO – Poly(ethylene oxide)
PFU – Plaque forming units
PI – Protease inhibitors
PLCL – Poly(lactide-co-caprolactone)
PLGA – Poly(lactic-co-glycolic acid)
PLLA – Polylactide (Poly(lactic acid)
PrEP – Pre-exposure prophylaxis
PVA – Polyvinyl alcohol
PVP – Polyvinylpyrrolidone
RhB – Rhodamine B
RLU – Relative luminescence unit
SDS – sodium dodecyl sulfate
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SEM – Scanning electron microscopy
SiRNA – Small interfering RNA
SIV – Simian immunodeficiency virus
STI – Sexually transmitted infection
SSF – simulated semen fluid
SVF – Simulated vaginal fluid
TCID50 – Median tissue culture infectious dose 50%
TEER – Transepithelial/transendothelial electrical resistance
TFE – 2,2,2 –Trifluoroethanol
TDF –Tenofovir disoproxil fumarate
TFV – Tenofovir
WK – Week
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